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Section 1 
Introduction 
Summary 
Shiga toxin (ST) and the Escherichia coli Shiga-like toxins (SLTs) are type 11 
ribosome inactivating proteins (RIPs). All members of this group exhibit specific 
RNA N-glycosidase activity, the prototype being the plant toxin ricin. ST and the 
SL Ts are bipartite toxins composed of a catalytic A subunit and a pentamer of cell 
binding B subunits. These toxins show overall structural similarities to ricin, which 
is also a bipartite toxin with a catalytic A chain and a single cell binding B chain. 
The A chains of ST and SL T 1 show homology to ricin A chain, particularly in the 
active site region, and appear identical in their enzymatic mechanism. The respective 
B chains however are structurally very different and interact with quite different 
cellular components. 
In this study, the role of intracellular proteolytic activation of SL T 1 is addressed 
using a molecular biological approach. The biological characteristics of several 
mutant SL Ts has been investigated both in vitro, by addition of exogenous protease, 
and in vivo by comparing the relative cytotoxicities of mutant and wild type proteins 
in Vero cells. The intracellular processing of these mutant toxins has also been 
examined. In parallel, the biological properties of a ricin A chain SL T 1 chimeric 
protein has been investigated. The ultimate aim of this study was to extend our 
knowledge of the proteolytic processing requirements of SL T 1 and it has led to the 
conclusion that proteolytic removal ofthe A2 portion of SL T 1 is not an essential 
prerequisite for intoxication of Vero cells with SL T 1. 
2 
1.1 History and Disease 
In 1898 , after an epidemic of dysentery in Japan, Kiyoshi Shiga first described the 
causative agent of a dysentery which was distinct to that of amoebic dysentery and 
named it Bacillus dysenteriae. This was latter named Shigella dysenteriae and the 
disease it caused shigellosis. Shiga toxin was first described by (Conradi (1903)) 
where it was reported that intravenous inoculation of a lysate of the bacillus Shigella 
dysenteriae paralyzed and killed rabbits. It was this observation which led 
researchers at the time to consider ST as a neurotoxin. It was later shown that ST acts 
on various animal species with variable consequences but that only the rabbit and 
mouse show neurological disorders (Cavanagh et at (1956)). Shiga toxin does not act 
directly on the neurons but can cause secondary neurological disorders by its action 
on the vascular system of the brain (Howard (1955); Baldini et at (1983)). In 1972 
Keusch et at reported that inoculation of Shiga toxin in ligated rabbit ileal loops 
caused inflammatory enteritis and resulted in net fluid accumulation. 
Konawalchuk et at (1977) first described a toxin from E. coli which was toxic to Vero 
cells and was distinct from the heat labile and heat stable toxins from the same 
organism. This observation led to this toxin being named Vero toxin (VT). Antibody 
neutralization and molecular biology studies showed that these cytotoxins are 
3 
anti genically and genetically related to Shiga toxin (O'Brien et al (1982); Strockbine 
et aI1986,1988». These observations resulted in the renaming of the toxins to the 
Shiga-like toxins (SLTs). Further studies of Ecoli 0157:H7 strain 933 revealed the 
presence of two toxin-converting phages 933J and 933W (O'Brien et al (1984». 
These phages carry the structural genes for two distinct cytotoxins (Scotland et al 
(1985», one of which is neutralized by anti Shiga toxin antisera and one which is 
not. These two toxins are designated Shiga-like toxin 1 and Shiga-like toxin 11 
respectively. The genes for these two toxins and those of Shiga toxin have been 
cloned and the nucleotide sequences determined (Calderwood et at (1987); 
Strockbine et al (1988); Jackson, et al (1987». The predicted amino acid sequences 
have shown that SL T 1 is virtually identical to ST and SL T 11 is 56% homologous to 
ST. The Ecoli Shiga-like toxins have been shown to be identical or similar in 
biological activities to that of ST including receptor specificity (Waddel et al (1988); 
Cohen et al (1987» and enzymatic action (Endo et al (1988». Hence it is proposed 
that Shiga toxin is the prototype for a family of toxins termed the Shiga-like toxins. 
The role that ST and SL Ts have in disease is unclear and the method by which these 
toxins are administered to the host has served to complicate studies. Shigella 
dysenteriae invades and multiplies within the epithelial cells during infection 
(Sansonetti (1991». This makes it difficult to distinguish between the responses due 
to invagination and those attributed to free toxin. Studies in which a toxin-deletion 
4 
mutant of S. dysenteriae type 1 (Fontaine et al (1988)) was used to infect primates, 
showed that they retained their ability to produce intestinal disease, albeit less severe 
than disease caused by the wild type tox+ strain. However these data are complicated 
by the fact that these mutants still produce toxin under certain in vitro conditions. 
The presence of the functional Shiga toxin gene is associated with severe lesions of 
the colon in rhesus monkey infections not seen with the to x- mutant. The situation 
with E. coli infection is more simple. Infection with SL T -producing E. coli does not 
result in invasion of the epithelial cells. These toxin producing strains have been 
classed as enterohaemorrhagic E. coli (EHEC) and are able to adhere to colonic 
epithelia and colonize the gut. Numerous outbreaks ofhaemorrhagic colitis (HC) and 
the haemolytic uraemic syndrome (HUS) have established a link between these 
disorders and infection with SLT-producing E.coli (Karmali et al (1983); Bopp et al 
(1987); Carter et al (1987)). Epidemiological studies have demonstrated that E.coli 
serotype 0157:H7 was associated with severe instances of bloody diarrhoea in the 
United States and Canada (Johnson et al (1983); O'Brien et al (1983); Riley et al 
(1983); Wells et at (1983)). Evidence in favor ofa toxin effect in vivo is that non 
invasive EHEC 0157:H7, which produce large quantities of both SLT 1 and SLT 11, 
cause colonic damage from inflammation and ulceration to exacerbation of ulcerative 
colitis (Hunt et al (1989); Ljungh et al (1988); Von Wulfen et at (1989)). No animal 
model for HUS or HC has been developed. Rabbit intestine is often used as an in 
vivo model and results using this assay have shown that the effects from ST and SL T 
from E. coli 0157 :H7 are similar (Keenan et al (1986)). 
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1.2 Structure and function of ST/SL T 1 
SL T is a bipartite toxin composed of a single catalytic A subunit non-covalently 
associated with five receptor binding B subunits (Donohue-Rolfe et al (1984, 1989); 
Olsnes et al (1981 )). Comparison of deduced amino acid sequences between ST and 
SL T has shown that the two toxins are identical (Takao et al (1988)) or differ by a 
single amino acid at position 45 (threonine in ST and serine in SL T 1) (Calderwood 
et al (1987); DeGrandis et al (1987) and Strockbine et at (1988)). The mature A 
chain is composed of 293 amino acids with a molecular weight of 32,217 Da and the 
B chain 69 amino acids molecular weight 7692 Da (Calderwood et at (1987); 
Strockbine et at (1988)) Figure 1.3 shows a schematic representation of the SLT 1 
structure. 
The SL T liST B chain is responsible for receptor binding. The B chain pentamer 
binds to the cell surface glycolipids with the carbohydrate sequence Gala 1-4Galp 
(galabiose). Lingwood et at (1987) isolated the natural receptor for SLT from Vero 
cells and showed it to be a glycolipid-globotriosylceramide containing the 
carbohydrate sequence galactose a 1-4galactosep 1-4glucose-ceramide often referred 
to as Gb) or CD77. Figure!. 1 shows the structure of the carbohydrate moitey of the 
Gb3 receptor. 
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Figure 1.1 The structure of globotriose, the carbohydrate component of 
the Shiga-like toxin 1 receptor globotriosylceramide. 
HO 
OH 
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HO __ ~ __ -----~ 
o 
~OH 
HO~-~O 
HO 
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__ ,,-_- 0 
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Figure 1.1 The carbohydrate portion of the SLT liST receptor globotriosylceramide 
is a trisaccharide galactose a 1-4galactosep 1-4glucose. This trisaccharide is (1 ~ 1) 
linked to ceramide to form globotriosylceramide. 
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SL T 1 B chain has been crystallized (Hart el al (1991» and the structure determined 
by X-ray analysis (Stein et af (1992)). From these studies it was confirmed that the B 
chain associates as a pentamer. Each monomer of 69 amino acids is comprised of 
two three-stranded antiparallel p-sheets and an a-helix. p-sheets from adjacent pairs 
of monomers form six stranded anti parallel p-sheets at the outer surface of the 
pentamer and the five helices line a pore-like structure in the center of the pentamer. 
The pore is reported to be 11 ~ in diameter and is lined with neutral and non-polar 
residues. In this study they proposed that the carbohydrate binding site lay within a 
cleft formed by the p-sheets of adjacent monomers. This cleft is occupied by polar 
and acidic side chains which it is proposed could make hydrogen-bond interactions 
with polar groups of the carbohydrate. A schematic representation of the subunit 
composition of SLT 1 is given in figure 1.3. Several mutagenic studies of SL T/ST B 
chain are in good accordance with these data. lackson et af (1990) demonstrated that 
the residues Asp 17 and Lys 53 were important for receptor binding both oh\hich 
are found in the proposed carbohydrate binding cleft. Mutation of residues 
Gln64~Glu and Lys66~Gln in SLT IIv (VTE) (a variant ofSLT II which is 
specific for binding to globotetraosylceramide (Gb4) with terminal GaINAc~ 1-
3Gala 1-4Gal is seen to disrupt Gb4 binding and allow binding to Gb3, effectively 
changing the specificity of SL T IIv to that of SL T 1 (Tyrrell et al( 1992)). Residues 
64 and 66 are located at the lower portion of the carbohydrate binding site proposed 
by Stein et af (1992). Phaedria et af (1994) investigated the binding of SL T 1 B 
8 
subunit to the trisaccharide [methyI4-0-(4-0-a-D-galactopyranosyl)-4-0-P-D-
galactopyranosyl-p-D-glucopyranoside] and its constituent disaccharides. By 
Scatchard analysis of binding data they determined that the SL T I B pentamer has 
five identical non-interacting binding sites. On the basis of the thermodynamics of 
binding, optical spectroscopy and binding-induced protein aggregation they propose 
a model of SL T I membrane interaction which relies on protein-carbohydrate 
interaction for specificity and protein-lipid interaction for tight binding. 
The fatty acid content of the ceramide group of the Gb3 receptor is important in 
determining SL T I binding. The study of the requirements for toxin binding are 
complicated by the fact that heterogeneous mixtures of GB3 molecules with mixed 
chain lengths appear to bind SL T I more effectively than anyone homogeneous 
synthetic receptor (as measured by the TLC overlay assay) (Pellizzari et al (1992)). It 
is postulated by Pellizzari and colleages that the increased affinity is due to 
cooperative binding of isoreceptors present in Gb3 of mixed fatty acid content. These 
mixed isoreceptors would present a non-planar 'receptor surface' which may be a 
better fit for the three dimensional configuration of the pentameric binding site of the 
SL T I holotoxin. Changes in fatty acid composition can also change the overall 
orientation of the terminal carbohydrate moiety, which it is speculated, may 
profoundly affect its receptor function. The actual requirements for effective toxin 
receptor binding are still not fully understood although it also appears that the lipid 
9 
environment in which the receptor molecule resides is also important (Kiarash el a! 
(1994)). 
The A chain of ST/SLTs can be separated into two domains by a trypsin-sensitive 
region. Trypsin treatment generates two fragments-AI approximately 27,000Da and 
A2 approximately 4000Da, joined by a disulphide bond (O'Brien and LaVeck 
(1983)). The Al fragment has catalytic activity (Brown (1980» and residues within 
the A2 fragment are required for association with the B chain pentamer (Haddad and 
.Tackson (1993)). 
The crystal structure of ST holotoxin has been solved at 2.5 ~ resolution (Fraser el a! 
(1994)) (shown in figure 1.2). The arrangement of all six subunits is seen. The C-
terminus of the A subunit lies in the center of the ring of B subunits. The residues 
279-286 form an a-helix which is packed anti parallel to the five helices of the I3 
subunits. The helix is initiated at residue Asp278 at the helix cap position. The first 
three residues of the helix lie above the B subunit pentamer, the next six residucs 
(occupying lIA) penetrate the 20 2. pore. The last six residues (Arg288-Ser293) 
could not be seen in the structure. A mutagenic study of residues required for 
holotoxin assembly was conducted by Haddad and Jackson (1993) which also 
revealed the importance of re si dues 279-287 in stabilizing the holotoxin structure. 
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The disulphide bond which links the Al and A2 fragments after mild trypsin 
treatment was confirmed to be between Cys 242 and 261. As seen in figure 1.2 a 
portion of the A2 fragment lies on top of the B subunit pentamer. 
The major contacts between A chain and the B chain pentamer are residues of A2 
and a ~-hairpin structure from A 1. Half of the residues buried in the B subunit 
pentamer are from the C-terminal helix and this constitutes an area of about 1 OOO~2 . 
These data exclude any contacts made by the residues 288-293 for which density was 
not seen. Interaction between the A chain and the B pentamer is not symmetrical, the 
majority of the contacts between the pentamer and the A 1 portion of the A chain are 
primarily with just 3 of the five subunits. The residues involved in cleavage of toxin 
are thought to lie within a loop subtended by a disulphide bond. However the 
residues of this loop are not seen in the crystal structure. The reason for this is that 
either the loop is disordered and hence has no definable structure, or that during 
crystallization, the toxin became nicked. The disulphide loop is placed close to the 
active site since methionine residue 260 is seen to lie in the active site cleft. 
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Figure 1.2 Ribbon diagrams of Shiga toxin. 
The six subunits of the hexomeric ST holotoxin are shown with the A subunit in 
yellow above the five B subunits. The carboxy and amino terminals are labelled C 
and N respectively. The positions of the two cysteine residues Cys 242 and 261 are 
marked. The approximate position of residues Arg 220 and Arg 223 are also marked. 
The diagram was reproduced with the kind permission ofMarie Fraser.University of 
Alberta, Edmonton, Alberta, Canada. T6G 2H7 
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Figure 1.2 Ribbon diagrams of Shiga toxin. 
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The residues which form the active site are highlighted in the SL T 1 sequence in 
appendix 5. These include glutamic acid 167, tyrosine 114, tyrosine 77, alanine 168, 
arginine 170 and tryptophan 203. The active site was identified by using information 
from other ribosome inactivating proteins such as ricin A chain. The active site 
residues of Shiga toxin were identified prior to the X-ray crystal structure by 
sequence alignment and computer modelling (see appendix l)(Calderwood (1987); 
Deresiewicz et af (1992)) and by specific site-directed mutagenesis. Hovde et af 
(1988) found that mutation of glutamic acid 167, a residue conserved in the active 
site of ricin A chain, to aspartic acid reduced the protein synthesis inhibition activity 
of SL T 1 (taken from crude periplasmic extracts) by a factor of 1000. Deresiewicz et 
af (1993) mutated tyrosine 114 to serine and observed a reduction in activity of 500 
to 1000 fold as judged by testing (crude) extracts in protein synthesis inhibition 
assays. 
Many previous studies with ST/SLT have shown that proteolytic cleavage and 
separation of the two domains of the A chain is necessary for the full activity of the 
toxin in vitro. The crystal structure of ST provides a clear structural basis for this 
phenomenon. The residues 258-262 of A2 lie adjacent to the active site cleft and the 
side chain of methionine 260 is inserted into the active site of the enzyme. This 
structural feature explains why removal of the A2 portion of SLT/ST, including 
residue 260, results in an elevation in enzyme activity. 
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1.3 Purification of Shiga toxin and the Shiga-like toxins 
The purification of ST and the SL Ts has been critical in the biochemical 
characterisation of these toxins and the role they play in the onset of disease caused 
by Shigella dysenteriae and Shiga-like toxin-producing E.coli. Numerous methods 
have been described for their purification both from producer strains and from genes 
cloned into laboratory strains of E.coli. These protocols are of two main types. 
Early methods for toxin purification were based on multiple chromatography 
purifications. One such method described by Donohue-Rolfe et at (1984) was used 
for the purification of ST from a non-pathogenic strain of S. dysenteriae type 1 strain 
60R (Dubos and Geiger (1946)) This method used bacteria grown to the stationary 
phase at 37°C in iron-depleted syncase broth. A sonic lysate of the bacteria is 
subjected to Cibacron Blue F3G-A-Sepharose chromatography followed by 
chromatofocussing where Shiga toxin elutes in buffer pH 7.0-7.1. The final step of 
the purification scheme is molecular sieve chromatography with Bio-Gel P-60. Using 
this method, a yield of Img from a 4liter starting culture was obtained, with a 1300 
fold increase in toxin specific activity. 
More recently methods for the purification of ST and SL Ts have been described 
which take advantage ofthe specific binding of ST/SLTs to carbohydrates via the B 
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chain pentamer. Ryd et al (1989) describe the production and subsequent use of a-O-
galactose-(1 ~4)-p-O-galactose-(1 ~4)-P-D-glucose-(1 ~) (globotriose or Gb3) 
linked to polyacryllpolyvinyl (Fracto gel) for the purification of ST from Shigella 
dysenteriae type 1 strain 114Sd. A yield of 36mg of toxin from 12 liters of culture 
was purified in a single step by this method. A second receptor affinity method 
reported at the same time (Donohue-Rolfe et al (1989» used PI glycolipid isolated 
from the hydatid cyst fluid of sheep infected with Echinococcus granulosus. This 
glycolipid contains galactose a 1 ~4 galactose (to which ST could to bind (Jacewicz 
et al (1986», linked to activated Sepharose 48. In a similar method to that ofRyd et 
al (1989), they purified large quantities of ST in a single step. Analog affinity 
methods of ST ISL T purification prove very successful in the purification of these 
toxins, they are simple and relatively quick methods which yield highly pure 
preparations. 
1.4 Catalytic action of Shiga toxin and the Shiga-like toxins 
ST ISL Ts have potent RNA N-glycosidase activity comparable with that of the plant 
toxin ricin (Endo et al (1988». Once located within the cytosol of a eukaryotic cell 
this action leads to inhibition of protein synthesis followed by cell death. Thompson 
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et al (1976) provided the first evidence that ST inhibits protein synthesis in a cell 
free system using a partially purified ST preparation. Brown et al (1980) 
demonstrated that a pure preparation of Shiga toxin inhibits protein synthesis directly 
by studies using cell free protein synthesis systems. Since they saw elevated activity 
in the cell free system after treatment with strong denaturants and reducing agents it 
was proposed that Shiga toxin is synthesized as a proform. A 70 fold increase in ST 
activity was seen after treatment with 8M urea and 10mM DTT, they concluded that 
toxin requires activation prior to exerting its full activity. Reisbig (1981) 
demonstrated that Shiga toxin or a fragment of it could inactivate salt-washed 
ribosomes in simple buffered solutions at a rate of 40 ribosomes/minute. Ribosome 
inactivation does not appear to have a cofactor requirement since addition of 500~M 
NAD, ATP, NADP and NADH or addition ofpH5 supematant from salt washed 
ribosomes (containing elongation factors and aminoacyltransferases) did not increase 
the activity of toxin in vitro. Addition of antitoxin during these assays prevented any 
further inactivation but did not rescue activity already lost indicating that ribosome 
inactivation is irreversible. Endo et al (1988) determined the exact site of action of 
SL T 11 and ST. They observed that treatment of eukaryotic ribosomes with either 
toxin causes release of a 400 nucleotide fragment generated from the 28S ribosomal 
RNA when the isolated rRNA was treated with acetic-aniline. Analysis of the 3' 
fragment from cleaved rRNA showed that the adenine base at position 4324 is 
removed. They also demonstrated that treatment of rat liver ribosomes with toxin 
resulted in a loss of adenine as judged by thin layer chromatography. Depurination of 
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rRNA was correlated to inhibition of protein synthesis and of binding of elongation-
factor-I-dependent amino acyl-tRNA to ribosomes. They conclude that both SL T II 
and ST inactivate 60S ribosomal subunits by cleaving the N-glycosidic bond at 
adenine 4324 in 28S rRNA of the 60S ribosomal subunits. Furutani et al (1992) 
compared the modes of action of SL T and ricin and concluded that they are identical. 
Osbom and Hartley (1990) examined the effects of ricin A chain (RT A) on the 
partial reactions oftranslation of globin messenger RNA (m RNA) in a reticulocyte 
lysate system. They have shown that the primary block by RTA is the elongation 
factor 2-dependent stage. Since ST/SLT and ricin are thought to inhibit protein 
synthesis in an identical manner this is thought to be the mode of action of ST/SL Ts 
also. 
1.5 Common features of selected bacterial and plant toxins. 
The Shiga toxin family share many structural elements with other bacterial and plant 
toxins. This feature is important in structural studies of SL T as it allows predictions 
to be made about the function of structural elements of SL T by analogy with other 
toxins. 
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The most striking similarities with SL T are between cholera toxin (CT) and E. coli 
heat labile enterotoxin (LT). Since cholera toxin is considered to be the prototype for 
the heat labile enterotoxins (Finkelstein (1988)), only this toxin will be considered 
here. Like SL T, cholera toxin is a bipartite toxin comprised of a single catalytic A 
chain and a pentamer of cell binding B subunits. Cholera toxin has been crystallized 
(Spangler (1989)) and the high resolution structure published (Zhang et at (1995)). 
With the structures of CT and LT available (Sixma et at (1991) ; (1992)) the 
structure of the holotoxin and the receptor binding sites can be seen. The overall 
structural arrangement of the six subunits of CT is identical to that of SL T. Like 
SLT, CT is proteolytically processed at the junction of the AI-A2 domains. The 
location at which this processing occurs however is different, CT being nicked by a 
protease produced by V. cholerae hemagglutinin / protease (Booth et at (1984)). 
Hence under normal conditions, the toxin only encounters target cells in the nicked 
form. This is in contrast to SLT which is secreted to the E.coli periplasm in the 
unnicked form and is thought to be processed later during transport in the target cell 
(Burgess and Roberts (1993); Garred et al (1995a)). As with SLT, CT A interacts 
with its cell binding pentamer via an A2 domain which inserts into a pore formed by 
the B chain pentamer. Studies have shown that treatment of the nicked holotoxin 
with reducing and mild denaturing agents can remove the CT A 1 portion leaving, the 
CT A2-B5 portion intact (Mekalanos et al (1979)). This demonstrates that the CT Al 
is not required to maintain the non-covalent interaction between the A2 domain and 
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the B chain pentamer. In a later study the A2 portion of eT was expressed as a fusion 
with bacterial alkaline phosphatase (BAP), maltose binding protein (MAP) or 13-
lactamase (BLA) and all three fusion proteins were able to bind to GM1 ganglioside 
(the eT receptor) and the enzyme markers retained activity. This provides further 
evidence that the A2 portion of eT is responsible for the interaction with its B chain 
and that the A I portion is not required to form any of the essential non-covalent 
contacts (Jobling and Holmes (1992». When these fusion proteins are expressed in 
Vibrio cholerae they are found in the periplasm rather than being exported as normal 
to the external medium. This suggests that the Al domain may be involved in toxin 
transport across the bacterial outer membrane. However, the possibility that the 
foreign protein domains fused to eT prevents membrane translocation is also 
probable. The function of the catalytic domain of eT is different to that of ST. eT 
Al catalyses the ADP ribosylation of Gsa, and GTP-binding protein that functions to 
regulate a component of the plasma membrane adenylate cyclase system, and 
ultimately acts to activate adenylate cyclase (Gilman (1984». Despite their 
difference in function and receptor specificity, the overall structural arrangements of 
SL T and eT are extremely similar. A detailed comparison ofthe B chain pentamers 
of SL T and heat labile enterotoxin was carried out by Sixma et al (1993). Despite an 
almost complete absence of sequence homology between the two pentamers, 
structural features are highly conserved, with seven out of eight secondary structure 
elements of the pentamers being retained in the two toxins. 
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Pseudomonas exotoxin A is a bipartite A-B structure toxin from Pseudomonas 
aeruginosa, the three dimensional structure for which was solved by Allured et al 
(1986). PE is translated as a single polypeptide that has both catalytic and cell 
binding domains. During toxin entry the protein is separated into two domains by 
proteolytic activation at a protease sensitive site which remain linked by a disulphide 
bond (Ogata et at (1990)). Numerous mutagenic studies have identified the 
functional domains of PE. Residues 1-252 (domain la) constitutes the cell binding 
domain, deletion of these residues prevented binding to cells (Hwang et at (1987)). 
Domain 11 residues 253-364 contains a disulphide-bonded loop in which two trypsin-
sensitive arginines lie (Ogata et at (1990)). Mutation ofthese Arg residues reduces 
cytotoxicity by preventing intracellular processing of the toxin and release of a 
catalytic portion capable of membrane translocation. A second site within domain II 
is thought to be responsible for membrane translocation of a catalytic fragment 
across an internal membrane. Alanine residues 339 and 343 are implicated in this 
function because mutation to glycines still results in the generation of a catalytic 
fragment during target cell entry but cytotoxicity is eliminated suggesting that the 
mutant catalytic fragment can not reach its cytosolic target (Siegall et al (1991)). 
Furthermore fusion of domains I and II of PE with the ribonuclease bamase results in 
a cytotoxic fusion protein presumably capable of translocation to the cytosol (Prior et 
aI1992).The C-terminal domain of PE contains catalytic activity. Its function is the 
ADP-ribosylation of cytosolic EF-2 thus preventing host cell protein synthesis 
(Carroll and Collier 1987). The structural elements of PE described can be seen to 
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have analogous elements in the SLT structure. For example, a cell binding domain 
analogous to that of the SL T B pentamer and a catalytic domain which must be 
cleaved away from other elements of the toxin in order to be fully cytotoxic similar 
to the Al domain in SLT. A translocation domain for SLT has not been identified. 
Diphtheria toxin (DT) provides another example of a bipartite A-B structure toxin. 
Like PE, DT is translated as a single polypeptide 62,000 Da (Gill and Dinius (1971); 
Collier and Kandel (1971)). DT, like other A-B toxins, can be cleaved into two at a 
surface exposed protease-sensitive loop subtended by a disulphide bond. The loop 
contains three arginine residues and is sensitive to nicking by trypsin and bacterial 
proteases (Michel et af (1972); DeLange et af (1976)). Sandvig and Olsnes (1981) 
demonstrated that DT required proteolytic cleavage in order to express its full 
cytotoxicity. The DT structure consists of three domains, the N-terminal catalytic 
domain (C-domain), the transmembrane domain (T-domain) and the C-terminal 
receptor binding domain (R-domain) (Choe et af (1992); Bennett et af (1994)). The 
C-domain is the portion which enters the cytosol and ADP-ribosylates the side chain 
of the residue diphthamide, a post-translationally-modified histidine of EF -2 (Van 
Ness et af (1980)). After secretion from Corynebacterium diphtheriae and possible 
extracellular cleavage within the disulphide bonded loop between the C and T 
domains, DT binds to the DT receptor at the surface of target cells via a p-hairpin 
loop in the R domain (Shen et af (1994)). Internalization to the acidic endosome 
follows (Morris et af (1985)) and the T domain facilitates the translocation of the C 
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domain across the membrane. From solution of the crystal structure at 2.5 ~ (Choe el 
al (1991» a model for membrane translocation has been proposed. It is thought that 
the T domain is able to penetrate the membrane in such a way as to form a pore 
structure through which the catalytic domain can translocate. The charge of two 
helices within the T domain is highly pH dependent, in the low pI I environment of 
the endosome two of the helices in the T domain become neutral in charge due to 
partial protonation. It is proposed that following exposure to low pH the tips of these 
two helices become "membrane soluble daggers" which lead the apolar helix pairs 
into the membrane. Further experimental evidence for this model was provided by 
10hnson el al (1993) where mutation of proline 345, a residue known to undergo a 
cis/trans isomerization reaction and thus thought to play a role in conformational 
changes seen when OT enters a low pH environment, was seen to reduce the 
cytotoxicity of the toxin by 100 fold. 
The plant toxin ricin is a potent cytotoxin found in castor oil plant seeds (Stillmark 
(1888». Ricin is isolated as a heterodimer, consisting of a 32 OOOOa A chain 
glycoprotein linked by a disulphide bond to a 32 OOOOa B chain glycoprotein 
(Olsnes and Pihl (1976». The B chain of ricin has lectin activity and can bind cell 
surface galactosides (Olsnes and Pihl (1982». The A chain has catalytic activity and 
is responsible for the RNA N-glycosidase activity of ricin (Endo et al (1987» 
identical to that of ST/SL T 1. The crystal structure of ricin was solved at 2.8 A by 
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Montfo11 et af (1987) and more recently refined by Rutenber et af (1991) to 2.52.. 
The A chain of ricin has some homology to that of SL T 1 (appendix 1 contains an 
alignment of the active site residues of SL T and ricin). The region of homology lies 
between the active sites of the two proteins. In a stretch of73 amino acids, the two 
proteins have identical residues in 32% of positions and either identical or 
chemically similar residues in 53% of positions. Using the Chou-Fasman algorithm, 
virtually identical secondary structure predictions for the two proteins in the active 
site region were made (Calderwood et af (1987)). Interestingly this was one early 
indication of evolutionary relationships between prokaryotic and eukaryotic toxin 
genes. The B chains of ricin and SL T 1 have no sequence homology. However both 
serve the function of binding the toxin moiety to different cell surface molecules and 
may also be involved in later translocation events. Proteolytic processing of mature 
ricin A chain (RT A) has been reported by (Fiani et af (1993» in macrophages. 
However, this work has not been repeatable (Argent (1995» and it is considered in 
the absence of other data that R TA remains intact during intoxication. Ricin provides 
another example of the bipartite A-B family of toxins to which SL T 1 conforms. 
Several experiments have demonstrated that isolated domains from bacterial toxins 
have specific functions. These isolated domains can be transferred from one protein 
to another. For example the translocation domain of PE, domain 11. was fused with 
the ribonuclease barnase. This protein fusion was potently cytotoxic and thus it was 
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proposed that domain 11 of PE was sufficient for translocation of toxin into the 
cytosol of target cells (Prior et al (1992)). In a similar experiment Guidi-Rontani 
(1992) fused domain 11 of PE with the catalytic A domain ofDT. This chimeric toxin 
was cytotoxic demonstrating that domain 11 of PE is sufficient to direct and 
translocate an enzymatically active heterologous polypeptide segment into the 
cytosol of sensitive cells and that the A fragment of DT alone contains the catalytic 
function. In SL T 1 residues involved in carbohydrate recognition were identified by 
mutation of specific residues of SL T 1 B to the equivalent residues in SL T 11 v B 
(Tyrrell et at (1992)). The resultant mutant SL T 1 toxin became specific for binding 
to the trisaccharide Gb4 as opposed to the natural SL T 1 receptor Gb). These 
experiments and those discussed previously highlight the similarities between a 
diverse group of toxins. By studying the toxins as a group a general theme emerges. 
All the toxins discussed contain cell binding domains analogous to SL T 1 B and a 
catalytic domain analogous to SLT AI. In addition in several cases a translocation 
domain has also been identified. By analogy with the toxins discussed it seems 
reasonable to assume that a translocation domain for SL T / ST is also present, 
however such a domain has not yet been delineated. 
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Figure 1.3 Schematic representation of the subunit compositions of 
selected bacterial and plant toxins. 
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1.6 Proteolytic processing of SLT/ST: Possible analogy with other 
bipartite toxins. 
All the toxins discussed in section 1.5 with the notable exception of ricin, which is 
cleaved in the seed to the mature form, appear to show an absolute requirement for 
proteolytic processing in order to generate a catalytic fragment which presumably is 
capable of translocating an internal membrane. The need for proteolytic processing 
of SL T 1 is the main area of investigation in the present study. The study of 
intracellular processing during intoxication with bacterial toxins has been a field of 
considerable interest in recent years. Observations that many of the bacterial toxins 
isolated included at least a proportion of nicked toxin led to the hypothesis that these 
toxins were extremely sensitive to proteases. Improved methods of purification and 
advances in recombinant protein expression have led to the production of unnicked 
samples of bacterial toxins and this has allowed their detailed study with respect to 
the need for proteolytic activation. With the exception of cholera toxin, a single 
mammalian protease has been implemented in the processing events which take 
place during intoxication of eUkaryotic target cells with bacterial toxins. The protease 
responsible is the ubiquitous, subtilisin-like endoprotease furin (for review see BaIT 
(1991a)). 
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Furin has a broad pattern of tissue expression and is conserved amongst eukaryotic 
species (Schalken et al (1987); Barr et al (1991 b». The role offurin is to cleave 
mammalian prohormones and proproteins such as human proinsulin and chicken 
proalbumin (Brennan and Peach (1991 ». It is a dibasic endoprotease which cleaves 
after the sequence R X RIK R (Barr (1991a» with a minimum requirement for 
RXXR (Watanabe et at (1993». Furin has been localized primarily to the trans-Golgi 
(Bresnahan et at (1990); Misumi et at (1991» however other reports indicate that 
furin has a more extensive cellular location (Tsuneoka et at (1993); Klimpel et al 
(1992»). 
One well studied example of bacterial toxin processing is that of Pseudomonas 
exotoxin A. Native PE is a proenzyme and to detect its ADP-ribosylation activity in 
biochemical assays it has to be treated with urea and dithiothreitol to partially unfold 
the protein (Leppla et al (1989); Lory and Collier (1980». A study by Ogata et al 
(1990) used radiolabelled PE to track the processing events which occur during 
intracellular uptake and translocation to the cytosol. Their results showed that PE is 
cleaved within domain 11 near Arg 279. This cleavage site is within the disulphide 
loop region and reduction is seen to follow proteolysis. A 37,000 Da fragment is 
released when Swiss 3 T3 cells are incubated with radiolabelled toxin. They 
determined that this fragment is generated from the C-terminus by comparing the 
fragments produced by cells following intoxication with N-terminalIy and C-
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terminally labelled toxin. A mutant form of PE where Arg 276 is changed to Gly is 
1000 fold less toxic to cells. Incubation of this mutant with cells revealed that it is 
not proteolytically processed to the 37 kDa size. Further investigation showed that 
the 37 kDa fragment is the only PE-related fragment which can be detected in the 
cytosol following wild type PE intoxication. They conclude that proteolytic 
processing of PE is required for cellular intoxication. This processing was said to 
occur after Arg residues within the disulphide loop of domain 11 and, following 
proteolysis, a 37 kDa fragment was believed to translocate to the cytosol. 
More recent studies have revealed that furin is the proteolytic enzyme involved in PE 
processing. Fryling et al (1992) showed that the protease responsible is associated 
with membranes and is stimulated by divalent ions. This protease is independent of 
A TP and has a pH optimum of 5.5. Inocencio et al (1994) have demonstrated that a 
Chinese hamster ovary cell line resistant to PE is mutated within the furin gene. This 
cell line can be made susceptible to PE by transfection of a mouse furin expressing 
cDNA gene (Moehring et aI1993). 
Diphtheria toxin has an identical catalytic mechanism to that of PE. Its activity in 
vitro relies on proteolytic cleavage and separation of a 21 kDa fragment from the rest 
of the toxin (Collier and Kandel (1971)). Sandvig and Olsnes (1981) purified 
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unnicked DT and were able to show that nicked DT is more toxic and that it inhibits 
protein synthesis more quickly than unnicked toxin. Furin-cleavage of DT was 
demonstrated by Tsuneoka et al (1993), providing evidence that DT can be cleaved 
in vitro by soluble furin. The cleavage site for furin is proposed to be between Arg 
193-Ser 194. This site conforms to the minimal consensus recognition sequence for 
furin (Watanabe et al (1992» and is located in a disulphide loop shown in the crystal 
structure to be exposed on the protein surface (Choe et al (1992». Furthermore, 
using an approach similar to that of Moehring with PE (Moehring et at (1993», 
Lo Vo cells, a human colon carcinoma cell line which lack functional furin, were 
incubated with DT. Lo Vo cells were known to be resistant to intoxication with DT 
whereas Lo Vo cells transfected with a mouse furin expressing cDNA were 
susceptible. It has been reported that DT can also be nicked by furin at the cell 
surface and in the culture medium in addition to nicking in endosomes (Tsuneoka et 
al (1993». These results challenge previous studies which indicate that furin is 
located primarily in the trans-Golgi Network (Bresnahan et al (1990); Misumi et al 
(1991» though it is not clear whether such external enzyme represents a very minor 
fraction offurin which has escaped the TGN. 
Perhaps the first evidence of the involvement offurin in toxin activation was 
provided by the study of anthrax toxin protective antigen (P A). The causative agent 
of anthrax is Bacillus anthracis. It produces three proteins which, when combined 
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appropriately, form two toxins. P A and edema factor combine to form edema toxin 
and P A and lethal factor form lethal toxin. The two toxins are known collectively as 
anthrax toxin and both conform to the A-B structure toxin model (Leppla (1991 )). 
For intoxication to take place, PA must bind to the cell surface where it is processed 
by proteolytic cleavage. The bound, activated PAis then able to form ion-conducting 
channels in cells (Milne and Collier (1993)). Release of a 20kDa fragment allows 
binding ofLF or EF to form ET or LT (Leppla et al (1988)) which is then 
internalized by receptor-mediated endocytosis (Freidlander (1986); Gordon et af 
(1988)). The cleavage ofPA occurs after the sequence ArgI64-Lys-Lys-ArgI67 
(Singh et af (1989)). Mutagenesis revealed that the toxin must contain the sequence 
R-X-X-R i.e. Arg residues in the -I and -4 positions in order to be cytotoxic 
(Klimpel et af (1992)). In the same study it was demonstrated that PAis a substrate 
for furin in vitro and known inhibitors of furin prevent cell surface cleavage of P A. 
The processing events described are thought to occur at the cell surface, another 
indication that furin has a ubiquitous cellular location. They concluded that PAis 
proteolytically-processed by a protease indistinguishable from furin. 
A recent study by Gordon et al (1995) has provided evidence that P A and DT are 
cleaved by at least one protease other than furin. It was showed that in contrast to the 
work of Tsuneoka et al (1993), LoVo cells are sensitive to DT using longer 
incubation periods than studied previously. A mutant CHO cell line (FDl1) which is 
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furin-deficient, is also sensitive to DT and P A but not to a P A mutant with the wild-
type cleavage sequence R-K-K-R mutated to R-A-A-R (a cleavage site which does 
not contain a paired dibasic sequence). They conclude that the sensitivity of this 
mutant and of DT is due to proteolytic processing by a second enzyme distinct to that 
of furin which is capable of recognizing paired dibasic sequences. So, although DT 
can be cleaved by furin in vitro, furin may not exclusively nick this toxin in vivo. 
Cholera toxin has a similar structure to that of heat labile enterotoxin from 
Escherichia coli with a 80% homology between the A chains (Dallas and Falkow 
(1980». Despite a lack of sequence homology between CTIL T and SLT these two 
toxins share remarkable homology with the tertiary structure of SL T 1. Both toxins 
are seen to require proteolytic cleavage prior to target cell intoxication (Fisherman 
(1982); Clements and Finkelstein (1979». However, in contrast to Escherichia coli 
heat labile enterotoxin, cholera toxin is secreted from the bacterium in a cleaved form 
(Booth et al (1984», whereas Escherichia coli heat labile enterotoxin (LT) is 
produced largely in the unnicked form. By analogy with CT, studies have been 
conducted to compare the activity ofunnicked LT with that of nicked LT. It is 
reported that nicked LT has greater activity in the skin permeability test than 
unnicked toxin (Rappaport et al (1976». Experiments with LT intoxication of cells 
have produced conflicting results. Unnicked toxin appears less toxic to YI adrenal 
cells than nicked toxin (Donta et al (1982» but not to CHO cells (Tsuji et al (1984». 
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This evidence may suggest that Yl cells are disabled in their ability to process LT. A 
more recent study demonstrates that mutation of Arg 192 to Gly (the residue thought 
to be susceptible to trypsin cleavage in vitro) does not reduce the cytotoxicity to 
CHO cells by a large amount. A slight decrease in the rate of intoxication and a 4 
fold reduction in cytotoxicity between unnicked R192-G protein and trypsin nicked 
wild-type protein was observed (Grant et al (1994)). These results do not rule out 
processing which may occur at a site other than Arg192. In fact LT contains a furin 
consensus motif at amino acid residues 141-146 which is highly conserved amongst 
all LT variants (Pickett et al (1989)). The data regarding proteolytic activation of LT 
remains ambiguous and more in vivo experiments are required to clarify its role in 
toxin activation. 
As discussed in section 1.4, ST and SL T 1 only display full protein synthesis 
inhibition activity after separation of the cell binding B subunits and the A2 region 
away from the catalytic Al domain. Like many other bacterial toxins, ST/SLT 1 
display the structural features of typical A-B toxins. By analogy with other bacterial 
toxins it seems reasonable to suggest that ST ISL T 1 also have a requirement for 
proteolytic activation. In common with PE, DT, PA and LT, SLT/ST have 
disulphide-bonded protease-sensitive loops which contain minimal furin recognition 
sequences. Kongmuang et al (1988) investigated the effect of nicking of SL T 1 on 
toxicity to Vero cells. Trypsin-treated and intact SL T 1 were incubated with Vero 
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cells, however no increase in cytotoxic activity between nicked and unnicked toxin 
was reported. Whether toxin was nicked intracellulary however was not investigated. 
SLT I contains the sequence R248-V-A-R25I in the exposed loop region. Burgess 
and Roberts (1993) made a mutant SL T 1 R248, R25I ~G248,G251 which is more 
resistant to trypsin in vitro but is only 10 fold less toxic to Vero cells than the wild 
type when incubated with cells for 3 hours or less. It was found that if the incubation 
period is extended the mutant appears as toxic as wild-type protein. Garred et al 
(1995a) mutated the same loop arginine residues of ST and converted them to 
histidines. They demonstrated by direct visualisation that the mutant ST is still 
cleaved during Vero cell intoxication and that the AI-sized fragment generated 
appears identical in size to that generated from the wild-type toxin. In contrast to the 
processing of ST wild-type, the mutant is not processed in cells pretreated with the 
fungal metabolite brefeldin A. Brefeldin A (BF A) causes disassembly of the Golgi 
apparatus and thus prevents transport through the Golgi (Fujiwara et al (1988); 
Lippincott-Schwartz et al (1989)). They concluded that the mutant protein is 
processed more slowly and that for this to occur the toxin must reach a later cellular 
compartment. They also observed that the mutant toxin is not processed in the 
presence of the membrane-permeable calpain inhibitor I where as the wild-type toxin 
is unaffected by treatment of cells with this inhibitor. From these data they conclude 
that in the absence of the most likely cleavage site in ST, the protein can still be 
processed by an alternative protease which is inhibited by calpain inhibitor 1. It isn't 
clear from the current literature as to what structural features are recognised by the 
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ubiquitous Ci+-requiring enzyme, calpain, nor is the cellular location of this enzyme 
confirmed, though it is generally believed to be cytosolic (for a recent review see 
Suzuki et af (1995». From the intoxication time-points used in the study by Garred 
et af (1995a), namely two and four hours, it is conceivable that toxin has by this 
stage reached the cytosol. That cleavage by calpain might occur in the cytosol to 
activate the reduced Al fragment by causing its release from the A2-Bs complex, 
suggests that holotoxin itself might be capable oftranslocating an internal 
membrane. In the present investigation, shorter incubation times oftoxin mutants 
with cells have been used in an attempt to distinguish any processing in the endocytic 
pathway from possible processing in the cytosol. 
In a separate study by Samuel and Gordon (1994), the loop arginines in SLT IIv were 
mutated to glutamic acid or histidine residues, toxin labelled with 1251 was used to 
trace toxin processing in target cells. Since the mutant toxins made in this study 
remained cytotoxic but were processed less efficiently they concluded that 
proteolytic toxin activation can be mediated by proteases with different specificities 
to those which cleave the wild-type protein and that efficient cleavage is not required 
for toxicity. 
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Garred et al (1995b) demonstrated that wild-type ST can be a substrate for furin in 
vitro and that Lo Vo cells nicked wild-type ST more slowly than Lo Vo cells 
transfected with a furin expressing cDNA. LoVo cells pretreated with BFA or 
calpain inhibitor I were not able to nick mutant ST (Garred et al (1995b )). This 
report clearly demonstrates that furin is the enzyme normally responsible for efficient 
cleavage of ST in Lo Vo cells but that other cellular proteases can also cleave the 
toxin, albeit less efficiently. 
In a report by Takao et al (1988) the molecular structures of SL T 1 and ST were 
compared. By performing Edman degradation of trypsin-generated fragments of ST 
it was observed that the toxin is nicked between Ala 253 and Ser 254. Since this 
nicking could not have been performed by trypsin they concluded that the ST 
preparation was pre-nicked at this site. The fragments generated by this nicking were 
linked by a disulphide bond. Since mutation of the residues Arg 248 and Arg 251 
(Garred et al (1995a)) did not result in a protein totally resistant to proteolytic attack 
it is hypothesized that the Ala Ser residues in the loop region may constitute sites for 
alternative processing. The disulphide loop of SL T 1 contains two pairs of Ala-Ser 
residues either side of the proposed nicking site Arg248-Arg251. In this study the 
possible relevance of these residues in the proteolytic activation of SL T 1 is 
addressed by mutating them to glycine and serine residues. In addition, a second 
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potential furin-recognition site located upstream at residues Arg 220-Arg223 is also 
investigated. 
Clearly in comparison with other bacterial toxins the number of reports on SL T 1ST 
processing are limited. The only report where protease-resistant mutants have been 
constructed, expressed and visualized in cells has shown that the mutant protein 
remains sensitive to host cell proteases (Garred et al (1995a). This report, and others 
using either similar SLT mutants (Burgess and Roberts (1993); Samuel and Gordon 
(1994)) or using protease-deficient cells (Garred et al (1995b)), have yielded 
information about the physiological events which may occur during target cell 
intoxication. However there is no literature to address whether the proteolytic 
separation of the A2 domain away from Al is a absolute requirement for intoxication 
and whether the A2 domain provides an efficient block to activity in vivo. In the 
present study mutant SL T 1 proteins which are apparently resistant to host cell 
proteases are described. The mutant proteins remain cytotoxic in the apparent 
absence of intracellular proteolytic cleavage. The implications of this for the 
membrane translocation of SL T 1 and ricin are discussed. 
1.7 Endocytosis, intracellular trafficking and membrane 
translocation of SLT/ST and ricin. 
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ST/SL T and ricin enter cells via receptor-mediated endocytosis (Sandvig et al 
(1989); van Deurs et al (1986); van Deurs et al (1988». Receptor binding sites for 
ST are located randomly on the cell surface. However following treatment of target 
cells with ST at 37°C the binding sites become localized in coated pits. Horse radish 
peroxidase conjugates and colloidal gold conjugates have been used to trace toxin 
endocytosis and transport. Ricin appears to be endocytosed by clathrin-dependent 
and clathrin-independent endocytosis (Sandvig et al (1982» whereas ST appears to 
be internalized exclusively by the clathrin-dependent mechanism (Sandvig et al 
(1989». The reason for ST being endocytosed by the clathrin-dependant mechanism 
only is unclear. However this may be due to interactions of the multivalent receptor 
binding sites on ST with the glycolipid receptors and with underlying coat and 
plasma membrane proteins. These interactions may be strong enough to ensure that 
the toxin remains in coated pits. The mechanisms by which clathrin-independent 
endocytosis occurs are still unclear. A complete understanding of these processes 
will inevitably reveal the significance between the two mechanisms. 
Transport to or through the Golgi complex appears to be important for intoxication 
of target cells with ST/SLT and ricin. Following endocytosis, toxin conjugates are 
seen in endosomes, lysosomes and in the Golgi region (van Deurs et al (1986); 
Sandvig (1989». In the case of ricin the pattern of labelling can be dependent on the 
type of conjugate used. For example, ricin conjugated to HRP (ricin-HRP) in 
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polyvalent complexes or ricin conjugated to gold (ricin-Au) is not seen in the Golgi, 
whereas monovalent complexes ofricin-HRP and native ricin are seen in the Golgi. 
There are several other lines of evidence which suggest a role for the Golgi complex 
in ricin and ST/SL T intoxication. Youle and Colombatti (1987) demonstrated that a 
hybridoma cell line expressing anti ricin B chain antibodies is less susceptible to 
intoxication by ricin than a hybridoma which does not express the anti ricin JgG. By 
ruling out cell surface neutralization with a series of controls they conclude that ricin 
must meet the antibody on the secretory pathway presumably at a point where 
secretory and endocytic pathways converge, possibly the trans-Golgi network. 
Transport to the Golgi is inhibited at 18°C (Sandvig et at (1986); Deurs et at (1987». 
and cells are protected from both ricin and ST at this temperature (Deurs et at (1987); 
Sandvig et at (1989» but are not protected from DT which is known to enter the 
cytosol from acidified endosomes (Sandvig et al (1984». Perhaps more 
compellingly, brefeldin A (BF A), which disrupts the Golgi stack in Vero cells 
preventing transport from the TGN to the Golgi stacks and ER, protects cells from 
ricin and ST (Sandvig et at (1991); Yoshida et al (1991». Since it is conceivable that 
BF A has, as yet ill defined pleiotropic effects, an even better approach has been to 
block specific transport steps using trans-dominant interfering mutants. Simpson et 
al (1995a) disrupted ER to Golgi trafficking by expressing mutants of Sar 1, intra-
Golgi trafficking by expressing mutants of ARF 1 and early Golgi trafficking by 
expressing mutants of Rab 1. In all cases a significant protection against ricin was 
observed. E.coli SLT 1 likewise was also protected (unpublished data). These data 
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together suggest that ricin and ST/SLT must either travel to or through the Golgi 
stack or that they must receive a secreted component while they are located within 
the TGN, possibly a molecule to assist translocation from the TGN. It has been 
postulated that transport through the Golgi stack and delivery to the ER is required 
for ricin, PE, ST and SLTs (Pelham et af (1992) .This begs the question can these 
toxins ever be seen within this compartment? 
Visualization of toxins in the ER has proven difficult presumably because in so many 
cases so little toxin is expected to reach this organelle. In several reports (Sandvig et 
al (1992); Sandvig et al (1994)) ST has been demonstrated visually in the ER. In the 
first description of this, A431 cells had been sensitized to ST with (2mM) butyric 
acid. Butyric acid sensitizes some insensitive cell lines to ST by altering the 
composition of fatty acid chains in the ST receptor (Sandvig et al (1994)). ST-HRP 
complexes were clearly seen in endosomes, Golgi, endoplasmic reticulum and in the 
nuclear envelope following intoxication of A431 cells pretreated with butyric acid 
(Sandvig et af (1992)) The fact that this appearance of toxin in the ER was correlated 
with acquisition of toxin sensitivity led to the belief that for ST at least, the ER was 
the translocation compartment. In the later study both ST-HRP and the ST B chain-
HRP alone were observed in the ER following intoxication of A431 cells pretreated 
with butyric acid or with cAMP. These data suggest that the ST B chain is capable of 
transport from the cell surface to the ER in a retrograde manner in the absence of the 
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A chain, and that this transport is regulated by fatty acid composition of the receptor 
molecule and by physiological signals. 
Ricin has not been visualized in the large volume of the ER by the same methods and 
this may reflect the quantity of toxin reaching this destination compared with ST. 
However there is evidence which supports the hypothesis that ricin like ST requires 
transport in a retrograde manner to the ER in order to translocate to the cytosol. The 
data includes that described above (BF A effects and protection against intoxication 
by mutants of early regulators of secretory vesicle transport). As stated earlier 
however, these data only suggest a routing of ricin through the Golgi. They can also 
be interpreted to mean that for ricin, a factor must reach it in the TGN by normal 
anterograde transport, a process disrupted by BF A and the trans-dominant mutants. 
For ricin to reach the ER it presumably needs to interact with a recycling component. 
The most well defined recycling component is the KDEL-receptor, first identified in 
yeast as the erd2 gene product (Semenza et at (1990); Lewis et at (1990)), the human 
homologue of which was described by Lewis and Pelham (1990). The KDEL-
receptor has been located throughout the Golgi and is present, albeit in very small 
amounts, even within the TGN. It is known to retrieve escaped ER residents 
throughout the Golgi stack (Pelham (1988); Pelham (1990)). One of these retrieved 
proteins appears to be CaBP3-calreticulin which is galactosylated (Peter et at 
(1992)). There may be other examples of galactosylated ER residents that remain to 
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be discovered. It has therefore been hypothesised that ricin in the TON may 
encounter many newly galactosylated proteins, some of which, like calreticulin, may 
be ER escapees that are retrieved by the circulating KDEL-receptor and returned to 
the ER. A very small proportion of the TON-located ricin may therefore piggy-back 
to the ER using a carrier (like calreticulin) bound to the KDEL receptor. It has been 
observed that intracellular galactose-binding is important for full cytotoxicity of ricin 
(Newton et al (1992), a finding compatible with this model. Of course,not all toxins 
may need such an indirect association with the KDEL-receptor. PE has a C-terminal 
tail (REDLK) which, if the C-terminal K is processed intracellularly, resembles the 
endoplasmic reticulum retention sequence KDEL (Munro and Pelham (1987». This 
REDLK sequence is essential for toxicity and is thought to mediate transport of the 
toxin through the Golgi to the ER via a direct interaction with the KDEL receptor 
(Chaudhary et al (1990». Interestingly, CT and LT have C-terminal KDEL and 
RDEL sequences respectively and may use the same strategy to reach the ER. 
Addition of a KDEL sequence to either whole ricin (Wales et al (1992» or to the A 
chain (Wales et al (1993» increases its cytotoxicity suggesting that ricin is at least 
capable of transport to the Golgi where it can be "seen" by the KDEL receptor and 
that it possibly travels to the ER via an indirect association with this membrane 
component. The findings here also suggest that the TGN is probably not the site of 
ricin translocation. If the TON was the site of toxin entry to the cytosol then addition 
of a KDEL tag leading to a presumed retrieval to the ER, should result in a decreased 
rather than an increased potency. Therefore of the two interpretations mentioned 
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earlier, the model of ricin moving through the Golgi to the ER remains the current 
favourite. 
The ER is an attractive compartment for membrane traversal since it contains cellular 
machinery which may aid the translocation of a toxic fragment. This organelle is 
known to contain the enzyme protein disulphide isomerase (Freedman (1989)) which 
could effect disulphide bond reduction, as well as molecular chaperones (Gething 
and Sambrook (1992)) and a complete apparatus for translocation of nascent proteins 
and peptides. It has been proposed that these factors may be required for the reverse 
translocation of certain toxins (Pelham et af (1992)). 
Domains responsible for translocation of an internal membrane have been identified 
in PE and DT. The best studied of these examples is DT which translocates the 
endosomal membrane to reach its cytosolic target (Sandvig et af (1984)). The low pH 
environment of the endosome is important for the insertion of the DT B-fragment 
into the membrane (Moskaug et af (1991)). Translocation ofDT can be mimicked at 
the plasma membrane by exposing cells to low pH (Sandvig and Olsnes (1980)). 
Exposure to low pH is seen to induce partial unfolding of the toxin molecule 
(Dumont and Richards (1988); Jiang et af (1991)). Consistent with this idea, it has 
been found that internal disulphide bonds introduced to the A fragment of DT, to 
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prevent unfolding, resulted in a significant reduction in the level of translocation 
either after endocytosis or when surface bound toxin is exposed to low pH (Falnes et 
af (1994)), data which suggests that the low pH-induced unfolding is physiologically 
relevant to membrane traversal. In addition to unfolding, low pH is thought to be 
responsible for the insertion of a-helical domains into the membrane which its 
proposed initiates membrane translocation (Gray et af (1993); Moskaug et af (1991 )). 
The intense study of the translocation of DT has led to a good understanding of the 
mechanisms involved in membrane traversal. However, DT appears to be a unique 
case since it translocates from the endosome and simply requires a low pH to induce 
the relevant conformational changes. As previously described, other well studied 
bacterial and plant toxins do not translocate from the endosome but may translocate 
from more distal intracellular compartments. These proteins, like ST,SLT and ricin 
cannot be induced to translocate the plasma membrane by exposure to low pH. For 
these reasons caution must be used in extrapolating results obtained with DT to 
ST/SLT and ricin. 
A translocation domain in PE has been roughly delineated (Siegall et af (1991); Prior 
et af (1992)). In the later report, domains I and 11 of PE are shown to be capable of 
translocation of the ribonuclease protein bamase into cells which have the PE 
receptor. Its suggested that this fusion protein binds to target cells via the cell 
binding domain I. Translocation is attributed to domain n. However no direct 
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evidence of membrane translocation is presented other than the measurement of 
cytotoxicity of this fusion. 
Specific translocation signals or domains as yet have not been identified for ST/SL T 
and ricin although some recent work has indicated the importance of certain C-
terminal residues of ricin A chain that appear to impede the translocation event 
(Simpson et al (1995b ». However it is always difficult in the absence of a direct 
translocation assay to be certain that protein stability, routing etc. have not been 
affected and that any reduction in cytotoxicity observed is exclusively due to a block 
in membrane transport. The situation is further complicated by the fact that some of 
these toxins may translocate an active fragment from the ER possibly with the help 
of their cell binding B subunits. Results presented in a previous study (Garred et al 
(l995a); Garred (l995b) have suggested that proteolytic release of an Al fragment 
from the ST/SLT holotoxin is potentially very important for full toxicity. From work 
with immunotoxins and other ricin A chain fusions it would appear that toxicity and 
translocation of ricin can occur in the absence of the B chain a finding in apparent 
contradiction to results with ricin containing a galactose-binding deficient B chain 
(Newton et al (1992». Finally, there is the attractive possibility that all these proteins 
may exploit in reverse, transport machinery already in place for the translocation of 
nascent polypeptides from the cytosol to the ER. Study in this area is in its infancy. 
In the absence of a direct membrane translocation assay, studies to determine the 
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precise structural and factor requirements for translocation of SL T, ST ricin and PE 
are extremely difficult. Whether ricin, PE and ST /SL T translocate membranes by 
similar mechanisms and how such toxins are unfolded and rendered competent for 
this process are piquant questions which as yet remain unresolved. 
This present study therefore aims to resolve the absolute need for proteolytic 
processing of SLT 1 (and, by analogy, ST) as a prelude to other studies on membrane 
translocation. Using a source of unnicked SL T 1 cellular processing events have been 
followed. 
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Project aims 
1: To test a new analogue affinity chromatography matrix for purification of 
unnicked, biologically active SL T 1. 
2: To clone the coding sequence for SLT 1 into an expression vector and devise a 
quick efficient method for the expression and purification of SL T 1 holotoxin and 
mutant derivatives. 
3: To introduce specific mutations into the A chain of SLT 1 at sites potentially 
involved in intracellular processing. To express and purify these mutant proteins in 
order to characterize them in vitro and in vivo in an attempt to examine further the 
importance of proteolytic processing for SL T 1 cytotoxicity. 
4: To produce a chimeric fusion protein which incorporates the A chain of the plant 
toxin ricin with the C-terminal A2 portion of SL T 1 and the cell binding B subunits 
of SL T 1. The entry characteristics and the requirements for processing of this 
chimeric holotoxin are examined to determine more about the need for proteolytic 
processmg. 
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Section 2 
Materials and Methods 
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2.1. Suppliers and reagents 
2.1.1 Suppliers. 
The majority of analytical grade chemicals used were obtained from either BDI I 
Chemicals Ltd. Or FSA / Fisons where available. The sources of other specific 
reagents are detailed below. 
Amersham International PLC, Amersham, Buckinghamshire. 
Amplify ™ 
[a35S] dATP (lOmci/ml, 1200ci/mmol) 
L-e5S] methionine (15mcilml, lOOOci / mmol)\ 
Hybond™-C; nitrocellulose membrane, Hybond™_N; nitrocellulose membrane. 
BIO 101 Inc. Lajolla, USA 
Genelean II kit 
Bio-Rad Laboratories Ltd. Hemel Hempstead, Herfordshire. 
Pre-stained mid-range molecular weight markers. 
Boehringer Mannheim (UK) Ltd., Lewes, East Sussex 
calf intestinal phosphatase, creatine phosphate (CIP), sequencing grade trypsin, 
calpain inhibitor 1. 
Cruachem, Glasgow, UK. 
PCR primer PSDO 
DIFCO Laboratories, Basingstoke, Hampshire. 
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Bacto-agar, Bacto-tryptone, yeast extract. 
Becton Dickinson Labware, New Jersey, USA. 
Falcon disposable tissue culture centrifuge tubes. Falcon 3002 60X15 and 3003 
100x20 tissue culture dishes. 
GIBeO I BRL Life technologies Ltd., Paisley Renfrewshire, Scotland. 
T4 DNA ligase, T7 RNA polymerase, deoxyribonucleotides. Taq DNA polymerase, 
restriction enzymes, T4 polynucleotide kinase 
New England BioLabs, Beverley, USA 
Msc 1 restriction endonuclease, VentR DNA polymerase. 
Nunclon, Roskilde, Denmark. 
175cm2 tissue culture flasks. 
Paterson, Hertfordshire, England 
All darkroom reagents. 
Pharmacia., Milton Keynes, Buckenhamshire. 
M7G(5')ppp(5')G, Sodium (CAP) 
Pierce and Warner (UK) Ltd. Chester, England. 
Disposable Sml columns, Iodogen (1,3,4,6,-tetrachloro-3a-6a-diphenylglycouril) 
iodination catalyst. 
Polaroid, Cambridge, USA. 
Polaroid 665 positive and negative, Polaroid positive 665 film. 
Promega, Biotechnology P&S Biochemical Ltd., Liverpool Merseyside. 
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Rnasin, Rabbit reticulocyte lysates, protein molecular weight markers, Plasmid 
pOEM2 
QIAGEN Inc., Chatsworth, USA. 
QIApre-spin plasmid purification kit. 
Sigma Chemical company Ltd., Poole, Dorset. 
Ampicillin, bovine serum albumin (BSA), Coomasie blue 0250, dithiothreitol 
(DTT), ethidium bromide, L-amino acids, phenylmethylsulphonyl fluoride (PMSF) 
peptide protease inhibitors, TLCK, brefeldin A (BF A). Cell culture media. 
United States Bioscience, Cambridge Bioscience, Cambridge. 
Sequenase™ DNA sequencing kit version 2.0, T7_0ENTM in vitro mutagenesis kit, 
2.1.2 Reagents. 
2.1.2 Coomassie blue G250 stain. 
Coomassie blue 0250 stain was prepared by dissolving Coomassie blue 0250 in hot 
distilled water to a final concentration of 0.025% w/v with stirring on a hot plate. 
When the dye was completely dissolved the solution was allowed to cool and 
perchloric acid was added to a final concentration of 3.8% v/v. 
2.1.2 Aniline reagent. 
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iAniline was prepared from aniline which had been distilled twice. lml of this aniline 
was mixed with 7ml of autoclaved distilled water and O.5ml glacial acetic acid in a 
sterile glass universal. The pH of the aniline was adjusted to 4.5 by addition of more 
glacial acetic acid and the final volume made up to 11 ml. Aniline reagent was stored 
in the dark at 4°C. 
2.1.3 Kirby buffer. 
Kirby buffer was prepared by dissolving 6g 4-aminosalicylic acid in 4x Tris-
HClIKCI (Tris-HCI200mM pH7.6, KCI40mM). To this solution was added IOml of 
10% Tri isopropylnaphaline-sulphonic acid-Na salt (TNS) w/v. On addition ofTNS 
the solution becomes cloudy, Tris saturated phenol was then added drop wise until 
the solution cleared. Following addition of phenol the solution was made up to 50ml 
and stored in aliquots at -20°C. 
2.2. Growth and maintenance of bacteria and eukaryotic cells. 
2.2.1 Growth and maintenance of bacteria. 
All DNA manipulations were performed using E.coli strain TG2 with the exception 
ofM13 mutagenesis which requires transformation of mutant single stranded DNA 
into SDM2. JMI05 was used for expression of re comb in ant proteins. 
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TG2- SupE hsd~ 5 thi~ (lac-proAB) ~(srl-recA)306::TnlO(te{) 
, + q 
F [traD36 proAB lac I lacZ MI5] 
JMI05- SupE endA sbcB15 hsdR4 rpsL thi ~(lae-proAB) 
F' [traD36 proAB+ lac q laeZ ~M15] 
SDM2- ~80~ lac Z ~ M15 mcrA ~(mrr hsd RMS merBC) ~(lac-proAB) ~(rec A 
1398) deoR rpsL srI thi 
F'[traD36 proAB+ lac Iq lacZ ~MI5] 
Bacterial strains were maintained on minimal medium agar plates consisting of 1 x 
M9 salts (12.8% (w/v) Na
2
HP04.7H20, 3% (w/v) KHl04, 0.5% (w/v) NaCl, 1% 
(w/v) NH4CI), 2~g/ml thiamine, 4% (w/v) glucose, 0.1 M CaCI2, 10mM MgCI2, 10 
mM MgS04 for up to one month before re-streaking onto fresh plates. 
Liquid culture of both TG2 and JMl05 was performed in L-broth (Luria Berani 
medium: 1 % (w/v) NaCl, 1% (w/v) bactotryptone, 0.5% (w/v) yeast extract). 
Selection pressure for the retention of plasmids in E. coli was provided by including 
ampicillin to a final concentration of 1 OO~g/ml in both plates (Lamp) and liquid 
media (L-brothamp) 
2.2.2 Preparation of competent cells. 
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Competent cells were prepared by calcium chloride treatment. 1 ml from a 10ml 
overnight culture of E.coli in L-broth was used to inoculate 40ml ofL-broth. This 
culture was incubated at 37°C 200rpm until the optical density at 600nm reached 0.9. 
Cells were harvested by centrifugation at 2000 x g for 10 minutes at 4°C, the cell 
pellet was resuspended in 10ml of ice cold 0.1 M MgCl2 and the cells immediately 
centrifuged. The washed cell pellet was resuspended in 2.5ml of ice cold 0.1 M CaCl
2 
and incubated on ice for at least 2 hours. Cells were then used within 24 hours or 
were frozen as 200J.lI aliquots in 50% glycerol at -70°C. 
2.2.3 Growth and maintenance of Vero cells. 
Vero cells were routinely grown in 175 cm2 vented Nunclon tissue culture flasks 
with Dulbecco Modified Eagle's Medium (DMEM) (DME plus 5% heat inactivated 
foetal calf serum, 2mM glutamine, 50 IV/ml penicillin, 300J.lg/ml streptomycin) in a 
5% CO2 incubator. Vero cells were stored frozen in freezing mix (50% heat 
inactivated foetal calf serum v/v, 40% DMEM v/v, 10% DMSO v/v) under liquid 
nitrogen. 
2.3 Manipulation of nucleic acids. 
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2.3.1 Transformation of plasmid DNA 
100~1 of fresh competent cells or 200~1 of frozen cells were used in each DNA 
transformation. Plasmid DNA was added to the cells and mixed gently. The cells 
were held on ice for 45 minutes then exposed to heat shock, 2 minutes 42°C. The 
transformed cells were returned to ice briefly prior to plating on dry Lamp plates. 
Plates were incubated overnight at 37°C 
2.3.2 Transformation of M13 DNA. 
1 00~1 of fresh or 200~1 of frozen competent cells were used in each DNA 
transformation. M13 DNA (double or single stranded) was incubated with competent 
cells on ice for 45 minutes. The cells were exposed to heat shock for 2 minutes at 42° 
C and returned to ice. 3ml ofB-top (0.8% (w/v) bactotryptone, 0.5% (w/v) NaCI, 
0.6% (w/v) bactoagar), 100~llog phase TG2, 10 J.tl 100mM IPTG and 25~1 X-GAL 
(50mg/ml) were added to sterile universals and maintained at 42°C. The transformed 
cells were added to the molten agar, mixed and poured onto dry B-agar plates (0.8% 
(w/v) bactotryptone, 0.5 % (w/v) NaCI, 2% (w/v) bactoagar) and incubated overnight 
at 37°C. 
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2.3.3 Purification and concentration of nucleic acids from aqueous 
solution. 
Phenol extraction 
To a protein contaminated DNA solution an equal volume of ph en 011 chloroform was 
added. The sample was vortexed briefly and centrifuged at 13 000 x g for 1 minute. 
The upper aqueous phase was transferred to a clean tube. 
Ethanol precipitation 
To an aqueous solution of DNA a one tenth volume of3M sodium acetate and 2 
volumes of ice cold ethanol was added. The sample was mixed and held on dry ice 
for 15 minutes. DNA was pelleted by centrifugation at 15 000 x g for 20 minutes at 4 
°C. The pellet was rinsed in cold 70% ethanol, vacuum dried and re suspended in TE 
buffer (lOmM Tris HCI pH 7.4, ImM EDTA pH 8.0). 
2.3.4 Separation of nucleic acids by agarose gel electrophoresis. 
0.8% w/v agarose gels were routinely used for separation, visualisation and isolation 
of DNA fragments. 
0.8g of agarose was melted in a microwave oven in 100mls of 1 x TBE (900mM Tris 
Hel, 900mM Boric acid, 25 mM EDTA). 10111 of et hi diu m bromide (lOmg/ml) was 
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added, the gel cast, placed in a horizontal electrophoresis tank and covered with 1 
litre of Ix TBE buffer. Samples were loaded in Ix loading buffer (lOx THE, 50% 
(v/v) glycerol, 0.01 % bromophenol blue). A 60mA current was applied to the gel and 
migration was monitored by visualising under a long wave UV source. 
F ormamide - Agarose gels. 
Resolution of aniline-treated ribosomal RNA was achieved using 1.2% w/v agarose 
in 0.1 x TPE buffer (3.6mM Tris, 3mM NaH2P04, 0.2mM EDTA), 50% formamide. 
100ml in a 15xl5cm gel former. Aniline treated RNA was heated to 65°C for 5 min 
and cooled briefly on ice and sample buffer (50% v/v glycerol, 0.1 % w/v 
bromophenol blue) 3 III was added to lOll1 of sample. Prior to loading all wells were 
filled with 60% formamide in O.lx TPE. RNA samples were loaded on to the gel and 
the apparatus filled with 0.1 x TPE just enough buffer not to submerge the gel was 
added and the gel run 20mA for approximately 2 hours. Gels were stained by 
immersing in I litre of ethidium bromide solution 20llg /ml for 30 min followed by 
de-staining in water for approximately I hour with several changes in wash. RNA 
was visualised by UV illumination. 
2.3.5 DNA polyacrylamide gel electrophoresis. 
e2 P]-labelled oligonucleotides were separated on 16% polyacrylamide urea gels. A 
gel mix was made and stored at 4°C. 
57 
Gel mix:, 80ml 40% acrylamide w/v 2% bisacrylamide w/v, 20ml 10xTBE, 92g 
urea, made upto 200ml with water. 
A single gel was made by polymerisation of 45ml gel mix with 90JlI 25% APS w/v 
and 90JlI TEMED. Gels were run at 40mAmps constant current for the appropriate 
period of time. Gels were then dried and exposed to Fuji RX x-ray film at -70°C with 
an intensifying screen. 
7.2% w/v polyacrylamide urea gels were used for the separation of sequencing 
products. 
Gel mixture: 9m140% w/v acrylamide 2% bisacrylamide w/v, 6ml 10xTBE, 25.2g 
urea, 25ml water, 140Jl125% APS w/v, 140Jll TEMED. Gels were then dried and 
exposed to Fuji RX x-ray film at room temperature. 
2.3.6 Preparation of plasmid DNA 
Small scale preparations of plasmid DNA from E.coli were made using the QIAprep 
spin miniprep kit (a modification of the alkaline lysis method of Birnboim and Doly 
1979) according to the manufacturers instructions. Briefly the method involves lysis 
of an overnight culture of E.coli followed by precipitation of contaminating protein 
and chromosomal DNA. The resulting plasmid DNA solution is then adsorped onto a 
DNA binding membrane washed and eluted with low TE buffer (IOmM Tris HCl, 
0.1 mM EDTA). 
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Large scale DNA preparation was performed using a modification of the alkaline 
lysis method of Birnbiom and Doly (1979). E. coli transformed with the plasmid of 
interest were grown overnight in 40ml of L-brothamp with shaking (200 rpm). Cells 
were pelleted 2000 x g 10 minutes 4°C. The cell pellet was resuspended in 2ml of ice 
cold SET (25mM Tris HCI pH 8.0, 10mM EDTA, 15 % sucrose). To this cell 
suspension 0.2mllysozyme (20mg/ml) was added and placed on ice for 5 minutes. 
4mllysis mix (0.2M NaOH, 1 % SDS w/v) was added whilst vortexing and placed on 
ice for 10 minutes. 3ml of3M sodium acetate (pH 4.8) was added whilst vortexing 
and placed on ice for 15 minutes. Cell debris was removed by centrifugation at 
17,500 xg for 20 minutes at 4°C. The supernatant was extracted twice with 
phenol/chloroform and precipitated as in (2.3.3) 
2.3.7 Preparation of single stranded M13 DNA 
M13 DNA consists of two strands + and -, single stranded + form DNA was prepared 
for use in mutagenesis reactions or for single stranded sequencing by exploiting the 
life cycle of the MI3 phage. 
To sterile universals 3.5ml L-broth was added, IOOll1 of overnight T02 culture and a 
plaque plug (taken from an agar plate with a sterile Gilson tip) from an MI3 
transformation (2.3.2). This culture was incubated at 37°C with shaking (300 rpm) 
for 6 hours. I.5ml of this culture was centrifuged at 13 000 x g at room temperature 
for 5 minutes. The supernatant was transferred to a clean tube (the pellet was used to 
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make double stranded DNA using the QIAprep method (2.3.6) (if required). To the 
supernatant was added IS0J-lI (20% (w/v) PEG 6000, 2.SM NaCI), mixed and 
incubated at room temperature for at least 20 minutes. The aggregated virus was 
pelleted by centrifugation 13 000 x g at room temperature and the PEG solution 
removed. The tubes were re-centrifuged and the remaining PEG solution removed by 
aspiration. The pellet was re suspended in 120 JlI TE buffer and the viral proteins 
removed by extraction with SOJ-lI of phenol and DNA precipitated from the aqueous 
phase (2.3.3). The dried pellet was resuspended in 20J-lI TE and stored at -20 C. 
2.3.8 Preparation of double stranded M13 DNA. 
2SJ-lI oflog phase TG2 was used to inoculate lOml ofL-broth into which was added a 
plaque plug from an M13 transformation (2.3.2). This culture was incubated 
overnight at 37°C with shaking (200 rpm). 40ml ofL-broth was inoculated with 1 ml 
of a 1 amI L-broth TG2 overnight culture and incubated with shaking (200rpm) until 
the optical density at 600nm reached O.S. lOOJ-lI from the M13 containing culture was 
added and the culture incubated at 37°C with shaking (300rpm) for 4 hours. The cells 
from this culture were pelleted and viral DNA isolated using the alkaline lysis 
method (2.3.6). 
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2.3.9 Gel isolation of DNA fragments. 
Restricted plasmid vector DNA, excised DNA fragments and peR products were 
purified prior to subsequent cloning steps using the Geneclean 11 kit (Bio 101 Inc.). 
DNA fragments are first separated by agarose gel electrophoresis (2.3.4). The band 
of interest is excised from the gel and dissolved in Nal. A DNA binding resin is 
added which binds DNA under conditions of high ionic strength. The resin is then 
washed and pure DNA is eluted using low salt buffers such as TE or low TE. 
2.3.10 Enzymatic modification of DNA 
All enzymatic modifications to DNA were made as directed by manufactures unless 
stated otherwise. 
2.3.11 Phosphorylation of oligonucleotides. 
Oligonucleotides used for site directed mutagenesis were phosphorylated prior to 
use. Several oligonucleotides were also phosphorylated in the presence of gamma e2 
P]-ATP in order to visualise and assess the integrity of DNA or for use as a probe in 
Northern blot analysis (by phosphorylation of the 5' terminus of the DNA with 
radioactive phosphate and visualising by polyacrylamide gel electrophoresis (2.3.5). 
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A kinase buffer was prepared to 10x working concentration; I M Tris IICI pI I 8.0, 
100mM MgCI2, 70mM DTT, 10mM ATP (ATP was omitted when labelling DNA 
with radioactive phosphate) and stored at -20°C. Phosphorylation reaction: 2.5fll 
oligonucleotide (5 OD260nm units/ml) was added to 3fll 10x kinase buffer, 24fll 
water and 0.51l1 T4 polynucleotide kinase. For the preparation of radioactive 
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oligonucleotides, 0.5 fll (1 0IlCi) y[ P]-ATP was added. The reaction mixture was 
incubated at 37°C for 15 minutes followed by inactivation by incubation at 70°C for 
10 minutes. 
2.3.12 Oligonucleotide Site directed mutagenesis. 
The USB T -7 GEN in vitro mutagenesis system was used for the preparation of 
mutant MI3 DNA. The system functions by binding a mismatch oligonucleotide to 
the template to be mutated, this oligonucleotide is then extended in the presence of 5-
methyl dCTP producing a double stranded hetroduplex DNA in which the mutant 
strand is methylated. The parental strand is then nicked and destroyed by 
exonuclease activity leaving only the mutant strand which is then transformed into 
competent SDM2 cells. The kit was used as directed by the manufacturers 
instructions. Transformants were screened by DNA sequencing (2.3.13). 
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2.3.13 DNA sequencing. 
Single stranded M13 DNA (2.3.7) was sequcnced using Sequenase® T7 DNA 
Polymerase kit version 2.0 (United States Biochemical) using oligonucleotide 
primers complementary to the sequence of interest. This kit exploits the chain 
termination DNA sequencing method (Sanger et al 1977). The kit was used in 
accordance with the manufactures instructions. Products of the sequencing reactions 
were separated on high resolution polyacrylamide gels (2.3.5) and visualised by 
autoradiography. 
2.3.14 DNA quantitation. 
DNA was quantified by reading absorbance at 260nm Maniatis et al (1989). 
2.3.15 Polymerase chain reaction amplification. 
Specific mutagenic PCR methods are discussed in subsequent sections. All reactions 
were carried out using a Hybaid thermocycler. PCR products were purified by phenol 
extraction and ethanol precipitation (2.3.3) followed by gel isolation (2.3.9) prior to 
all enzyme treatments. 
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2.3.16 Preparation of rabbit reticulocyte ribosomes. 
Rabbit reticulocyte ribosomes were prepared from rabbit reticulocyte lysate (non-
nuclease treated) (Promega). 1 ml of rabbit reticulocyte lysate was centrifuged 
through a Iml ice cold IM sucrose pad in Ix ENDO buffer (25mM Tris-IICl pH7.6, 
2SmM KCI, SmM MgCI2) at 100000 x g for Ihr at 4°C. The supernatant was poured 
off, 2ml of ice cold Ix ENDO buffer was added to the tube and immediately poured 
off. The resulting partially purified ribosome pellet was resuspended in 1 ml of ice 
cold Ix ENDO buffer on ice with a glass rod. The ribosomes were re-pelleted by 
centrifugation at 100 000 x g for 1 hour and the supernatant discarded. The ribosome 
pellet was re suspended in 1001-.tl of 1 x ENDO buffer. The ribosome concentration 
was estimated by spectrophotometery using the formula that 1 mg/ml of ribosomes is 
equivalent to 12.5 OD units at 260nm. Ribosomes were stored in small aliquots at -
70°C. 
2.3.17 Northern blot analysis. 
Northern blot analysis was used to visualise the specific 400 nucleotide RNA species 
produced by cleavage of modified rRNA on aniline treatment (2.7.3). The primer 
CL580 with the sequence 5'CAT AAT CCC ACA GAT GG 3' end labelled with 
C2p]-yATP (2.3.11) was used as probe in these analysis. 
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Following separation of RNA (2.3.4) on denaturing formamide gels, rRNA was 
transferred to a nitro-cellulose membrane (Hybond-N). The gel was first soaked in 
0.05M NaOH for 20 min then rinsed briefly in distilled water and then immersed 
with agitation on a rotating platform in 20x SSC (NaCl 175.32gll. Tri sodium 
citrate:2H20 88.2gl1 pH7.0). Following equilibration with 20x SSC the gel and a 
piece of nitro-cellulose pre-soaked in 20xSSC were assembled in a vacuum blotting 
apparatus (vacugene, Pharrnacia) according to the manufacturers instructions and 
transferred for 60min. When transfer was complete the apparatus was disassembled 
and the membrane rinsed in 6x SSC to remove gel debris. The air dried membrane 
was fixed by UV irradiation using a Stratalink set on autolink (1200 joules). 
Northern blots could be stored at this stage or probed directly. Northern blots were 
pre-hybridized by incubation at 37°C for 2 hours in pre-hybridization buffer (6x 
SSC, 0.3% SOS, 5x Denhardts solution (100x Denhardts 20g/1 Ficoll type 400,20g/1 
polyvinylpyrridine, 20g/1 bovine serum albumin), 90llg heat denatured sonicated 
salmon sperm DNA (Pharmacia)) using a hybridization oven (Hybaid). When pre-
hybridization was complete 50pmoles oflabelled CL580 oligonucleotide (2.311), 
precipitated in the presence of 30 Ilg sonicated salmon sperm DNA, was added in 10 
ml of fresh pre-hybridization buffer by passage through a Dynoguard filter. 
Hybridization was achieved by incubation overnight at 37°C. The following morning 
the membrane was washed once in 2x SSC at room temperature then twice at 37°C 
for 30 min. The membrane was then removed from the bottle, wrapped in cling film 
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and exposed to pre-flashed RX x-ray film with an intensifying screen overnight at -
70°C 
2.4 in vitro Transcription / Translation. 
2.4.1 In vitro transcription 
Recombinant SL T 1 A coding DNA was cloned into pOEM 2 vector and orientated 
such that transcription in vitro could be driven by the viral promoter T7. Prior to 
transcription reactions, plasmids were linerised at convenient restriction sites. 
Transcription was carried out by the method of Maniatis et al (1989). 
2.4.2 Wheat germ lysate in vitro translation. 
Wheat germ lysate was a kind gift from Dr J. Chaddock and Dr A. Messiah 
(Warwick). Wheatgerm translations were carried out using standard methods 
Maniatis et al (1989). Translations were carried out in the presence of C5S]-
methionine and the products separated on 15% SDS polyacrylamide gels (2.7.7). 
2.4.3 Rabbit reticulocyte lysate in vitro translation. 
(i) Double translation assay. 
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Rabbit reticulocyte lysate (Promega) translations were carried out in the presence of 
esS] methionine as directed in the manufacturers instructions. However to detect the 
expression of a protein with potentially N-glycosidase activity, the ability of a rabbit 
reticulocyte in vitro translation reaction to translate a second message was examined. 
Following expression of a potentially toxic protein 30 min at 30°C a second non-
toxic messenger RNA (yeast prepro-alpha factor) was added to the reaction for a 
further 30 min 30°C. The translation products were then separated on 15% SDS 
polyacrylamide gels (2.7.7). 
(ii) Examination of ribosomal RNA following in vitro translation. 
In order to detect small quantities of potentially toxic proteins translated in vitro, 
ribosomal RNA can be extracted from a standard rabbit reticulocyte translation 
reaction and examined for characteristic depurination. A rabbit reticulocyte in vitro 
translation reaction using a mRNA coding a potentially toxic protein was set up 
using the manufacturers instructions. Radioactive label is substituted for unlabelled 
methionine. Following translation of the test mRNA, ribosomal RNA is extracted 
(2.7.3), treated with aniline (2.7.3) and separated on a denaturing formamide gel 
(2.3.4). 
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2.5 In vivo expression of recombinant proteins. 
Expression of all recombinant proteins was performed in Escherichia coli JM 1 05. 
All recombinant in vivo expression plasmids were constructed in pUC19 
incorporating the ampr gene. Expression was driven by the IPTG inducible promoter 
lal. The SL T 1 B chain expression plasmid pSBC32 Calderwood et al (1990) 
contains the SLT 1 B coding sequence in the plasmid pKK233.2 under the trc 
promoter and was a kind gift from Dr S. Calderwood (Boston, USA). 
2.5.1 Expression of unlabelled recombinant proteins. 
Plasmids coding for the protein of interest were transformed into JM 1 05 (2.3.1). A 
single colony was used to inoculate a 10ml LBamp overnight culture. The following 
day 1 litre of LBamp was inoculated with 10ml of overnight culture. The culture was 
grown with shaking at 37°C 250rpm until the optical density at 600nm reached 0.6. 
The culture was then induced by addition of IPTG to a final concentration of 1 mM 
and shaking incubation was continued for a further 3 hours. All the recombinant 
holotoxin protein expression and periplasm extraction was carried out in a category 
III containment laboratory. 
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2.5.2 Preparation of periplasm extracts 
Following growth and induction of transformed Escherichia coli, cells were 
harvested by centrifugation at 700 x g at 4°C for 30 min. The resulting cell pellet was 
gently resuspended in 20ml Tris/Sucrose (0.3M Tris pH8.0, ImM EDTA, 0.5 mM 
MgCl2 200g/1 Sucrose) and incubated at room temperature for 10 min. Cells were 
then re-centrifuged at 4400 x g at 4°C for 5 min. The supernatant was carefully 
removed from the cell pellet and discarded. The cell pellet was then re suspended in 
IOml of ice cold ImM Tris pH7.5 and incubated on ice for 10 min before removing 
cell debris by centrifugation 31 000 x g at 4°C for 15 min. The resultant supernatant 
containing the periplasmic fraction was filter sterilised before removal from the 
category III laboratory and subsequent purification. 
2.6 Protein purification. 
2.6.1 Purification of recombinant proteins. 
Gala144Galp144Glc (globotriose) linked to activated Sepharose 4B via a 6(CH2) 
linker (GbrSeph.) was a kind gift from Dr D. Muller (Warwick). This matrix was 
used for the affinity purification of SL T 1 and mutants, it was also used in the 
purification of RT AST A2 and SL T 1 B chain alone. 
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A Iml column of GbrSeph. was equilibrated with 0.5M NaCI in PBS. 10ml of 
periplasm extract from an SLT expression (2.4.1) was applied to the column at a 
flow rate of 0.4 ml/min. The column was then washed with approximately 40 column 
volumes of 0.5M NaCI in PBS to remove all traces of non-specifically binding 
Escherichia coli proteins. Elution of pure fractions of SL T I was achieved by 
addition of 6M Guanidine Hel pH6.7 at 0.4 mllmin. 0.5 ml fractions were collected 
in Ependorff tubes preloaded with 0.5 ml of 6M Guanidine HCI pH6.7 to 
immediately dilute protein 2 fold. After collection of approximately 15 fractions the 
absorbance of each fraction was determined at 280nm in a spectrophotometer. 
Fractions in the peak were immediately dialysed against PBS, with buffer changes 
after 1, 3 and 12 hours, overnight. All purification procedures were carried out at 4 QC 
in a cold room. Purified proteins were analysed by SDS PAGE and quantified as 
described in (2.7.1) 
2.6.2 Purification of Native SLT 1 from Escherichia coli 026:"11, 
strain E3787 
Escherichia coli 026:Hll strain E3787 was obtained from the National Type culture 
collection on the advice of Dr S M Scotland (Public Health Laboratory Service, 
Collingdale). This was then grown under category II containment at PHLS CAMR, 
PoTton Down using the method ofO'Brein et al (1982b). The resulting cell paste 
from 2x 10 !iter cultures was a kind gift from Dr B Burgess, Warwick. 
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Purification was a modification of the method ofRyd et al (1989). Approximately 4g 
of cell paste was re-suspended in 20ml PBS and sonicated using an MSE Soniprep 
150 sonicator 10x 20 sec bursts at amplitude setting 22. Centrifugation at 10 000 x g 
for 45 min at 4°C was used to remove cell debris. The supernatant was then 
precipitated with ammonium sulphate to 60% saturation (Petric et al (1987)) for 1 
hour with stirring at 4°C. Precipitated proteins were separated by centrifugation at 10 
000 x g for 10 min at 4°C. The precipitated protein pellet was then resuspended in 
20ml PBS and dialysed against PBS overnight at 4°C. This protein preparation was 
filter sterilised and applied to a Iml GbrSeph. column. Further purification steps 
were as in (2.6.1). 
2.6.3 Storage of recombinant proteins 
Recombinant SL T 1 holotoxins and fusion proteins were stored for short periods of 
time in PBS at 4°C, if proteins were likely to be stored for more than one month 
small aliquots were kept in PBS at -70°C. Recombinant ricin A chain (lCI) and 
native ricin holotoxin (Sigma) were routinely stored at 4°C. SLT 1 B chain was 
stored in PBS at -20°C. [1251] labelled proteins were stored in small aliquots in PBS 
at-70°C. 
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2.6.4 [125I]-labelling of recombinant proteins. 
Recombinant proteins were radio labelled using an iodination catalyst, Iodogen 
according to the manufactures instructions. 50llg of recombinant protein was labelled 
in each case. 
2.6.5 Expression and purification of SL T 1 B subunit 
pSBC32 in Escherichia coli JM 1 05 was a kind gift from Dr S B Calderwood 
(Boston, USA). It was grown and expressed as described by Calderwood et al 
(1990). Following expression a periplasmic extract was prepared using the method 
described in section 2.5.2. Purification was achieved by binding to a GbrSepharose 
affinity matrix column as described in section 2.6.1. 
2.6.6 Metabolic labelling of RASTA2 
RAST A2 was labelled with eSS]-methionine during expression in Escherichia coli 
JMI05. pRASTA2 in JM105 was grown on M9 minimal media amp agar plates prior 
to liquid culture. Transformed cells were grown overnight in 100mls of M9 minimal 
media with 1001lg/ml ampicillin (in a 250ml flask) at 37°C with shaking at 250rpm. 
The following morning 1 DOml of fresh prewarmed M9 minimal media plus 1001lg/ml 
amp (in a 1000ml flask) was inoculated to a starting optical density at 600nm of 0.2. 
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Escherichia coli were grown at 37°C with shaking until the optical density at 600nm 
reached ~ 0.6. Protein expression was then induced by addition of IPTG to a final 
concentration of ImM. ImCi of eSS]-methionine was also added and the flask was 
incubated with shaking for a further 3 hours at 30°C. An Escherichia coli 
periplasmic extract was made (section 2.5.2) and protein was purified as described in 
section 2.6.1. All bacterial manipulations were carried out under category III 
biological containment conditions. 
2.7 Protein analysis and Characterisation. 
2.7.1 Determination of protein concentration. 
The concentration of recombinant SL T 1 holotoxins was determined by 
spectrophotometry using a Shimadzu UV 160 A. Optical density values at 280nm 
were converted to protein concentrations from a calculated extinction co-efficient of 
0.984 from the formula: 
A280nm =12.075x[N2 Try +(5xN2..Irp}} 
Total N° Amino acids. 
The concentration of RAST A2 fusion protein was determined by scanning 
densitometry of West em blots. Samples of ricin A chain of known concentration 
were run against RASTA2 samples on 15% PAGE (2.7.7). Proteins were transferred 
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to nitro-cellulose membranes and probed with anti RTA antibodies (2.7.2). The 
optical density of RTA standards was used to create a calibration curve which was 
used to quantify the concentration of unknown samples. This method was used since 
the RAST A2 protein was highly contaminated with free SL TB. The method 
described quantifies chimeric A chain alone which is directly proportional to the 
concentration of holotoxin present. 
2.7.2 Western blot analysis 
Western blot analysis was used to identify specific proteins on polyacrylamide gels. 
Rabbit anti-ST antibodies were a kind gift from Prof. A Donohue-Rolfe. Following 
separation of proteins by SDS PAGE (2.7.7) proteins were transferred to nitro-
cellulose membranes (Hybond-C). Gel, nitro-cellulose and blotting paper (Whatman) 
soaked in transfer buffer (1.44% w/v glycine, 0.3% w/v Tris, 20% methanol v/v) 
were assembled in a semi-dry transblot apparatus according to the manufactures 
instructions. Following transfer the nitro-cellulose membrane was agitated in 
blocking solution 20% w/v dried milk (Marvel) in TBS (lOmM Tris pHS.O, 150mM 
NaCl) plus 0.1 % v/v Tween 20 for 30 min. Primary antibody was applied in 10ml of 
blocking solution and agitated for a minimum of 3 hours. The membrane was then 
washed four times 5 min TBS + 0.1 % v/v Tween 20. Secondary antibody conjugated 
to alkaline phosphatase was applied in 10ml of blocking solution and agitated for 1 
hour. After incubation of the second antibody the membrane was washed twice with 
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TBS+O.l % v/v Tween 20 followed by two washes with TBS. The membrane was 
allowed to air dry and was then developed in developing solution (100mM Tris-IICI, 
pH9.5, 100mM NaCl, SmM MgCl2 plus 33~150mg/ml BCPIP in dimethyl 
formamide and 66~1 SOmg/ml NBT per 10ml). When colour development was 
complete the reaction was stopped by addition of SOml stop solution (20mM Tris-
HCI pH8.0, SmM EDTA). 
2.7.3 RNA N-glycosidase activity 
Endo et al (1988) first described the cleavage of ricin A chain modified rRNA. This 
method was modified by May et al (1989). Potential toxins were incubated with 
30llg of rabbit reticulocyte ribosomes (2.3.16) in a 30~1 reaction in 1 x ENDO buffer 
(2SmM Tris/HCI pH7.6, 25mM KCl, 5mM MgC12) plus p-mecaptoethano16mM and 
6.SmM vanadyl ribonuclease complex (VRC), for 30 min. Reactions were stopped 
by addition of 100 1l12x Kirby buffer (2.1.3) plus 100 III water on ice. Following two 
rounds of phenol extraction (2.3.3) rRNA was precipitated with ethanol (2.3.3). 
To 4-Sllg of modified rRNA 20111 of acetic aniline (lM aniline-acetic acid pIl4.S 
(2.1.2)) was added and incubated for 2 min at 60°C followed by addition of 2.6 III 
7M Ammonium acetate and 65 III ethanol at -20°C. rRNA was precipitated on dry 
ice for 30 min followed by centrifugation at 4°C for 30 min IS 000 x g. Pelleted 
RNA was washed by addition of2 x 100 III 70% ethanol and dried under vacuum. 
Dry RNA pellets were resuspended in 60% formamide in 0.1 x TPE prior to gel 
electrophoresis and held on dry ice or stored at -70°C. 
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2.7.4. Cytotoxic action of recombinant proteins to Vero cells. 
Vero cells were plated out in flat bottomed 96 well tissue culture plates at density of 
1.5xI04 cells per well in Dulbecco Modified Eagle's Medium (DMEM) (DME plus 
5% v/v heat inactivated foetal calf serum, 2mM glutamine, 501U/ml penicillin 
300~g/ml streptomycin). Following incubation overnight at 37°C in a 5% CO2 
incubator cells formed a confluent monolayer. Media was removed and plates were 
washed with PBS. Toxin diluted in 100JlI DMEM was added to appropriate wells 
and incubated at 37°C in a 5% CO2 incubator for a specified period oftime less 30 
min. Following toxin incubation the cells were washed with PBS and 1 JlCi of esS]-
methionine in 100JlI ofPBS was added to each well. Plates were incubated once 
more at 37°C in a 5% CO2 incubator for 30 min. Following labelling the esS]-
methionine was shaken off and monolayers were washed 3 times with 5% ice cold 
trichloroacetic acid and once with PBS. Addition of 100JlI of O.SM NaOH to each 
well solubilized TCA precipitated protein and after a 30 min incubation the contents 
of each well was transferred to a liquid scintillation vial containing 4ml of 
scintillation fluid. Quantitation of eSS]-methionine incorporated into cells was 
achieved by scintillation counting. For each time point or toxin concentration four 
identical wells were set-up. Percentage incorporation was measured against the 
radioactivity in 6 untreated wells. Results from this assay were plotted as the mean of 
counts in test quadruplicates as a percentage of the mean of the no toxin controls, 
against toxin concentration to give ICso values or against time to give tl/2 values. 
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2.7.5 In vivo cleavage ofSLT 1 and Mutants. 
Recombinant SLT 1 and mutants were labelled with [1251] using the lodogen method 
(2.6.4) to a specific activity of approximately 25 000 cpm/ng. Vero cells were grown 
in 6 well plates in DMEM at a density of approximately 5.OXI 05 cells per well. After 
washing with PBS 100ng/ml e251]-labelled toxin was added to each well in 1.5 ml 
DMEM and cells were incubated for the specified period of time. Following toxin 
incubation the cells were washed three times with PBS and lysed in cell lysis buffer, 
1% Triton X-WO, 150mM NaCI, 50mM Tris pH 7.4, leupeptin 210j.lM, chymostatin 
82j.lM, elastatinol 6j.lM, pepstatin A 1.6jlM, aprotinin 0.3jlM, PMSF 1 mM, EDTA 
ImM. Cellular debris and nuclei were removed by centrifugation 7 500 x g at 4°C for 
5 min and protein precipitated by addition of acetone followed by centrifugation at 
15 000 x g for 15 min at 4°C. The resulting protein pellets were dried under vacuum, 
re suspended in SDS PAGE loading buffer and run on 15% gels (2.7.7). 
2.7.6 In vitro protease treatment. 
The sensitivity of mutant proteins to trypsin or proteinase K was assessed by 
treatment in vitro with sequencing grade trypsin (Boehringer) or proteinase K 
(Sigma). 1 jlg of mutant proteins in PBS was digested with varying concentrations of 
protease. All trypsin digests were performed at 37°C for 7 min in a 30jll reaction. 
Proteinase K digestions were performed either at 37°C for 7 min or at O°C for 40 
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min. The products of protease digestions were separated on 15% SDS PAGE (2.7.7) 
and stained with coomassie G250 or transferred to nitro-cellulose membranes 
(Hybond-C) for Western blot analysis (2.7.2). 
2.7.7 SDS-Polyacrylamide gel electrophoresis (SDS PAGE). 
Proteins were routinely separated on 15% polyacrylamide gels. By the method of 
Laemmli (1970) under reducing or non-reducing conditions. The latter was achieved 
by omission of f3-mercaptoethanol from the sample loading buffer (0.06M Tris-IICI 
pH6.8, 0.2% SDS w/v, 20% glycerol v/v, 0.05% f3-mercaptoethanol v/v, 0.1 % 
bromo-phenol blue). Protein was visualised in several ways. 
(i) Visualisation of radio-labelled proteins. 
C2SI]-labelled proteins were visualised by exposure of dried gels to preflashed Fuji 
RX x-ray film with an intensifying screen at -70°C. Where [14C]-labelled molecular 
weight markers were used, gels were fluorographed with Amplify (Amersham) prior 
drying and exposure to Fuji RX x-ray film. 
eSS]-methionine labelled proteins were visualised using fluorography by immersing 
gels in Amplify prior to drying and exposure to Fuji RX x-ray film at -70°C (no 
screen). 
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(ii) Silver staining. 
Gels were silver stained as described by Merril et al (1981). 
(iii) Coomassie blue G250 staining. 
Gels were stained by immersing in Coomassie blue G250 stain reagent (0.025% 
coomassie blue 0250, 3.8% perchloric acid) at 80°C for 30 min or room temperature 
overnight. Developing is achieved by 3 rounds of heating in distilled water in a 
microwave oven on high for 5 min with fresh changes of distilled water. 
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Section 3 Results and Discussion. 
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Chapter 1. 
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3.1 Cloning, expression and purification of wild-type Shiga-like 
toxin 1. 
Introduction 
Previous work at Warwick involving expression and purification of SL T I had relied 
upon separate expression of SL T 1 A and B chains followed by purification of B 
chain using a commercially available affinity matrix provided by BioCarb (Gb3-
Fractogel). Following reassociation of impure SLT 1 A chain with pure SL T 1 B 
chain, holotoxin and unreassociated SL T 1 B chain were co-purified on the Gbr 
Fractogel column. This method has several disadvantages. It was time consuming, 
results in very low yields of holotoxin, and resultant holotoxin is contaminated with 
unassociated excess B chain. Since this study was to involve the production of 
several toxins mutated in the A chain, and large quantities of these mutant toxins 
were required for biochemical analysis, it was decided to design a new expression 
system which would not have these technical difficulties. In addition the cost of the 
affinity matrix was prohibitively expensive and is in very short supply since its 
manufacture has been ceased. Dr. D. Muller (Warwick) chemically synthesized the 
trisaccharide globotriose (galactose al-4galactosepl-4glucose) (figure 1.1) and 
immobilization of this sugar via a six carbon spacer arm ((CH2)6) onto cyanogen 
bromide-activated Sepharose (see appendix 2) provided a means by which the 
biological properties of this compound could be tested as an affinity matrix for SL T 
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1. The new expression system and method of purification presented here were 
designed to allow rapid expression and purification of large quantities SL T I wt and 
variants. The purification protocol described is based on the method of Ryd et af 
(1989) (section 1.2) 
3.1.1 Cloning 
The genes coding for the SLT 1 operon including the associated Shine-Dalgarno and 
periplasmic targeting sequences were amplified by PCR from Escherichia coli 
026:Hl1 cell paste (a strain which produces SLT 1 only). Two primers were 
designed which anneal to the 5' and 3' ends of the sequence and in addition to the 
complementary sequence, a PsI 1 site was incorporated in the 5' end of the 5' primer 
and a EcoR 1 site in the 5' end of the 3' primer (Figure 3.1.1). Amplification was 
achieved by 25 cycles of PCR in the presence of Taq DNA polymerase in a 1 00 ~l 
reaction volume. 
PCR conditions: IX reaction buffer, 1.5mM MgCI2, 100pmoles primers (EST03' 
and PST05'), 0.2 mM dNTPs, 0.05 U/~l Taq DNA polymerase. 94°C 1 min, 39°C 1 
min, 72°C 1.5 min. 
The PCR generated two fragments one of approximately 1300 base pairs and a 
smaller fragment which runs just above the unincorporated primer band on a 0.8% 
agarose gel (figure 3.1.2). The larger fragment is the amplified SL T 1 coding 
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sequence and this was established by restriction analysis. Digestion of the PCR 
reaction with NruI or SspI cleaves the 1300 base pair fragment to two smaller 
fragments with the predicted sizes (figure 3.1.2). The 1300 base pair fragment was 
gel isolated (2.3.9) phenol extracted (2.3.3) and cut overnight at 37°C with EcoR I 
and Pst I. The cut PCR fragment was then gel isolated again and ligated into M 13 
mp 18 previously cut with EcoRI and PsII, gel isolated and treated with calf intestine 
phosphatase (CIP) to create M13SLTwt. The ligated plasmid DNA was thcn 
transformed into E.coli strain TG2 (2.3.2). A single white plaque was used to make 
single stranded DNA (2.3.7) which was used for DNA sequencing (2.3.13) and 
subsequent mutagenesis. The sequence of the PCR amplified DNA in M 13 mp 18 
was confirmed by DNA sequencing prior to subcloning into the expression vector. 
Double stranded M 13SLTwt DNA was prepared (2.3.8) and digested overnight with 
EcoR I and Pst I. Digested DNA was phenol extracted and the SL T 1 coding 1300 
base pair fragment gel isolated. pUC 19 plasmid DNA was also digested with EcoR I 
and Pst I and gel isolated. Cut plasmid DNA was treated with CIP before being 
ligated with the 1300 base pair fragment from M 13 SL Twt to create pS L Twt. Ligated 
DNA was transformed into TG2 and transformants screened for insert by Hind III 
digestion of mini prep plasmid DNA. Hind III digestion releases a diagnostic 580 
base pair fragment from pSL Twt. The cloning of M 13 SL Twt and pSL Twt are 
described schematicaUy in figure 3.1.3 
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Figure 3.1.1 Sequence of oligonucleotide primers EST03' and 
PST05' used for amplification of SLT I from Escherichia coli 
026:HII cell paste. 
EST03' 
EcoRI Complementary sequence 
5'-GCT AGA ATT CTC AAC GAA AAA TAA CTT-3' 
PST05' 
Ps/I Complementary sequence 
5'-CGG AAC TGC AGC AAG GAO TAT TOT GTA ATA T-
3' 
Figure 3.1.1 shows the sequence of the primers used in the peR of the SL T 1 coding 
sequence from Escherichia coli cell paste. EST03' contains DNA complementary to 
the 3' end of the SL T 1 operon. This primer adds an EcoR I site to the 3' end of the 
SLT 1 coding sequence. PST05' contains sequence complementary to the 5' end of 
the SLT 1 coding sequence including the Shine-Dalgarno-sequence. This primer adds 
a PsI I site to the 5' end of the SL T 1 coding sequence. 
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Figure 3.1.2 Agarose gel electrophoresis of amplified SL T 1 DNA 
from Escherichia coli 026:011 and subsequent restriction analysis. 
Figure 3.1.2 shows the peR amplified fragments from Escherichia coli (serotype 
026:Hll strain H19) cell paste. The reaction generated two fragments one which has 
a size consistent with that of the full length SLT 1 operon (1271 base pairs) and a 
second smaller fragment presumably generated by non-specific priming and 
amplification. Restriction analysis was performed in order to confirm the identity of 
the amplified fragment Nru I cuts at position 1136 and produces two fragments of 
approximately 850 and 450 base pairs. Ssp I cuts at position 1219 and produces two 
fragments of approximately 900 and 320 base pairs. Both restriction digests confirm 
that the larger fragment produced in the peR reaction described is the amplified SL T 
1 operon sequence. Numbering is from the sequence published by Calderwood et at 
(1987). 
Lane 11 A DNA digested with EcoR I and Hind III 
Lane 21 3 III uncut PCR reaction. 
Lane 31 3 III Nru I digested peR reaction. 
Lane 41 3 III Ssp I digested peR reaction. 
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Figure 3.1.2 Agarose gel electrophoresis of amplified SLT 1 DNA 
from Escherichia coli 026:Hll and subsequent restriction analysis. 
1584 
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983 
831 
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Figure 3.1.3 Cloning steps used for the production of M13SLTwt 
and pSLTwt. 
Figure 3.1.3 shows a schematic diagram of the steps used to clone a DNA fragment 
coding for the full length SL T 1 operon generated by PCR from Escherichia coli 
026:H II cell paste. The positions of Ssp 1 and Nru 1 used for restriction analysis of 
the PCR fragment are marked. The peR fragment was digested with Pst 1 and EcoR 
1 and ligated into M13 mplS digested similarly to generate MI3SLTwt. M13SLTwt 
was used to generate single stranded DNA for sequencing. Double stranded 
M 13 SL Twt was cut with Pst 1 and EcoR 1 to release a fragment of approximately 
1300 base pairs (bp) which was ligated into pUC 19 similarly digested to generate 
pSLTwt. 
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Figure 3.1.3 Cloning steps used for the production of M13SL Twt 
and pSLTwt. 
Pst 1 Nru 1 Ssp 1 EcoR 1 
SLT 1 wild-type coding sequence amplified by PCR 
Psi 1 
EcoR1 
M13 mp18 
7250 bp 
pUC19 
2700bp 
pSLTwt 
4000bp 
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Hindll! 
Pst 1 
Hind III 
Psi 1 
lacZ 
promoter 
M13SLTwt 
8500bp 
I EcoR llPsl 1 releases a 1300bp 
fragment 
Pst 1 
3.1.2 Expression/purification of SL T 1 wt. 
pSLTwt was expressed in Escherichia coli JM1 05 (as in section 2.5.1). Following 
expression the periplasm was extracted (section 2.5.2) and recombinant protein was 
purified using a receptor analogue affinity matrix column (section 2.6.1). 0.5 ml 
fractions were collected on addition of denaturing 6M guanidine hydrochloride (850 
mM Tris HCI pH6.7, 6MGuHCI pH6.7). These fractions were collected in Eppcndorf 
tubes pre-Ioaded with 0.5 ml of 6MGuHCI pH6.7. The reason for this is that in 
previous experiments some fractions collected from the Gb3 -Sepharose column were 
often highly concentrated and protein precipitated in these fractions. After collection 
of 20 0.5 ml fractions, samples were analyzed by reading their absorbance at 280nl11. 
The absorbance values were plotted against fraction number to give a peak. The peak 
fractions were immediately dialyzed against PES in order to remove the denaturing 
GuHCl as soon as possible and thus prevent damage to the sample. Figure 3.1.4 
shows a typical elution profile obtained from plotting A280nm against fraction 
number. Following extensive dialysis, protein was quantified (2.7.1) and analyzed by 
SDS PAGE (2.7.7). Purification ofSLT 1 wt using the method described routinely 
resulted in the production of approximately 1 mg of pure SL T 1 from a 1 liter starting 
culture. Figure 3.1.5 shows the purification ofSLT 1 wt analyzed by SOS PAGE. 
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Figure 3.1.4 Profile of SL T 1 wt protein eluted with guanidine 
hydrochloride from a Iml Gb3-Sepharose column. 
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Figure 3.1.4 shows the elution profile of SLT wt from a Iml Gb3-Sepharosc column. 
Periplasrn containing SLT 1 wt was bound to a lrnl GbrSepharose column and 
washed with 40 column volumes of O.SM NaCl in phosphate buffered saline (PBS). 
O.Srnl fractions were eluted with 6M GullCl pII6.7 and collected in tubes containing 
O.Srnl 6M GuHCI pH6.7. The absorbance of each eluted fraction (total volume 1 ml) 
was analyzed at 280nm and plotted against fraction number to give an elution profile. 
Fractions within the peak were dialyzed against PBS. 
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Figure 3.1.5 Analysis of expression and purification of SLT 1 wt by 
SDS polyacrylamide gel electrophoresis 
Figure 3.1.5 shows the binding and subsequent elution of wild type SL T 1 on a 1 ml 
GbrSepharose analogue affinity column. Lane 2 shows Escherichia coli JMl 05 
periplasm foHowing expression ofpSL Twt, Lane 3 shows proteins which do not bind 
to the affinity matrix (flow through) and Lanes 4-8 show proteins eluted with 6M 
GuHCl pH6.7 and dialysed against PBS i.e. fractions from the peak shown in figure 
3.1.4. Lanes 1 and 9 are molecular weight markers. The arrows indicate the positions 
of SL T 1 A chain (32kDa) and SL T 1 B chain (7.7 kDa). Molecular masses are given 
in kDa. 
Lane 1 molecular weight markers 
Lane 2 precolumn periplasm (101l1) 
Lane 3 flow though (20Il1) 
Lane 4 fraction 10 (301l1) 
Lane 5 fraction 11 (30IlI) 
Lane 6 fraction 12 (301l1) 
Lane 7 fraction 13 (30Ill) 
Lane 8 fraction 14 (301l1) 
Lane 9 molecular weight markers 
92 
Figure 3.1.5 Analysis of expression and purification of SLT 1 wt by 
SDS polyacrylamide gel electrophoresis 
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3.1.3 Discussion. 
The aim of these experiments was two fold, firstly an expression system was to be 
designed which would facilitate the rapid expression of wild-type SL T 1 (wt) which 
would could easily be modified for the expression of mutant forms of SL T 1. 
Secondly the aim was to test and optimize a novel receptor analogue affinity 
chromatography matrix. 
The former was achieved by creating two plasmids both of which contain the full 
length coding sequence for SL T 1 and its associated Shine-Dalgarno and periplasmic 
targeting sequences. Ml3SLTwt contains this sequence in M13 mplS which allows 
easy production of single stranded DNA for sequencing and mutagenesis. pSL Twt 
contains this sequence in the expression plasmid pUC19 where expression can be 
driven by the lac Z promoter. These two plasmids provide a simple method for the 
production of mutant toxins since mutant DNA made in the M 13 SL Twt background 
can easy be substituted into pSLTwt for expression. The results in figure 3.1.5 
clearly show that pSLTwt allows the expression of SL T 1 holotoxin, furthermore it 
can be seen that the recombinant protein is being targeted to the periplasmic space. 
Periplasmic targeting is designed to allow physiological assembly of the A and B 
chains in a compartment analogous to that in natural producing strains of Escherichia 
coli. It is also thought that targeting to the periplasm would allow correct disulphide 
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bond production and hence gives the best chance of producing correctly folded 
soluble holotoxins. This expression system circumvents the separate expression of A 
and B chains with its associated technical problems. The single disadvantage of the 
current method is that all manipulations involving the SL T containing plasmids in 
bacterial cells, including expression, must be conducted under category III biological 
containment conditions. The reason for this is that this plasmid contains a holotoxin 
gene under the control of a strong promoter. 
The method of purification described is a modification of the method of Ryd et al 
(1989). In addition to the change in the analogue affinity matrix O.5M NaCl was 
added to the wash buffer to prevent the small amount of non-specific protein/column 
matrix interactions. Small amounts of contaminating proteins had previously been 
seen in guanidine-eluted fractions. 
By SDS PAGE analysis ofpre-column periplasm, flow though and eluted protein 
fractions (figure 3.1.5) it can be seen that the new GbrSepharose matrix effectively 
binds toxin. The binding capacity of this matrix was not investigated, however since 
at least Img of pure toxin can be eluted from a Iml column and no toxin is detcctcd 
in the flow-though fractions the capacity must be in excess of 1 mg per ml matrix. 
The cost of the previously commercially available GbJ-Fractogel matrix precluded 
the purchasing of large quantities of this material. Although this matrix could be 
regenerated and used several times, its ability to bind toxin was reduced with 
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repeated use. In contrast GbrSepharose appears to be extremely stable and tolerates 
reuse well. 
In summary the new expression and purification system described provide a cheap 
and rapid method for the production oflarge quantities of biochemically pure SL T 1. 
The expression system can easily be adapted for the production of mutant SLT 
provided that the integrity of the receptor binding sites in SL T 1 B chain is 
maintained and that the mutant A chain is capable of association with the B chain. 
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Chapter 2 
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3.2 Cloning, expression and purification of mutant Shiga-like toxin 
1 proteins. 
Introduction 
The role of proteolytic processing of SL T 1 in susceptible eukaryotic cells is the 
main area of investigation in this study. Current literature involving processing of 
SL T 1 and other bacterial toxins is covered in section 1.6. The results presented in 
chapter 2 show the strategy used to clone and express five mutant proteins which 
were designed to address further, the question of proteolytic processing of SL T 1 in 
eukaryotic cells. 
The expression and purification methods used for the production of these mutant 
molecules are based on the findings presented in chapter 1 where a system for the 
expression and purification of wild type recombinant SL T 1 is described. 
Four holotoxins, mutant in potential processing sites within the A chain, were made. 
1. pSLTPl codes for SLT 1 Arg248~Gly / Arg251~Gly 
2. pSLTP2 codes for SLT 1 Ala246~Gly / Ser247~Ala / Ala 253~Gly / Ser 
254~Ala 
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3. pSL TP3 codes for SLT 1 Arg248~Gly / Arg251 ~Gly / Ala246~Gly / 
Ser247~Ala / Ala 253~Gly / Ser 254~Ala (A combination ofpSLTPl and 
pSLTP2) 
4. pSL TP4 codes for SL T 1 Arg248~Gly / Arg251 ~Gly / Ala246~Gly / 
Ser247~Ala / Ala 253~Gly / Ser 254~Ala / Arg220~Gly / Arg 223~Gly 
(pSLTP3 with a second arginine rich site disrupted) 
5. A fifth mutant was made for translation in vitro which has a stop codon inserted 
in place of Arg 223. 
pGEM223stop codes for SL T 1 Arg223~stop 
3.2.1 Cloning of mutant Shiga-like toxins. 
pSL TP 1, pSL TP2 and pSL TP3 were all produced by oligonucleotide-site-directcd 
mutagenesis (SDM) (2.3.12) ofSLT 1 coding DNA in an M13mpl8 background 
followed by subcloning of the mutant sequence into pUC19. 
M13SLTPl and M13SLTP2 were created by SDM ofM13SLTwt (section 3.1) with 
the oligonucleotide PI or P2i and P2ii (figure 3.2.1). M 13SLTP3 was created by 
SDM of M 13SLTP2 DNA with the oligonucleotide P3 (figure 3.2.1). Following 
mutagenesis, single stranded DNA was screened for mutation by sequencing 
(2.3.13). Double stranded DNA was made from the appropriate M13 phage clone 
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(2.3.8) and digested with EcoRI and PstI to release a fragment of approximately 1300 
base pairs. This fragment was gel isolated (2.3.9) and subcloned into pUC 19 to 
create pSLTPl, pSL TP2 and pSLTP3 by ligation into pUC 19 previously cut with 
EcoRI and PstI gel isolated and treated with CIP. The resulting ligation was 
transformed into TG2 and mini prep plasmid DNA was screened for insert by 
HindlII digestion. Digestion of pSL TP 1, pSL TP2 and pSL TP3 with lIindIII releases 
a fragment of 580 base pairs. The amino acid changes introduced to SL T 1 coded in 
pSLTP1, pSLTP2 and pSLTP3 are shown in figure 3.2.3. Plasmid maps are given in 
figures 3.2.4, 3.2.5 and 3.2.6 respectively. 
Site directed mutagenesis methods were also attempted to make two further mutants 
pSL TP4 and pGEM223stop. However, repeated attempts to produce mutations in 
this region of the SLT 1 sequence by conventional methods failed. The reasons for 
this are not clear, but since production of both of these mutants required binding of 
an oligonucleotide to the same region in the SL T 1 sequence it is considered that 
DNA secondary structure in this region may prevent efficient binding of a mutagenic 
primer. Four primer mutagenic recombinant PCR was used in place of SDM to create 
these two mutants. 
Four primer PCR involves three separate PCRs. In the first and second reactions two 
DNA fragments are produced which have the sequence of the 3' and the 5' ends of 
the template sequence, both DNA fragments also contain a small region of 
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homology. In the third round ofPCR the gel isolated products of the first two 
reactions are combined with outside 3' and 5' primers to amplify a single full length 
product. Taq DNA polymerase often adds a 3' adenine base following amplification 
of the template DNA. This would produce a single base insertion in the third PCR 
described. However Vent DNA polymerase has an exonuclease activity and hence 
does not insert an additional A. For this reason Vent DNA polymerase was used in 
all four primer recombinant PCRs in place ofTaq DNA polymerase. 
pSL TP4 was produced by recombinant PCR using the outside primers EST03' and 
PST05' (figure 3.1.1) and mutagenic primers P4 and P4r (figure 3.2.1). 
pGEM223stop was produced by recombinant PCR using the primers EST03' and 
PST05' (figure 3.1.1) and mutagenic primers 223stop and 223stopr (figure 3.2.1). 
The steps involved in producing 223stop and SL TP4 PCR fragments are shown 
schematically in figure 3.2.2. 
PCR and cloning of233stop: 
reaction 1: IX Vent DNA polymerase buffer, O.2mM dNTPs, lOng dsM13SLTwt 
(template DNA), SOpmoles PSTOS', 50pmoles 223stopr, O.02U/1l1 Vent DNA 
polymerase. Final volume SO Ill. 94°C 1 min, 40°C 1 min, 72°C I.S min. 
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Reaction 2: IX Vent DNA polymerase buffer, O.2mM dNTPs, lOng dsM13SLTwt 
(template DNA), SOpmoles EST03', SOpmoles 223stop, 0.02U/IlI Vent DNA 
polymerase. Final volume SO Ill. 94°C 1 min, 38°C 1 min, 72°C I.S min. 
Reaction 3: IX Vent DNA polymerase buffer, 0.2mM dNTPs, 0.2S ~t1 gel isolated 
fragment from reaction 1, O.S III gel isolated fragment from reaction 2, 100pmoles 
EST03', 100pmoles PSTOS', 0.02U/IlI Vent DNA polymerase. Final volume 100 ~l 
1. 94°C 1 min, 44°C 1 min, 72°C 1.5 min for 3 cycles followed by 94°C I min,40°C 
1 min, 72°C I.S min for 12 cycles. 
This series ofPCR resulted in a DNA fragment of the correct size approximately 
1300 base pairs. This fragment was phenol extracted, gel isolated and cut with PslI 
and EcoRI. Plasmid DNA, pGEM2, was digested with PstI and EcoRI gel isolated 
and treated with CIP. Cut PCR fragment was then ligated into cut pGEM2 to produce 
pGEM223stop. Mutation was confirmed by plasmid sequencing. The changes made 
to the primary amino acid sequence ofSLT I coded in pGEM223stop are shown in 
figure 3.2.3. A plasmid map is given in figure 3.2.8 
PCR conditions for the production of SL TP4: 
reaction 1: IX Vent DNA polymerase buffer, 0.2mM dNTPs, lOng dsM13SLTP3 
(template DNA), SOpmoles PSTOS', SOpmoles P4r, 0.02U/IlI Vent DNA 
polymerase. Final volume SO Ill. 94°C 1 min, 40°C 1 min, 72°C I.S min. 
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Reaction 2: 1 X Vent DNA polymerase buffer, O.2mM dNTPs, lOng dsM 13SL TP3 
(template DNA), 50pmoles EST03', 50pmoles P4, 0.02U/~tl Vent DNA polymerase. 
Final volume 50 Ill. 94°e 1 min, 500 e 1 min,72°e 1.5 min. 
Reaction 3 IX Vent DNA polymerase buffer, 0.2mM dNTPs,0.25 III gel isolated 
fragment from reaction 1, 0.25 III gel isolated fragment from reaction 2, 100pmoles 
EST03', 100pmoles PST05', 0.02U/lll Vent DNA polymerase. Final volume 1 00 ~l 
1. 94°e 1 min, 72°e 1.5 min, 3 cycles followed by 94°C 1 min, 40°C I min, 72°C 1.5 
mm. 
This series ofPCR resulted in a DNA fragment of the correct size approximately 
1300 base pairs. This fragment was phenol extracted, gel isolated and cut with PS/I 
and EcoRI. Plasmid DNA, dsMl3mpl8, was digested with PsII and EcoRI gel 
isolated and treated with CIP. Cut PCR fragment was then ligated into cut M 13mp 18 
to produce MI3SLTP4. Following full sequencing to confirm mutation a 1300 base 
pair fragment was released from M13SLTP4, by digestion with EcoRI and PSI!, gel 
isolated and ligated into pue 19, cut previously with EcoRI and Ps/I gel isolated and 
treated with CIP, to produce pSL TP4. The resulting ligation was transformed into 
TG2 and mini prep plasmid DNA screened for insert by lIindIII digestion. pSL TP4 
releases a 580 base pair fragment following digestion with lIindIII. The amino acid 
changes made to the SL T 1 primary sequence coded in pSL TP4 are shown in figure 
3.2.3. A plasmid map is given in figure 3.2.7. 
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Figure 3.2.1 Oligonucleotide sequences of primers used for the 
construction of SL T 1 mutant toxins. 
Figure 3.2.1 shows the sequence of primers used for site directed mutagenesis and 
recombinant PCR of mutant Shiga-like toxins. Primers Pl, P2i, P2ii, and P3 were 
used for the SDM ofSLT 1 DNA in M13mp18. The primers P4, P4r, 223stop and 
223stopr were used in four primer PCRs to create mutant molecules. 
Mismatch bases are underlined, numbering denotes the position at which the primer 
anneals in the sequence published by Calderwood et af (1987) (see appendix 5). The 
sequences of primers EST03' and PST05' also used in recombinant PCR are shown 
in figure 3.1.1 
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Figure 3.2.1 Oligonucleotide sequences of primers used for the 
construction of SLT 1 mutant toxins. 
PI 5,_1130CAT GCA TCG GCA GTT GCC GGA ATG GCA l156_3' 
P2i 5,_1125AT CAT CAT GGA GCG CGA1144_3' 
P2ii 5,_1147C AGA ATG GGA GCT GAT GAG T I166_3' 
P3 5,_1t31AT GGA GCG GCA GTT GCC GGA ATG GGA1156_3' 
P4 5,_1046GAC TCT GTT GGT GTA GGA GGA ATT TCT T 1073_3, 
P4r 5,1073 A AGA AAT TCe TCC TAC ACe AAC AGA GTC 1046_3' 
223stop 5,_1056GT GTA GGAIGA ATT TCT1072_3' 
223stopr 5,_1072AGA AAT TCA TCC TAC AC 1056_3' 
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Figure 3.2.2. Recombinant mutagenic peR used for the production 
DNA coding for SLTP4 and 223stop mutant SLT Is. 
Reaction 1 : In the first reaction a single outside primer (1) and a mutagenic primer 
(2) were combined in a peR which amplifies the 5' portion of the template sequence. 
This fragment incorporates the mutation present in the mutagenic primer (2) and a 
restriction site coded in the 5' primer (1). 
Reaction 2: In the second reaction a single outside primer (4) and a second 
mutagenic primer (3) (which is complementary to primer (2» were combined with 
template in a peR which amplifies the 3' portion of the template sequence. The 
resulting fragment incorporates a restriction site coded in primer (4) and the mutation 
from primer (3). 
Reaction 3: In the final reaction the products from reaction 1 and reaction 2 (products 
A and B), after removal of primers by gel isolation (2.3.9), are combined in a third 
reaction where the a region of homology anneals and extends to produce full length 
peR product (dotted lines). Both outside primers (1) and (4) are also included in this 
reaction to amplify the final peR product. 
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Figure 3.2.2. Recombinant mutagenic peR used for the production 
DNA coding for SLTP4 and 223stop mutant SLT Is. 
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Figure 3.2.3 Amino acid changes made to the primary sequence of 
SL T 1 as result of mutagenesis. 
Figure 3.2.3 shows the portion of the primary sequence of SLT 1 A chain between 
residues 217 and 256 where amino acid changes were introduced by site directed 
mutagenesis and recombinant PCR. Changes to the wild type sequence are shown in 
bold. Numbering of amino-acyl residues is from Calderwood et al (1987) (see 
appendix 5). Residue numbering refers to the mature signal sequence-cleaved 
protein. 
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Figure 3.2.3 Amino acid changes made to the primary sequence of 
SLT 1 as result of mutagenesis. 
SLT 1 wt 
2170 S V R V G R I S F G SIN A I L G S V A L I L N C H H HAS R V A R M A S 0 Em 
SLTPl 
2170 S V R V G R I S F G SIN A I L G S V A L I L N C H H HAS G v A G M A S 0 E256 
SLTP2 
2170 S V R V G RI S F G SIN A I L G S V A L I L N C H H H G A R V A R M G A 0 E2~6 
SLTP3 
2170 S V R V G R I S F G SIN A I L G S V A L I L N C H H H GAG V A G M G A 0 E256 
SLTP4 
2170 S V G VG G I S F G SIN A I L G S V A L I L Ne H H H GAG V A G M G A 0 Em 
SLT 223stop 
2170 S V RV G STOP 
109 
Figure 3.2.4 Plasmid pSL TPl 
Construction of pSL TP 1 allowed expression of mutant SL TP 1 protein in Escherichia 
coli JM105. The plasmid was constructed by ligation of a EcoRI / PslI mutant DNA 
fragment coding for the full length SL TP 1 holotoxin and its associated Shine-
Dalgarno and periplasmic targeting sequences from M 13 SL TP 1 into EcoRI / Ps/I cut 
pUC 19. Transcription is under control of the inducible lacZ promoter. 
pSLTP1 
4000 bp 
Hind III 
lac Z promoter 
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Figure 3.2.5 Plasmid pSLTP2 
Construction of pSL TP2 allowed expression of mutant SL TP2 protein in Escherichia 
coli JMl 05. The plasmid was constructed by ligation of a EcoRI / Ps/I mutant DNA 
fragment coding for the full length SL TP2 holotoxin and its associated Shine-
Dalgarno and periplasmic targeting sequences from M13SL TP2 into EcoRI / Ps/I cut 
pUC 19. Transcription is under control of the inducible lacZ promoter. 
pSLTP2 
4000 bp 
Hind III 
lac Z promoter 
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Figure 3.2.6 plasmid pSLTP3 
Construction of pSL TP3 allowed expression of mutant SL TP3 protein in Escherichia 
coli JMl 05. The plasmid was constructed by ligation of a EcoRI / Ps/I mutant DNA 
fragment coding for the full length SL TP3 holotoxin and its associated Shine-
Dalgarno and periplasmic targeting sequences from M 13SL TP3 into EcoRI I Ps/I cut 
pUC19. Transcription is under control of the inducible lacZ promoter. 
pSLTP3 
4000 bp 
Hind III 
lac Z promoter 
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Figure 3.2.7 plasmid pSLTP4 
Construction of pSL TP4 allowed expression of mutant SL TP4 protein in Escherichia 
coli JM105. The plasmid was constructed by ligation of a EcoRI / Ps/I mutant DNA 
fragment coding for the full length SL TP4 holotoxin and its associated Shine-
Dalgamo and periplasmic targeting sequences from M13SLTP4 into EcoRI / PslI cut 
pUC19. Transcription is under control of the inducible lacZ promoter. 
pSLTP4 
4000 bp 
Hind III 
lac Z promoter 
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Figure 3.2.8 plasmid pGEM223stop 
Construction of pGEM223stop allowed expression in vitro of a truncated N-terminal 
222 amino acid SL T 1 A chain. The insertion of a stop codon TGA allows premature 
termination of translation following residue Gly 222. The plasmid was constructed 
by ligation of a 1300 base pair fragment produced by mutagenic PCR cut with EcoRI 
/ Ps/I into pGEM2 similarly digested with EcoRI / PsII. Transcription is controlled 
by the viral T7 promoter. 
p223stop 
4200 bp 
AGA>TGA 
promoter 
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3.2.2 Expression and purification of Mutant Shiga-like toxins ill 
vivo. 
The expression system and method of purification used for the production of mutant 
forms of SL T 1, cloned into the pUC 19 expression vector, was identical to that used 
for the expression and purification of SLT 1 wild type (section 3.1.2) 
SL TP 1, SL TP2, SL TP3 and SL TP4 were expressed using the expression plasmids 
pSLTPl, pSLTP2, pSLTP3 and pSL TP4 respectively transformed into Escherichia 
coli JMI05. Purification of toxins from Escherichia coli periplasm was achieved by 
binding to fresh Gb3-Sepharose affinity matrix columns described previously (3.1.2). 
In all four cases expression and purification using the protocols described yielded 
recombinant holotoxins with the expected molecular weight as analyzed by SOS 
PAGE (2.7.7). Approximately lmg of pure toxin was obtained for each mutant from 
a starting culture of 1 liter. The results of expression and purification of recombinant 
mutant holotoxins are shown in figures 3.2.9 - 3.2.12. Recombinant proteins were 
stored for short periods of time (approximately 1 month) at 4°C in PBS, proteins kept 
for longer periods of time were stored in small aliquots at -70°C in PBS. 
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Figure 3.2.9 Analysis of expression and purification of SL TPl by 
SDS polyacrylamide gel electrophoresis. 
Figure 3.2.9 shows the expression and subsequent purification of mutant SL TP 1 
protein analyzed on a coomasie G250 stained 15 % SDS PAG. Protein coded in 
pSLTPI, under the transcriptional control of the lacZ promoter, was expressed in 
Escherichia coli JMI05. Lane 2 shows the precolumn periplasm extracted from 
transformed Escherichia coli. Lanes 3-6 show eluted fractions of pure mutant protein 
from a 1 ml GbrSepharose affinity column with 6M guanidine hydrochloride pH6. 7. 
The arrows indicate the positions of SL T A chain (32kDa) and SL T B chain 
(7.7kDa). Molecular masses are indicated in kDa. 
Lane 1 Molecular weight markers 
Lane 2 precolumn periplasm (5j.ll) 
Lane 3 eluted fraction 2 (30j.l1) 
Lane 4 eluted fraction 3 (30j.l1) 
Lane 5 eluted fraction 4 (30j.l1) 
Lane 6 eluted fraction 5 (30j.l1) 
Lane 7 eluted fraction 6 (30j.l1) 
Lane 8 molecular weight markers 
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Figure 3.2.9 Analysis of expression and purification of SLTPl by 
SDS polyacrylamide gel electrophoresis. 
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Figure 3.2.10 Analysis of expression and purification of SLTP2 by 
SDS polyacrylamide gel electrophoresis. 
Figure 3.2.10 shows the expression and subsequent purification of mutant SL TP2 
protein analyzed on silver stained 15 % SDS PAGE. Protein coded in pSL TP2, under 
the transcriptional control of the lacZ promoter, was expressed in Escherichia coli 
JM105. Lane 2 shows the precolumn periplasm extracted from transformed 
Escherichia coli. Lanes 3-7 show eluted fractions of mutant protein from a 1 ml Gb3-
Sepharose affinity column with 6M guanidine hydrochloride pH6.7. The arrows 
indicate the positions of SLT A chain (32kDa) and SL TB chain (7.7kDa). Molecular 
masses are indicated in kDa. 
Lane I Molecular weight markers 
Lane 2 precolumn periplasm (5J.lI) 
Lane 3 eluted fraction 8 (30J.ll) 
Lane 4 eluted fraction 9 (30J.lI) 
Lane 5 eluted fraction IQ (30J.ll) 
Lane 6 eluted fraction 11 (30J.ll) 
Lane 7 eluted fraction 12 (30J.lI) 
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Figure 3.2.10 Analysis of expression and purification of SLTP2 by 
SDS polyacrylamide gel electrophoresis. 
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Figure 3.2.11 Analysis of expression and purification of SL TP3 by 
SDS polyacrylamide gel electrophoresis. 
Figure 3.2.11 shows the expression and subsequent purification of mutant SLTP3 
protein analyzed on a Coomasie G250 stained 15 % SDS PAG. Protein coded in 
pSLTP3, under the transcriptional control of the lacZ promoter, was expressed in 
Escherichia coli JM105. Lane 2 shows the precolumn periplasm extracted from 
transformed Escherichia coli. Lane 3 shows proteins which do not bind to the 
column. Lanes 4-8 show eluted fractions of pure mutant protein from a 1 ml Gb3-
Sepharose analogue column with 6M guanidine hydrochloride pH6.7. The arrows 
indicate the positions of SLT A chain (32kDa) and SL TB chain (7.7kDa). Molecular 
masses are indicated in kDa. 
Lane 1 Molecular weight markers 
Lane 2 precolumn periplasm (5fll) 
Lane 3 flow through 15 (fll) 
Lane 4 eluted fraction 4 (30fll) 
Lane 5 eluted fraction 5 (30fll) 
Lane 6 eluted fraction 6 (30fll) 
Lane 7 eluted fraction 7 (30fll) 
Lane 8 eluted fraction 8 (30fll) 
Lane 9 molecular weight markers 
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Figure 3.2.11 Analysis of expression and purification of SLTP3 by 
SDS polyacrylamide gel electrophoresis. 
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Figure 3.2.12 Analysis of expression and purification of SL TP4 by 
SDS polyacrylamide gel electrophoresis. 
Figure 3.2.12 shows the expression and subsequent purification of mutant SL TP4 
protein analyzed on a Coomasie G250 stained 15 % SOS PAG. Protein coded in 
pSLTP4, under the transcriptional control ofthe lacZ promoter, was expressed in 
Escherichia coli JMl05. Lane 2 shows the precolumn periplasm extracted from 
transformed Escherichia coli. Lanes 3-6 show eluted fractions of pure mutant protein 
from a 1 ml GbrSepharose affinity column with 6M guanidine hydrochloride pH6. 7. 
The arrows indicate the positions of SL T A chain (32kOa) and SL T B chain 
(7.7kOa). Molecular masses are indicated in kOa. 
Lane 1 Molecular weight markers 
Lane 2 precolumn periplasm (51-ll) 
Lane 3 eluted fraction 6 (30I-lI) 
Lane 4 eluted fraction 7 (30I-ll) 
Lane 5 eluted fraction 8 (30I-lI) 
Lane 6 eluted fraction 9 (30I-ll) 
Lane 7 molecular weight markers 
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Figure 3.2.12 Analysis of expression and purification of SLTP4 by 
SDS polyacrylamide gel electrophoresis. 
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3.2.3 In vitro expression of SL T223stop. 
RNA transcribed, under control of the viral T7 promoter, in pGEM223stop linerised 
by digestion with PvuI (2.4.1), was expressed in vitro using a wheat germ translation 
system in the presence of eSS]-methionine (2.4.2). Control translation reactions were 
also carried out in order to check that the translation reactions were working and to 
aid the sizing of the translation product. The controls used were SLT 1 A 1 (an SL T I 
protein truncated by insertion of a stop codon in place of the codon for Arg248 
approximately 27kOa in size) and SL T 1 A chain (a full length clone containing the 
entire SLT 1 A chain coding sequence approximately 32kOa in size) kind gifts from 
Or Beverley Burgess (Warwick). Both of these SLT 1 constructs are in the pGEM2 
background under control of the viral T7 promoter. PAP R3 (a pGEM2 construct 
transcriptionally controlled by the T7 promoter) which codes for an inactive mutant 
of the type I ribosome inactivating protein poke weed anti-viral protein (PAP) 
approximately 30kDa in size a kind gift from Dr John Chaddock (Warwick). 
Translation of pGEM223stop transcribed RNA results in a protein of approximately 
25 kDa as analyzed by SDS PAGE. Expression of SL T223 stop and controls is shown 
are figure 3.2.13. 
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Figure 3.2.13 In vitro translation of SL T223stop protein in wheat 
germ lysate. 
Figure 3.2.13 shows the separation of translated transcripts in a wheat germ cell free 
system on a 15% polyacrylamide gel. Il-lg of each transcript coding for rSL T 1 A 
chains or a mutant form of poke weed anti-viral protein was translated using a cell 
free wheat germ lysate in the presence of CSS]-methionine (3.2.3). Molecular masses 
are indicated in kDa. 
Lane 1 e4C]-molecular weight markers 
Lane 2 translated pGEMA 1 transcript 
Lane 3 translated pGEMSLTwt transcript 
Lane 4 translated pGEM223stop transcript 
Lane 5 translated pGEM2P APR3 transcript 
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Figure 3.2.13 In vitro Translation of SLT223stop protein in wheat 
germ lysate. 
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3.2.4 Discussion 
Cloning of the SLT 1 operon sequence into the bacteriophage M 13mp 18 afTord~d a 
rapid and simple method for the production of mutant coding sequences for SLT 1. 
DNA coding for the proteins SL TP4 and 223stop could not be made by standard 
SOM methods. The reasons for this are not clear. Recombinant PCR provid~d an 
effective yet costly alternative to SOM here. By the engineering of unique cloning 
sites at the 3' and 5' terminal ends of the operon sequence by PCR (3.1.1), mutant 
coding sequences could be subcloned into the multiple cloning site of pUC 19 
directly. DNA cloned in this manner was then ideally placed for expression und~r the 
transcriptional control of the lacZ promoter. The associated Shinc-Dalgarno 
sequence was also included in these constructs as it is considered that this sequence 
is probably optimally positioned in relation to the translational start site. 
The resulting expression constructs were all able to mediate expression of mutant 
forms of SL T 1 in quantities more than adequate for the purposes of this study 
approximately lmg in each case. All mutant proteins expressed were in the form of 
soluble holotoxins which were able to bind to the trisaccharide globotriosc linked via 
a spacer to cyanogen bromide-activated Sepharose 4B. Binding to this matrix 
allowed the purification of these toxins to single A and D chain bands on SOS 
polyacrylamide gels with migration rates as predicted. 
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pGEM223stop was constructed by cloning a full length SL T 1 coding sequence into 
which a stop codon had been introduced at the position coding for the amino acid 
Arg223 into the polylinker region ofpGEM2. The resulting construct is able to 
mediate the transcription and translation of a truncated form of SLT 1 I\. chain when 
transcribed and translated in a wheat germ cell free system. 
The resulting translation product has an apparent molecular weight of 25.1 kDa by 
measurement of migration on a 15 % polyacrylamide gel (figure 3.2.13). This figure 
compares with a predicted molecular weight of24.5kDa for this protein. This small 
discrepancy may be explained by aberrant migration in this gel system since SLT 1\.1 
also shown in figure 3.2.13 appears to have a molecular weight of 28.2kDa compared 
with the predicted molecular weight of27.3kDa. 
In summary the expression systems and where appropriate purification systems 
presented in this chapter allow the production of biochemically pure mutant proteins. 
In the case of potential processing mutant proteins, large quantities were prepared for 
subsequent biochemical analysis. 
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Chapter 3 
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3.3 Characterisation of SLTl and potential processing mutants. 
Introduction 
The aim of this study is to investigate the proteolytic processing requirements for 
SL T 1 during uptake into eukaryotic cells (scction 1.6). To achieve this aim several 
mutant proteins were made with specific amino acid changes at residues likcJy to be 
involved in proteolytic processing. In this chapter, the five mutant proteins described 
in chapter 2 are characterised with respect to their susceptibility to proteolytic 
processing both in vitro and in vivo. The effects of several membrane permeable 
reagents are also investigated. Brefeldin A is a fungal metabolite which is known to 
disrupt the Golgi stack with consequent peturbation of Golgi to ER trafficking. 
Brefeldin A-treated Vero cells are not able to transport SL T I from the TGN to the 
Golgi and ER where it is thought that translocation to the cytosol occurs (section 
1.6). Ammonium chloride is a reagent which increases lysosomal pI I. This reagent 
was used to inhibit proteolysis of toxin which might occur in the lysosome. Calpain 
inhibitor I is a potent inhibitor of the proteolytic enzymes known collectively as the 
calpains. Pretreatment of cells with calpain inhibitor I inhibits the activity of the 
intracellular calpain thought to play a role in alternative proteolytic processing of 
SL T 1 (section 1.6). 
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3.3.1 N-glycosidase activity of SLT 1 and potential processing 
mutants. 
The N-glycosidase activities of SLT 1 wild-type and the processing mutants 
described in chapter 2 towards isolated rabbit reticulocyte ribosomes were compared 
in vitro using the aniline assay (section 2.7.3). Rabbit reticulocyte ribosomes were 
incubated with three decreasing amounts of recombinant SL T 1, SL TP I, SL TP2. 
SL TP3 and SL TP4 (lOOOng, 100ng, lOng) prior to treatment with aniline. The 
resulting aniline-treated RNA was run on a 1.2% denaturing agarose gel (section 
2.3.4). Separated RNA was subjected to northern blot analysis (section 2.3.17) using 
a DNA probe specific for the 5' end of rabbit 28S ribosomal RNA. Figure 3.3.1 
shows an autoradiograph of a northern blot prepared in this manner. Dcpurination of 
rRNA followed by treatment with acetic aniline results in cleavage of the rRNA 
backbone at position 4324 releasing an RNA fragment of 394 bases from the 5' cnd 
of28S rRNA. The presence of this short fragment is diagnostic for the action of 
ribosome inactivating proteins. The northern blot in figure 3.3.1 clearly demonstrates 
that all five proteins investigated using the aniline assay possess N-glycosidase 
activity. This activity is not apparently altered as a result of the mutations made. 
though from such non-quantitative analyses it isn't possible to totally exclude slight 
changes in catalytic activity. 
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Figure 3.3.1 Comparison of N-glycosidase activity of SLT 1 and 
potential processing mutants using the aniline assay and visualized 
by northern blot analysis. 
Figure 3.3.1 shows a autoradiograph of a rRNA transferred to a nitrocellulose filter 
by northern blotting followed by hybridization of a DNA oligonucleotide e2p]_y 
A TP labelled probe, designed to hybridize to the 5' end of the 28S rRNA from 
rabbit. Rabbit reticulocyte ribosomes were treated with decreasing amounts of toxin 
at 30°C for 30 min. The resulting RNA was isolated and treated with acetic-aniline at 
60°C for 2 min. Aniline treated RNA was separated on a 1.2% denaturing formamide 
agarose gel before transfer to nitrocellulose. Specific depurination due to the action 
of SL T 1 followed by aniline treatment leads to release of a 394 base RNA fragment 
indicated by an arrow. 
Lane 1 1000ng rSL T wild-type 
lane 2 100ng rSL T wild-type 
Lane 3 lOng rSL T wild-type 
Lane 4 1000ng rSL TP 1 
Lane 5 100ng rSL TP 1 
Lane 6 lOng rSL TP 1 
Lane 7 1000ng rSL TP3 
Lane 8 100ng rSL TP3 
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Lane 9 lOng rSL TP3 
Lane 10 1000ng rSL TP4 
Lane 11 100ng rSL TP4 
Lane 12 lOng rSL TP4 
Lane 13 1000ng rSL TP2 
Lane 14 100ng rSL TP2 
Lane 15 lOng rSL TP2 
Figure 3.3.1 Comparison ofN-glycosidase activity of SLT 1 and 
potential processing mutants using the aniline assay and visualized 
by northern blot analysis. 
1 2 3 4 5 6 7 8 9 la 11 12 13 14 15 
133 
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The N-glycosidase activity ofthe protein 223stop described in Chapter 2 was 
assessed by its ability to depurinate rabbit reticulocyte ribosomes during in vitro 
translation (2.4.3ii). The 223stop construct was made in order to determine whether 
an SLT 1 A chain truncated at residue 223 had N-glycosidase activity. To preclude 
the need for purification of this protein, the coding DNA sequence was cloned into a 
in vitro expression vector where resulting transcrips could be translated and N-
glycosidase activity assessed directly on the translating ribosomes. The construction 
and subsequent expression ofpGEM223 in a wheat germ lysate cell free system are 
described in chapter 2. 
To assess whether 223stop maintained N-glycosidase activity, the in vitro transcript 
from pGEM223stop was translated in a non-nuclease treated rabbit reticulocyte 
lysate system. All transcripts were translated for 1 hour at 30°C. Following 
translation, rRNA was extracted from this reaction and subjected to hydrolysis with 
acetic-aniline. The extent of ribosome depurination was then determined by 
separation of isolated rRNA on a denaturing 1.2% formamide agarose gel. The 
appearance of a 394 base fragment following acetic-aniline cleavage is diagnostic of 
ribosome depurination. Figure 3.2.2 shows the results of such an assay. Control 
transcripts shown in chapter 2 were also translated in non-nuclease treated rabbit 
reticulocyte lysate. From the assay described the truncated protein, 223stop does not 
appear to have N-glycosidase activity. The positive controls SL T wt and SL TA I 
both display activity in this assay whereas the inactive PAP mutant, P APR3, does not 
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show activity. In addition to the three controls described a fourth control was used in 
which an in vitro transcript was omitted from the translation reaction, in its place, 
lOOng of ricin A chain were added. As expected the ribosomes in this reaction also 
show characteristic modification. 
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Figure 3.3.2 Depurination of rabbit reticulocyte ribosomes during in 
vitro translation of pGEM223stop in vitro transcript in a non-
nuclease treated rabbit reticulocyte lysate. 
Figure 3.2.2. shows rRNA extracted from in vitro translation reactions in which 
potential ribosome inactivating proteins have been translated. In vitro transcripts 
coding for toxins were translated in a rabbit reticulocyte lysate system for I hour at 
30°C. Extracted rRNA was then subjected to hydrolysis with acetic-aniline and 
separated on a 1.2% denaturing formamide agarose gel. The separated RNA was 
visualized by ethidium bromide staining. Release of a 394 base RNA fragment 
(indicated by the arrow) is characteristic of ribosome depurination. In addition to two 
positive controls (SL TA 1 and SL Twt) which possess N-glycosidase activity and a 
negative control (PAPR3) which lacks N-glycosidase activity, a reaction in which 
mRNA was replaced with lOOng RTA was included. 
Lane I Ribosomes translating pGEM223stop transcript 
Lane 2 Ribosomes translating pGEMSL TAl transcript 
Lane 3 Ribosomes translating pGEMSLTwt transcript 
Lane 4 Ribosomes translating pGEMP APR3 transcript 
Lane 5 IOOng RTA no transcript 
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Figure 3.3.2 Depurination of rabbit reticulocyte ribosomes during ill 
vitro translation of pGEM223stop in vitro transcript in a 110n-
nuclease treated rabbit reticulocyte lysate. 
1 2 3 4 5 
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3.3.2 In vitro trypsin sensitivity of SLT 1 and potential processing 
mutants 
The sensitivity of SL T I and the processing mutants to trypsin was used to assess the 
effects of mutations made to trypsin-sensitive amino acyl residues. The trypsin-
sensitive loop of wild-type SL T I contains two arginine residues. Treatment of SL T 
1 wt with trypsin in vitro results in cleavage of the toxin A chain to two fragments of 
molecular weight approximately 27kDa and 4kDa, the smaller of these fragments not 
being resolved on standard 15% SDS PAGE. Removal of exposed arginine residues 
within the loop should reduce sensitivity to this protease. The use of trypsin 
treatment of mutant proteins is also used as a measure of the degree of malfolding 
induced in proteins as a result of mutation. Figure 3.3.3 and 3.3.4 shows the 
separation by 15% PAGE of mutant and wild-type toxins treated with increasing 
concentrations of trypsin run under reducing and non-reducing conditions 
respectively. Under the conditions used wild-type toxin appears to be completely 
cleaved to the Al sized fragment at both 0.1 and 5~g/ml trypsin as is the SLTP2 
mutant. SL TPI and SLTP3 are mostly resistant to trypsin at the concentrations used. 
SL TP4 also remains mostly resistant to trypsin since no A I-sized fragment is 
generated. However a larger fragment of approximately 29kDa occurs. All fragments 
generated from the A chains of wild-type and mutant proteins are generated from 
within the disulphide bonded loop since when the same samples are run under non-
reducing conditions these bands are absent (figure 3.3.4). 
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Figure 3.3.3 Reducing 15%) SDS polyacrylamide gel electrophoresis 
of trypsin-treated SL T 1 and potential processing mutants. 
1 J.lg of wild-type and mutant toxins were treated with 0.1 and SJ.lg/ml of sequencing 
grade trypsin in a 30J.lI reaction for 7 min at 37°C. Reactions were stopped by 
addition of IJ.lI ofTLCK lmg/ml in O.OSM sodium acetate-acetic acid pHS.O and 
incubation on ice for 5 min prior to boiling in sample loading buffer. The resulting 
protein was separated on a 15% SDS P AG under reducing conditions and protein 
visualized by silver staining. 
Lane 1 SL T 1 wt -trypsin 
Lane 2 SL T 1 wt 0.1 J.lg/ml trypsin 
Lane 3 SL T 1 wt 5J.lg/ml trypsin 
Lane 4 SL TP I-trypsin 
Lane 5 SL TP 1 0.1 J.lg/ml trypsin 
Lane 6 SLTPI 5J-lg/ml trypsin 
Lane 7 SL TP2-trypsin 
Lane 8 SLTP2 O.IJ-lg/ml trypsin 
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Lane 9 SL TP2 5J.lg/ml trypsin 
Lane 10 SL TP3 -trypsin 
Lane 11 SL TP3 0.1 J-lg/ml trypsin 
Lane 12 SL TP3 5J.lg/ml trypsin 
Lane 13 SL TP4 -trypsin 
Lane 14 SL TP4 0.1 J-lg/ml trypsin 
Lane 15 SL TP4 5 J.lg/ml trypsin 
Lane 16 MW markers 
Figure 3.3.3 Reducing 15%, SDS polyacrylamide gel electrophoresis 
of trypsin-treated SLT 1 and potential processing mutants. 
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Figure 3.3.4 Non-reducing 15% SDS polyacrylamide gel 
electrophoresis of trypsin-treated SL T 1 and processing mutants. 
I/lg of wild-type and mutant toxins were treated with 0.1 and 5/lg/ml ofsequencing 
grade trypsin in a 30/ll reaction for 7 min at 37°C. Reactions were stopped by 
addition of I/ll ofTLCK Img/ml in 0.05M sodium acetate-acetic acid pH5.0 and 
incubation on ice for 5 min prior to boiling in sample loading buffer. The resulting 
protein was separated on a 15% SDS P AG under non-reducing conditions and 
protein visualized by coomasie blue G250 staining. 
Lane 1 molecular weight markers 
Lane 2 SL T I wt -trypsin 
Lane 3 SL T 1 wt O.I/lg/ml trypsin 
Lane 4 SLT I wt 5/lg/ml trypsin 
Lane 5 SL TP1-trypsin 
Lane 6 SLTPl O.I/lg/ml trypsin 
Lane 7 SLTPl 5/lg/ml trypsin 
Lane 8 SL TP2-trypsin 
Lane 9 SL TP2 O.l/lg/ml trypsin 
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Lane lO SL TP2 5/lg/ml trypsin 
Lane 11 SL TP3 -trypsin 
Lane 12 SL TP3 O.l/lg/ml trypsin 
Lane 13 SL TP3 5/lg/ml trypsin 
Lane 14 SL TP4 -trypsin 
Lane 15 SL TP4 O.I/lg/ml trypsin 
Lane 16 SL TP4 5/lg/ml trypsin 
Lane 17 MW markers 
Figure 3.3.4 Non-reducing 15%, SDS polyacrylamide gel 
electrophoresis of trypsin-treated SLT 1 and potential processing 
mutants. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
SLTA~ 31 
21 
SLT 1 B~ 
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3.3.3 Cytotoxicity of SLT 1 and the potential processing mutants. 
The cytotoxicity of wild-type SL T 1 and the processing mutants described in chapter 
2 was determined using Vero cells (section 2.7.4). ICso (the concentration of toxin 
required to reduce protein synthesis by 50%) values were calculated for the toxins 
described both on untreated Vero cells and also on Vero cells which had been treated 
with certain reagents, by analyzing protein synthesis inhibition as a function of toxin 
concentration. The kinetics of intoxication were also determined by analysing protein 
synthesis inhibition as a function of time. The results of these cytotoxicity 
experiments are shown in figures 3.3.5-3.3.10. 
Over a three hour toxin incubation on untreated Vero cells a large reduction in 
cytotoxicity between the wild-type toxin and the processing mutants lacking either 
the loop arginines (SLTPI and SLTP3) or the loop arginines and the upstream furin 
consensus motif (SL TP4) can be seen. The mutants SL TP 1 and SL TP3 are 25 fold 
less toxic than wild-type and SL TP4 is 132 fold less toxic than the wild-type protein. 
The toxicity of the SL TP2 mutant protein is identical to wild type toxin. After a 
longer (6 hour) incubation, the toxicity of SL TP 1 and SL TP3 are identical to that of 
the wild-type protein, however the mutant SL TP4 remains 62 fold less toxic than the 
wild-type toxin. 
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Where the cells are pretreated for 30 minutes with NH4CI no effect on the toxicity of 
the wild-type protein or the mutants SL TP 1 and SL TP3 is seen, however the toxicity 
of SL TP4 appears to be increased by a factor of 3 when compared with the same 
toxin in untreated Vero cells. Calpain inhibitor I has little effect on the wild-type 
protein and indeed appears to increase wild-type toxicity by a factor of 2. Calpain 
inhibitor I does however reduce the toxicity of the mutants SL TP 1 and SL TP3 by a 
factor of 4.5 and 6 respectively. Brefeldin A at a concentration of2J.lg/ml protects 
cells from intoxication with wild-type toxin completely under the conditions tested 
here. From kinetic measurements wild-type toxin is able to reduce protein synthesis 
by 50% more quickly than the mutants described giving a t50 of 53 minutes. SL TP 1 
and SL TP4 both have t50 values of 75 minutes followed by SL TP3 with a t50 of 82 
minutes. It is considered that the subtle differences between SL TP 1, SL TP4 and 
SLTP3 are probably not significant as these figures are the result of just two 
experiments 
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Figure 3.3.5 Cytotoxicity of SL T 1 wild-type and potential 
processing mutants: 3 hour incubation of toxin. 
1 x 10-4 to 10 ng/ml of each recombinant holotoxin, diluted in DMEM, was incubated 
with 1.2 to 1.5 xl 04 Vero cells plated in 96 well tissue culture plates for 2.5 hours at 
37°C in a 5% CO2 incubator. Following incubation with toxin the cell monolayers 
were washed once with PBS and 100J.lI ofPBS containing IJ.lCi of[35S]-methionine 
was added to each well. Cells were incubated for a further 30 min. Monolayers were 
then washed three times with 5% ice cold trichloroacetic acid and neutralized by a 
single wash with PBS. Acid-precipitated protein was then released with 100J.lI of 
O.5M NaOH and incorporated radioactivity was quantified by liquid scintillation 
counting. 
All values are the mean of four replicate samples. Protein synthesis inhibition was 
calculated as the percentage incorporation of radioactivity compared with the mean 
of six no toxin controls. 
Toxin ICso ng/ml 
rSLT 1 wt 0.019 
SLTPl 0.469 
SLIP2 0.019 
SLIP3 0.469 
SLTP4 2.509 
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Figure 3.3.5 Cytotoxicity of SLT 1 wild-type and potential 
processing mutants: 3 hour incubation of toxin. 
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Figure 3.3.6 Cytotoxicity of SLT 1 wild-type and potential 
processing mutants: 6 hour incubation of toxin. 
1 x 1 0-4 to 10 ng/ml of each recombinant holotoxin, diluted in DMEM, was incubated 
with 1.2 to 1.5 X 104 Vero cells plated in 96 well tissue culture plates for 5.5 hours at 
37°C in a 5% CO2 incubator. Following incubation with toxin the cell monolayers 
were washed once with PBS and 100,.d of PBS containing 1 ~Ci of e5S]-methionine 
was added to each well. Cells were incubated for a further 30 min. Monolayers were 
then washed three times with 5% ice cold trichloroacetic acid and neutralized by a 
single wash with PBS. Acid-precipitated protein was then released with 1001-l1 of 
O.5M NaOH and incorporated radioactivity was quantified by liquid scintillation 
counting. 
All values are the mean of four replicate samples. Protein synthesis inhibition was 
calculated as the percentage incorporation of radioactivity compared with the mean 
of six no toxin controls. 
Toxin IC50 ng/ml 
rSLT 1 wt 0.0058 
SLTPI 0.0071 
SLTP3 0.009 
SLTP4 0.361 
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Figure 3.3.6 Cytotoxicity of SLT 1 wild-type and potetial processing 
mutants: 6 hour incubation of toxin. 
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Figure 3.3.7 Cytotoxicity ofSLT 1 wild-type and potential 
processing mutants to Vero cells pretreated with lOmM NH4CI: 3 
hour incubation of toxin. 
1 x 10-3 to 100 ng/ml of each recombinant holotoxin, diluted in DMEM plus 10mM 
NH4Cl, was incubated with 1.2 to 1.5 xl04 Vero cells, pre treated with 10mM NH4Cl 
for 45 min in media, in 96 well tissue culture plates for 2.5 hours at 37°C in a 5% 
CO2 incubator. Following incubation with toxin the cell mono layers were washed 
once with PBS and 100J..ll ofPBS containing IJ..lCi of eSS]-methionine was added to 
each well. Cells were incubated for a further 30 min. Monolayers were then washed 
three times with 5% ice cold trichloroacetic acid and neutralized by a single wash 
with PBS. Acid-precipitated protein was then released with 1001-11 of 0.5M NaOH 
and incorporated radioactivity was quantified by liquid scintillation counting. 
All values are the mean of four replicate samples. Protein synthesis inhibition was 
calculated as the percentage incorporation of radioactivity compared with the mean 
of six no toxin controls. 
Toxin ICso ng/ml 
rSLT 1 wt 0.020 
SLTPl 0.342 
SLTP3 0.342 
SLTP4 0.774 
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Figure 3.3.7 Cytotoxicity of SL T 1 wild-type and potential 
processing mutants to Vero cells pretreated with lOmM NH4CI: 3 
hour incubation of toxin. 
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Figure 3.3.8 Cytotoxicity of SLT 1 wild-type and potential 
processing mutants to Vero cells pretreated with calpain inhibitor I 
(lOO).lg Iml): 3 hour incubation of toxin. 
Ix I 0-4 to 10 ng/ml of each recombinant holotoxin, diluted in DMEM plus calpain 
inhibitor I (lOOJ..lg/ml), was incubated with 1.2 to 1.5 x 104 Vero cells, pre-treated 
with calpain inhibitor I IOOJ..lg/ml for 30min in media, in 96 well tissue culture plates 
for 2.5 hours at 37°C in a 5% CO2 incubator. Following incubation with toxin the 
cell mono layers were washed once with PBS and IOOJ..lI of PBS containing 1 J..lCi of 
eSS]-methionine was added to each well. Cells were incubated for a further 30 min. 
Monolayers were then washed three times with 5% ice cold trichloroacetic acid and 
neutralized by a single wash with PBS. Acid-precipitated protein was then released 
with IOOJ..lI of 0.5M NaOH and incorporated radioactivity was quantified by liquid 
scintillation counting. 
All values are the mean of four replicate samples. Protein synthesis inhibition was 
calculated as the percentage incorporation of radioactivity compared with the mean 
of six no toxin controls. 
Toxin IC50 ng/ml 
rSLT 1 wt 0.0083 
SLTPI 2.099 
SLTP3 2.845 
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Figure 3.3.8 Cytotoxicity of SLT 1 wild-type and potential 
processing mutants to Vero cells pretreated with calpain inhibitor I 
(lOOJ-lg Iml): 3 hour incubation of toxin. 
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Figure 3.3.9 The kinetics of cytotoxicity of SLT 1 wild-type and 
potential processing mutants in Vero cells. 
100 ng/ml of each recombinant holotoxin, diluted in DMEM, was incubated with 1.2 
to 1.5 XlO4 Vero cells plated in 96 well tissue culture plates for time periods between 
20 and 120 min at 37°C in a 5% CO2 incubator. Following incubation with toxin the 
cell monolayers were washed once with PBS and lOO1l1 of PBS containing 1 llCi of 
eSS]-methionine was added to each well. Cells were incubated for a further 30 min. 
Monolayers were then washed three times with 5% ice cold trichloroacetic acid and 
neutralized by a single wash with PBS. Acid-precipitated protein was then released 
with I00111 of 0.5M NaOH and incorporated radioactivity was quantified by liquid 
scintillation counting. 
All values are the mean of four replicate samples. Protein synthesis inhibition was 
calculated as the percentage incorporation of radioactivity compared with the mean 
of six no toxin controls. The time axis shows the total period of toxin incubation i.e. 
that including the 30 min label. 
Toxin tso min 
rSLT 1 wt 54 
SLTPI 75 
SLTP3 82 
SLTP4 75 
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Figure 3.3.9 The kinetics of cytotoxicity of SL T 1 wild-type and 
potential processing mutants in Vero cells. 
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Figure 3.3.10 Cytotoxicity of SLT 1 wild-type to Vero cells 
pretreated with brefeldin A 2Jlg/ml: 3 hour incubation of toxin. 
lxlO-4 to 10 ng/ml of re comb in ant SLT 1 wild-type holotoxin, diluted in DMEM 
plus BF A 2Jlg/ml, was incubated with 1.2 to 1.5 x 104 Vero cells, pre-treated with 
BF A (2Jlg/ml) for 30 min in media, in 96 well tissue culture plates for 2.5 hours at 
37°C in a 5% CO2 incubator. Following incubation with toxin the cell monolayers 
were washed once with PBS and 100Jll ofPBS containing IJlCi of eSS]-methionine 
was added to each well. Cells were incubated for a further 30 min. Monolayers were 
then washed three times with 5% ice cold trichloroacetic acid and neutralized by a 
single wash with PBS. Acid-precipitated protein was then released with 100Jll of 
0.5M NaOH and incorporated radioactivity was quantified by liquid scintillation 
counting. 
All values are the mean of four replicate samples. Protein synthesis inhibition was 
calculated as the percentage incorporation of radioactivity compared with the mean 
of six no toxin controls. 
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Figure 3.3.10 Cytotoxicity ofSLT 1 wild-type to Vero cells 
pretreated with brefeldin A 2Jlg/ml: 3 hour incubation of toxin. 
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3.3.4 In vivo processing of SLT 1 and potential processing mutants. 
The sensitivity of mutant toxins to proteolytic processing during target cell 
intoxication was analysed using recombinant mutant and wild-type toxins 
radioactively labelled with 125lodine. 50~g of the mutant holotoxins SLTP1, SLTP3, 
SL TP4 and the wild-type toxin were labelled with 1251 using the non-harsh Iodogen 
method (section 2.6.4). All proteins were efficiently labelled to specific activities of 
approximately 25 OOOcpmlng in each case (Figure 3.3.11). Susceptibility of mutant 
and wild type toxins was measured over a time course of 2 hours with samples taken 
at 30 min, 1 hour and 2 hours. Following intoxication of cells with [125 I]-toxin for 
the specified period of time, cells were lysed in the presence of a cocktail of protease 
inhibitors before precipitation and separation of protein on 15% SDS PAGs (section 
2.7.5). The conditions used in previous cytotoxicity experiments were repeated with 
the aim of visualizing intracellular proteolytic processing of toxin. The results of in 
vivo proteolytic processing experiments are shown in figures 3.3.12 to 3.3.15. 
Whether proteolytic cleavage occurs within the extracellular medium, either by 
proteases present in DMEM or by proteases secreted by Vero cells, was also 
addressed. 20 ng of each iodinated toxin was incubated at 37°C for 2 hours with 100 
Jll DMEM removed from a confluent flask ofVero cells. Following incubation total 
protein was precipitated from the reaction with acetone. The resulting protein pellets 
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were re suspended in reducing sample loading buffer and separated on 15% SDS 
polyacrylamide gels. The results from this experiment are shown in figure 3.3.16. 
Wild-type toxin was efficiently processed to the Al subunit size in untreated Vero 
cells and in cells pretreated with calpain inhibitor I and brefeldin A. The two mutant 
toxins SLTPl and SLTP3 are processed in untreated Vero cells albeit more slowly. 
However, in contrast to the wild-type toxin, SLTPI and SLTP3 are not processed or 
are processed more slowly to the Al subunit size in Vero cells pretreated with either 
calpain inhibitor I or brefeldin A. SL TP4 apparently remains intact in both untreated 
Vero cells and in Vero cells treated with calpain inhibitor I and brefeldin A. When 
the incubation period for SL TP4 is extended to 6 hours in untreated Vero cells there 
is still no evidence of processing of this mutant toxin. The results obtained from 
Vero cells pre-treated with NH4CI were not conclusive and time did not allow 
repetition of this particular experiment. From figure 3.3.15 it appears none of the 
toxins tested are processed in NH4CI treated cells. As with all other conditions tested 
SL TP4 is not processed at all in Vero cells pre-treated with NH4Cl. Non of the toxins 
tested were processed by media removed from growing cells showing that all the 
observed processing events take place in target cells and not in the extracellular 
medium. 
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Figure 3.3.11. 15 % reducing SDS polyacrylamide gel 
electrophoresis of 12sI_labelled SL T 1 and potential processing 
mutants. 
Recombinant SL T 1 and the processing mutants described in chapter 2 were labelled 
with 125Iodine using the iodogen method. The resulting proteins were separated on a 
15% SDS polyacrylamide gel under reducing conditions. All proteins were labelled 
to a specific activity of approximately 25 000 cpmlng. The positions of SL T A chain 
and SL T B chain are marked, molecular masses are given in kDa. 
Lane 1 Sng [125I]_SLT 1 wt 
Lane 2 Sng e25I]-SLTPI 
Lane 3 Sng e25I]-SL TP3 
Lane 4 Sng e25I]-SL TP4 
Lane 5 [14C]-molecular weight markers 
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Figure 3.3.11. 15 % reducing SDS polyacrylamide gel 
electrophoresis of 12sI-Iabelled SLT 1 and potential processing 
mutants. 
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Figure 3.3.12 Proteolytic processing of SLT 1 and potential 
processing mutants in untreated Vero cells. 
Vero cells, grown to a confluent monolayer in 3 cm tissue culture dishes, were 
incubated at 37°C in a 5% CO 2 incubator with 125I-Iabelled toxins at a final 
concentration of 100ng/ml for the specified period of time. Following incubation the 
toxin was washed off and cells lysed in cell lysis buffer. Celllysates were 
centrifuged to remove cell debris and nuclei and protein was precipitated with 
acetone. The resulting protein pellets were resuspended in reducing sample loading 
buffer and separated on 15% SDS polyacrylamide gels. The positions of full length 
SL T A chain and SL TAl are indicated by arrows. The extent of cleavage to the Al 
sized subunit was quantified by scanning densitometry and is plotted against time of 
incubation in CB). 
Lanes labelled M contain [14C]-molecular weight markers. Lanes labelled 30 contain 
protein precipitated from cells after 30 minutes incubation, Lanes labelled 1 contain 
protein precipitated from cells after 1 hour incubation lanes labelled 2 contain protein 
precipitated from cells after 2 hours incubation. The lane labelled 6 contains protein 
precipitated from cells after 6 hours incubation. 
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Figure 3.3.12 Proteolytic processing of SLT 1 and potential 
processing mutants in untreated Vero cells. 
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Figure 3.3.12 (B) Proteolytic processing of SLT 1 and potential 
processing mutants in untreated Vero cells. 
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Figure 3.3.13 Proteolytic processing of SL T 1 and potential 
processing mutants in Vero cells pretreated with calpain inhibitor 1 
(100flg/ml) 
Vero cells, grown to a confluent monolayer in 3 cm tissue culture dishes, were 
preincubated with 1001lg/mJ caJpain inhibitor I for 30 min prior to incubation at 
37°C in a 5% CO 2 incubator with 125I-Iabelled toxins at a final concentration of 
100ng/ml for the specified period of time. Following incubation the toxin was 
washed off and cells lysed in cell lysis buffer. Celllysates were centrifuged to 
remove cell debris and nuclei and protein was precipitated with acetone. The 
resulting cell pellets were re suspended in reducing sample loading buffer and 
separated on 15% SDS polyacrylamide gels. The positions of full length SL T A 
chain and SL TAl are indicated. Molecular masses are given in kDa. The extent of 
cleavage to the A 1 sized subunit was quantified by scanning densitometry and is 
plotted against time of incubation in (B). 
Lanes labelled M contain [14C]-molecular weight markers, Lanes labelled 30 contain 
protein precipitated from cells after 30 minutes incubation, Lanes labelled 1 contain 
protein precipitated from cells after 1 hour incubation and lanes labelled 2 contain 
protein precipitated from cells after 2 hours incubation. 
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Figure 3.3.13 Proteolytic processing of SLT 1 and potential 
processing mutants in Vero cells pretreated with calpain inhibitor 1 
(lOOJlg/ml) 
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Figure 3.3.13 (B) Proteolytic processing of SL T 1 and potential 
processing mutants in Vero cells pretreated with calpain inhibitor 1 
(lOOJlg/ml) 
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Figure 3.3.14 Proteolytic processing of SLT 1 and potential 
processing mutants in Vero cells pretreated with brefeldin A 
(2Jlg/ml). 
Vero cells, grown to a confluent monolayer in 3 cm tissue culture dishes, were 
preincubated with brefeldin A (2Jlg/ml) for 30 min prior to incubation at 37°C in a 
5% CO 2 incubator with 125I_Iabelled toxins at a final concentration of 100ng/ml for 
the specified period of time. Following incubation the toxin was washed off and cells 
lysed in cell lysis buffer. Celllysates were centrifuged to remove cell debris and 
nuclei and protein was precipitated with acetone. The resulting cell pellets were 
re suspended in reducing sample loading buffer and separated on 15% SOS 
polyacrylamide gels. The positions of full length SL T A chain and SL TAl are 
indicated. Molecular masses are given in kDa. The extent of cleavage to the Al sized 
subunit was quantified by scanning densitometry and is plotted against time of 
incubation in CB). 
Lanes labelled M contain [14C]-molecular weight markers, Lanes labelled 30 contain 
protein precipitated from cells after 30 minutes incubation, Lanes labelled 1 contain 
protein precipitated from cells after 1 hour incubation and lanes labelled 2 contain 
protein precipitated from cells after 2 hours incubation. 
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Figure 3.3.14 Proteolytic processing of SLT 1 and potential 
processing mutants in Vero cells pretreated with brefeldin A 
(2 Jlg/m I). 
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Figure 3.3.14 (B) Proteolytic processing of SLT 1 and potential 
processing mutants in Vero cells pretreated with brefeldin A 
(2 Jlg/m I). 
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Figure 3.3.15 Proteolytic processing of SL T 1 and potential 
processing mutants in Vero cells pretreated with lOmM NH4CI. 
Vero cells, grown to a confluent monolayer in 3 cm tissue culture dishes, were 
preincubated with lOmM NH4CI for 45 min prior to incubation at 37°C in a 5% CO 2 
incubator with 12sI-Iabelled toxins at a final concentration of 100ng/ml for the 
specified period of time. Following incubation the toxin was washed off and cells 
lysed in cell lysis buffer. Celllysates were centrifuged to remove cell debris and 
nuclei and protein was precipitated with acetone. The resulting cell pellets were 
resuspended in reducing sample loading buffer and separated on 15% SDS 
polyacrylamide gels. The positions of full length SL T A chain and SLT Al are 
indicated. Molecular masses are given in kDa. The extent of cleavage to the Al sized 
subunit was quantified by scanning densitometry and is plotted against time of 
incubation in (B). 
Lanes labelled M contain [14C]-molecular weight markers, Lanes labelled 30 contain 
protein precipitated from cells after 30 minutes incubation, Lanes labelled I contain 
protein precipitated from cells after 1 hour incubation and lanes labelled 2 contain 
protein precipitated from cells after 2 hours incubation. 
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Figure 3.3.15 Proteolytic processing of SLT 1 and potential 
processing mutants in Vero cells pretreated with lOmM NH4Cl. 
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Figure 3.3.15 (B) Proteolytic processing of SLT 1 and potential 
processing mutants in Vero cells pretreated with 10mM NH4CI. 
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Figure 3.3.16 Proteolysis of SL T 1 and potential processing mutants 
by extracellular proteases. 
IOOlll of DMEM removed from a confluent flask of Vero cells was incubated with 
20ng of iodinated SL T 1 or processing mutants SL TP 1. SL TP3 and SL TP4 for 2 
hours at 37°C. Protein was precipitated with acetone and separated by reducing 15% 
SDS PAGE. The position of SL T 1 A chain is indicated. molecular masses are given 
in kDa. 
Gel loading. 
Lane 1 SL T 1 wt -media. 
Lane 2 SL T 1 wt +media. 
Lane 3 SL TP 1 -media. 
Lane 4 SLTPI +media. 
Lane 5 SL TP3 -media. 
Lane 6 SL TP3 +media. 
Lane 7 SL TP4 -media. 
Lane 8 SL TP4 +media. 
Lane 9 [14C]-molecular weight markers. 
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Figure 3.3.16 Proteolysis of SLT 1 and potential processing mutants 
by extracellular proteases. 
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3.3.4 Discussion 
The mutants described in chapter 2 were made in order that the proteolytic 
processing requirements for SL T 1 could be investigated. In total, five mutant toxins 
were constructed and their biological properties investigated. Following expression 
(described in chapter 2) the enzymatic properties of these mutant toxins was 
examined. There are no published data regarding the enzyme kinetics of SL T 1. For 
this reason the N-glycosidase activities of the mutant proteins were simply related to 
that of the wild-type toxin preparation made in this study. The northern blot shown in 
figure 3.3.1 clearly shows that, from a titration of toxin incubated with susceptible 
ribosomes, all the mutant proteins expressed in Escherichia coli have comparable N-
glycosidase activity. This allows direct comparisons of cytotoxicity data to be made 
between mutant and wild-type toxins. 
The N-glycosidase activity of a truncated SLT 1 A chain was also investigated by 
translation in vitro of a transcript coding for the N-terminal222 residues of SL T 1. 
The reason for doing this was to determine whether an A chain fragment potentially 
generated by proteolytic processing at the upstream furin consensus motif 
220ArgXXArg223 would have any enzymatic activity responsible for a cell killing 
effect. A previous report by Haddad et al (1993) had shown that residues 1-223 of 
Shiga toxin retained the ability to inhibit protein synthesis in a rabbit reticulocyte 
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lysate translation reaction. However the construct described was translated in fusion 
with up to thirty vector encoded amino acid residues. The findings in the present 
study are in contradiction to the findings of Haddad et al. Translation of the N-
terminal 222 amino acid residues of SL T 1 did not result in modification of rabbit 
reticulocyte ribosomes. The reasons for these conflicting results are not known 
though there are two possible explanations. Firstly, in the present study, although a 
translation product was produced in a wheat germ system (figure 3.2.13) no such 
product could be detected in a rabbit reticulocyte lysate translation system. llence 
there is no evidence that the 223stop transcript was translated to protein in the 
experiment shown in figure 3.3.2. However it is apparent that the control transcripts 
coding for SLTAl and SLTwt, produced in an identical manner, do translate well. 
Secondly, the incorporation of thirty vector encoded residues in the construct used by 
Haddad et al may stabilise this truncated protein and allow ribosome depurination to 
occur. The results presented in this study suggest a fragment generated by processing 
at the upstream furin site would have no enzymatic activity, though clearly further 
control experiments should be carried out to confirm these findings. 
Trypsin sensitivity is often used as a measure of the stability and accuracy of folding 
in mutant proteins. Relative to the wild-type toxin additional fragments generated on 
proteolysis using trypsin, can be indicative of misfolding. The reasons for analysing 
the trypsin sensitivity of the mutant toxins produced in this study however are two-
fold. In addition to assessing the accuracy of folding, digestion with trypsin was used 
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to demonstrate resistance to trypsin of the mutant proteins in which trypsin-sensitive 
amino acids had been mutated. Since the disulphide-bonded loop region of SL T 1 
contains just two trypsin sensitive arginine residues, mutation to glycines should 
render the proteins SL TP 1, SL TP3 and SL TP4 resistant to trypsin-mediated 
proteolysis within this loop region. From figure 3.3.3 it can be seen that SL T 1 wild-
type and the mutant SL TP2, which retains the two arginine residues in the trypsin-
sensitive loop, are indeed sensitive to this protease. Both wild-type and SL TP2 
produce an Al sized subunit on trypsin treatment. In contrast, neither of the mutants 
SL TP 1 and SL TP3 produce an A I sized subunit as a result of trypsin treatment. 
Furthermore no additional fragments are generated, indicating that these proteins are 
correctly folded. The mutant toxin SL TP4 also appears largely resistant to trypsin 
treatment, with no A I sized fragment being generated. However a small amount of a 
higher molecular weight fragment is produced, a possible indication that a degree of 
misfolding has occurred in this protein. Since this protein apparently retains N-
glycosidase activity and retains its ability to assemble into a holotoxin it is 
considered that perturbations to the structure are probably minor. Figure 3.3.4 shows 
an SDS polyacrylamide gel of the same samples as those in figure 3.3.3 run under 
non-reducing conditions. This gel indicates that the fragments produced by the wild-
type and SL TP2 proteins are generated from within the disulphide-bonded loop as 
was expected. The small amount of fragment produced by trypsin treatment of the 
SL TP4 toxin also appears to be generated from within the disulphide-bonded loop as 
the fragment is not seen on the non-reducing gel. This result is inexplicable since 
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there are no arginine or lysine residues within the region subtended by the disulphide 
bond in SLTP4. We can interpret this finding only by concluding that the batch of 
trypsin is impure. 
The cytotoxic action of SL T 1 and processing mutants SL TP 1, SL TP3 and SL TP4 
was investigated on Vero cells. In two previous studies using mutations identical or 
similar to the SLIPl mutation used in the present study (Burgess and Roberts 
(1994); Garred et al (1995a» a 10 fold reduction in cytotoxic activity between wild-
type and the double arginine mutant was observed. In the present study, a 25 fold 
reduction in toxicity between SLT 1 wild-type and SLTPI was observed following a 
3 hour incubation of toxin (figure 3.3.1). SLTP3 also gave an ICso 25 fold greater 
than that of wild-type over the same time period. Following a longer exposure of 
toxin (6 hours), SLT } wild-type, SLTP} and SLTP3 all give similar ICso values 
0.0019,0.0071,0.009 ng/ml respectively (figure 3.3.6). These results indicate that 
whilst an intact furin consensus motif is necessary for rapid intoxication, these 
mutant proteins can be highly toxic after longer incubations with intact cells. 
Since the previous study by Garred et al showed that the Al subunit generated by in 
vivo processing was produced as a result of proteolytic cleavage within the 
disulphide-bonded loop (by comparison of samples run on reducing and non-
reducing PAG) a search was made for amino acyl residues in this region which might 
constitute a known site for proteolysis other than Arg 248 andArg251, no such site 
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was identified. However a report by Takao et al (1988) showed that SL T 1 was 
fragmented between Ala 253 and Ser 254. Such a fragment could have been 
generated during toxin extraction from E.coli or extracellulary during purification 
either way, it suggests such sites are exposed and susceptible to some form of 
nicking. Such nicking might also occur during uptake into eukaryotic cells and since 
Garred et al showed alternative processing in the loop region which generated a 
fragment indiscernible in size to wild-type AI, the site of nicking in vivo must be 
very close to the natural furin site. It was decided to mutate the two nearby Ala/Ser 
pairs to Gly and Ala. Mutation of these two pairs of residues (SL TP2) resulted in a 
protein identical to that of the wild-type toxin. Therefore the mutations did not 
perturb enzymatic or translocation activities. In SL TP3 where the Ala/Ser pair 
mutations are together with the double arginine mutation (SL TP 1) the additional 
mutations do not appear to be important for toxicity since the cytotoxicity of SL TP3 
is identical to SL TP 1. 
By visualization of iodinated toxin in Vero cells, the reason for the transient 
reduction in cytotoxicity of the mutants SLTPI and SLTP3 can be explained. Figure 
3.3.12 shows protein precipitated from Vero cells exposed to iodinated wild-type and 
mutant proteins. As previously shown (Garred et a11995a) SL T 1 wild-type is 
processed to the Al subunit size. Similarly SL TP 1 and SL TP3 are also processed to 
the Al size although this occurs more slowly. These data show that in the absence of 
the wild-type furin consensus motif, proteolytic processing can still occur. This 
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alternative processing occurs more slowly than processing in the presence of the 
furin consensus and results in an increased lag period prior to full cytotoxicity of 
these mutant toxins. The kinetics of the cytotoxic action of SL TP 1 and SL TP3 are 
shown in figure 3.3.9. Wild-type toxin gives a t50 of 53 minutes compared to SLTPI 
and SLTP3 of75 and 82 minutes respectively. To conclude, the rate at which an Al 
sized fragment is generated appears to be related to the cytotoxic nature of these 
mutant toxins i.e. the small increase in resistance to cellular proteases is probably 
responsible for the small transient reduction in the toxicity of these proteins. 
Garred et al (1995a) showed that in Vero cells pretreated with brefeldin A, the 
proteolytic processing of the wild-type protein and the mutant Shiga-His was very 
different. They found that the mutant Shiga-His was not processed to the Al size in 
cells pretreated with brefeldin A and concluded that proteolytic processing of Shiga-
His occurs in an earlier compartment of the secretory pathway which the mutant does 
not reach in cells treated with brefeldin A. In a similar manner the effect of brefeldin 
A was investigated with regard to the proteolytic processing of SL TP 1 and SL TP3. 
In both cases these toxins remained largely unprocessed in BF A treated Vero cells 
(figure 3.3.14). These data indicate that SLTPl and SLTP3 both require trafficking to 
an earlier compartment of the secretory pathway in order for proteolytic processing 
to occur. No difference between SLTPI and SLTP3 was observed. Figure 3.3.10 
shows the results of SL T 1 wt intoxication of BF A treated Vero cells. These data 
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were collected simply to ensure that the preparation ofBFA used in this study did 
protect Vero cells from the cytotoxic action of SL T 1. 
Garred et af (I995a) observed that the mutant Shiga-His remained intact when 
incubated with Vero cell pretreated with the membrane permeable protease inhibitor 
calpain inhibitor I. They were also able to correlate these findings with cytotoxicity 
data in which Vero cells pretreated with calpain inhibitor I were protected from 
intoxication by the mutant toxin Shiga-His by a factor of 10. In similar experiments 
carried out with the mutants SL TP 1 and SL TP3, a protective effect of 4.5 and 6 fold 
respectively was also seen (figure 3.3.8) the wild-type toxin however was unaffected 
by this treatment. When the proteolytic processing of SL TP 1 and SL TP3 was 
visualized in Vero cells treated with calpain inhibitor I no cleavage to the Al size 
was seen (figure 3.3.13). These data collectively indicate that SLTPI and SL TP3 can 
be proteolytically processed in Vero cells but that the proteolytic enzyme responsible 
is different to that which normally cleaves wild-type toxin. Together with the results 
obtained with BF A treated cells this alternative processing enzyme occurs in a 
different cellular compartment (Golgi stack, ER, cytosol) to the primary processing 
enzyme assumed to be TGN-Iocated furin. 
SLTPl and SLTP3 both generate a fragment in cells when the proposed primary 
cleavage site in the disulphide bonded loop is mutated. The fragment is of very 
similar size to that of wild-type toxin, suggesting that a calpain specific site lies close 
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to the loop furin site. The specificity of calpain is unclear and no single motif has 
been identified as forming recognition or cleavage sites for these enzymes. The 
reason for this maybe that calpain recognises structural elements rather than specific 
primary amino acid sequences. The changes made here to the primary sequence 
(AlaJSer pairs and Arg 248/ Arg251) and combinations of the two clearly do not 
effect proteolytic processing by a calpain like enzyme. 
The cellular location of the calpains is generally believed to be cytosolic. The 
intoxication time course (2,4 hours) used by Garred et al when 1251 toxins were 
visualized for processing did not exclude the possibility that such alternative 
processing occured in the cytosol after translocation. The t1l2 of SL T 1 in Vero cells 
is 54 minutes (figure 3.3.9). After two hours the physiologically active fraction of 
toxin would be in the cytosol. In the present study therefore, time points of 30 
minutes and 1 hour were included. Since nicking of toxin occurs within the toxin lag 
this may be an indication that the nicking occurs in the endomemhrane system. 
However the possibility that toxin is cleaved in the cytosol can not he rulled out. 
Control experiments were carried out in order to exclude proteolytic processing 
which may occur in the external medium prior to uptake of toxin. Figure 3.3.16 
shows toxin incubated with media in which a confluent monolayer ofVero cells was 
grown. No cleavage of toxin is seen on treatment of toxin with media thus ruling out 
the possibility that proteases present in the medium or secreted from cells are 
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responsible for cleavage of toxin. Preincubation of cells with NH4CI was used to 
exclude the role of lysosomal and endosomal proteolytic enzymes in toxin cleavage. 
The pattern of toxin cleavage in Vero cells was not as expected when cells were 
pretreated with NH4CI (figure 3.3.15). All toxins including the wild-type remain 
largely unprocessed. This experiment however was only carried out once for each 
toxin. This experiment also coincided with a period in which old stocks of Vero cells 
were being used. As a result this experiment needs repeating in order to try to 
interpret these data. The precise pleiotropic effects ofNH4CI are ill defined and for 
this reason the results of this assay are probably flawed. NH4CI did appear to 
increase the toxicity of SL TP4 by a small amount, the reasons for this are not clear. 
Since the additional mutations made to the paired AlalSer residues did not result in 
increased resistance to proteolytic processing in vivo, further mutations were 
introduced into a second arginine rich region upstream of the proposed nicking site. 
Residues Arg220 and Arg223 were mutated to glycine residues in the SL TP3 
framework. The resulting mutant toxin was called SL TP4. SL TP4 was assayed under 
the same conditions as the mutants SLTPl and SLTP3. SLTP4 is 134 fold less toxic 
than SL T 1 wild-type after 3 hours incubation on Vero cells and remains 62 fold less 
toxic after a 6 hour exposure. These results are in contrast to those for SLTPI and 
SL TP3 where wild-type cytotoxicity was observed after prolonged exposure of cells 
to toxin. Visualization of in vivo processing of SL TP4 reveals that the toxin remains 
intact in untreated Vero cells and under all other conditions tested. An additional 
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time point of 6 hours was included in in vivo processing experiments to exclude the 
possibility that SL TP4 is processed after longer incubation with Vero cells. This is 
clearly not the case. Since the Al subunit generated from SLTP3 in Vero cells 
appears identical in size to that of wild-type AI, it seems unlikely that Arg220 or Arg 
223 would constitute an alternative nicking site. It would seem that the additional 
mutation in SL TP4 results in a downstream steric effect rendering the protease-
sensitive loop refractory to cleavage by calpian or other proteases. In spite of the 
apparent lack of cleavage, the SL TP4 IC50 of 0.36 ng/ml towards Vero cells suggests 
that the separation of the A2 moiety ofSLT I away from the catalytic Al domain is 
not essential for cytotoxicity. However using the methods descibed here one would 
not be able to detect very small amounts of nicked toxin. Hence the residual toxicity 
of the SL TP4 mutant may be explained by very small amounts of nicked toxin. The 
implication of these results is discussed in more detail in chapter 6. 
In summary, 
I: The role of proteolytic processing of the bacterial toxin SLT 1 during the 
intoxication ofVero cells was examined using site directed mutagenesis to introduce 
specific mutations into the A chain. 
2: SLTPI and SLTP3 containing mutations within the disulphide bonded loop of 
SL T I are as toxic as the wild-type SL T 1 after prolonged exposure to Vero cells. 
Both mutant proteins are cleaved in Vero cells to a fragment apparently identical in 
size to the A I fragment generated from the wild-type toxin. In combination with the 
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data of Garred et al (1995a) the alternative cleavage site must lie within the 
disulphide-bonded loop and the present study confirms that a calpain enzyme may be 
responsible for this nicking. 
3: An SLT 1 A chain truncated at residue 223 and translated in a rabbit reticulocyte 
lysate did not exhibit N-glycosidase activity a finding which is in contrast to that of 
Haddad et al (1993) in which a similarly truncated ST A chain retained 41 % of its 
activity relative to the full length A chain. Fragments of this size generated 
intracellularly (eg a fragment generated from Arg220-Arg223) will therefore be 
enzymatically inactive and are predicted to have no toxicity in vivo. 
4: The mutations introduced upstream of the proposed nicking site of SLT 1 at a 
second putative furin site (SLTP4) resulted in a toxin which is apparently refractory 
to nicking in target cells. In spite ofthis apparent lack of cleavage, SLTP4 has a ICso 
of 0.36 ng/ml. This may suggest for the first time that proteolytic processing of SL T 
1 A chain is not essential for cytotoxicity. However the possibility that a small 
amount of toxin becomes nicked but is not detected remains. 
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3.4.1 Cloning and expression of a ricin A chain-Shiga-like toxin 1 
fusion protein (RAST A2). 
Introduction. 
A ricin a chain-Shiga-like toxin 1 fusion protein was constructed by gene fusion for 
expression in Escherichia coli. The final construct contains two open reading frames, 
the first of which codes for the bacterial ompF periplasmic targeting sequence in 
fusion with the full length ricin A chain sequence, followed by the coding region of 
SL T A2. The second codes for a wild-type SL T 1 B chain with its natural 
periplasmic coding sequence. The plasmid pKH206 containing the coding sequence 
of ricin A chain fused with the ompF signal sequence was a kind gift from R.Argent 
(Warwick, UK) a plasmid map ofpKH206 is included in the appendix 3. 
For the purpose of this study, SLT 1 A2 was defined as residues 262-293. It is these 
residues which are included in the construct described here. It was predicted that the 
chimeric A chain of RAST A2 would be able to associate with the B chain pentamer 
of SL T 1 since the A2 portion of SL T 1 is responsible for the major interactions 
between SL T 1 A chain and the SL T 1 B chains. It was rationalized that the resulting 
holotoxin could be purified in an identical manner to that of wild-type SL T 1 via its 
interaction with a Gb3-receptor-affinity matrix (GbrSepharose). 
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This fusion protein was used to further investigate the processing requirements of 
SL T 1. Since properly folded ricin A chain (RTA) is known to be very resistant to 
protease (Walker et a/1996) and since reports that RTA is proteolytically processed 
during cell entry (Fiani et al (1993)) could not be repeated in our laboratory in spite 
of intensive efforts to identify specific proteolytic products, it is considered that the 
ricin portion of this fusion should be highly resistant to intracellular nicking. It is 
also known that ricin A chain is tolerant of C-terrninal extentions (Cook et af (1993); 
O'Hare et af (1990)). The RASTA2 fusion protein contains only the A2 portion of 
SL T 1 where the protease sensitive loop region is not included. It was predicted that 
the chimeric A chain should be insensitive to protease either in vitro or in vivo. I f this 
is the case, the effects of the A2 extension can be investigated. For example if this 
fusion protein remains toxic then the A2 portion is presumably able to translocate 
from an intracellular compartment to the cell cytosol i.e. the A2 portion of SL T 1 
does not form a block to membrane translocation. These results would be additional 
to evidence presented in chapter 3 that processing of SL T 1 to remove A2 moiety is 
not essential in order for SL T 1 to be cytotoxic. 
3.4.2 Cloning of RAST A2. 
The ricin A chain-SL T A2 chimera was constructed by three rounds of recombinant 
four primer peR using VentR DNA polymerase. In the first round, a fragment was 
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generated from pKH206 (ricin A chain with an ompF periplasmic signal sequence in 
pKK223.2). The 5' primer (PSDO) contained a PsII site, the Shine-Dalgarno 
sequence from SLT I A and a region complementary to the 5' end of the omp F 
signal sequence. The 3' primer (RTAF2) contained sequence complementary to the 
3' end of the ricin A chain sequence figure (3.4.1). This peR reaction was phenol 
extracted (2.3.3) and the product gel isolated (2.3.9). In a second round of peR a 
fragment containing the coding sequence of SL T I A2 SL T 1 B (DNA coding for 
residues Pro 262 of SL T A2 to Arg 69 of SL T B) was amplified. The 3' primer 
(EST03 ') contained sequence complementary to the 3' end of SL T 1 B chain 
followed by an EcoRl site. The 5' primer (RASTA2) contained sequence 
complementary to the 3' region of ricin A chain followed by sequence 
complementary to the A2 portion of SL T I (figure 3.4.1). This peR reaction was 
phenol extracted (2.3.3) and the product ge,1 isolated (2.3.9). Small amounts of each 
peR product were then combined with the outside primers PSDO and EST03' in 
order to amplify the full length product. This reaction however did not produce 
product of the expected size, probably because of the large difference between the 
Tm values of the two primers used. to get round this problem larger quantities of the 
two products were combined in a third peR reaction without primers with Vent 
DNA polymerase to create the full length coding sequence for the chimeric protein. 
This peR produced enough peR product for gel isolation and cloning, after suitable 
restriction, into the EcoRI and PsII sites ofMI3 mp18 to create M 13RASTA2. 
Following full sequencing of the insert in M13mp18 (2.3.13), a PstllEcoRl fragment 
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was released and ligated into similarly restricted pUC 19 to create pRAST A2. The 
RASTA2 DNA fragment generated by PCR contains a Bgl 11 site 590 bp from the 3' 
end, therefore digestion of pRAST A2 with EcoR I and Bgl 11 results in release of a 
590 bp fragment. This digest was used to confirm the identity of the clone 
pRAST A2. This clone was used to express recombinant chimeric protein. A 
schematic diagram in figure 3.4.2 shows the strategy used to amplify the RASTA2 
coding sequence by PCR. A plasmid map is shown in figure 3.4.3. 
PCR reaction conditions . 
reaction 1: IX Vent DNA polymerase buffer, O.2mM dNTPs, lOng pKH206 
(template DNA), 100pmoles PSDO, 100pmoles RTAF2, 0.02U/~1 Vent DNA 
polymerase. Final volume lOO ~l. 94°C I min, 56°C I min, 72°C 1 min for 25 
cycles. 
reaction2: IX Vent DNA polymerase buffer, 0.2mM dNTPs, lOng dsM13SLTwt 
(template DNA), 100pmoles RASTA2, 100pmoles EST03', 0.02U/~1 Vent DNA 
polymerase. Final volume 100 ~l. 94°C 1 min, 50°C 1 min, 72°C I min for 25 
cycles. 
reaction 3: IX Vent DNA polymerase buffer, 0.2mM dNTPs, 10~t1 gel isolated 
product A, 101-11 gel isolated product B, 0.02U/1-11 Vent DNA polymerase. Final 
volume 1001-11. 94°C 1 min, src 1 min, 72°C I min for 10 cycles. 
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Figure 3.4.1. Oligonucleotide sequences of primers used for the 
construction of the RASTA2 coding sequence. 
Figure 3.4.1 shows the sequence of primers used for the construction of the coding 
sequence of RAST A2 by recombinant peR. Primer PSDO contains the 
complementary sequence of a Pstl site followed by the SLT I Shine-Dalgamo 
sequence and a portion of the ompF sequence. EST03' contains sequence 
complementary to the 3' sequence of SL T I B chain followed by an EcoR 1 site. 
RT AF2 contains the sequence of the 3' portion of ricin A chain. RAST A2 contains 
the sequence of a 3' portion of ricin A chain followed by the 5' portion of SL T 1 B 
chain (including its Shine-Dalgamo sequence). 
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Figure 3.4.1. Oligonucleotide sequences of primers used for the 
construction of the RASTA2 coding sequence. 
PSDO 
PsI 1 so ompF complementary sequence 
5'-TAT GCT CTG CAG AGG AGT ATT GTG TAA TAT GAT GAA 
GCG CAA TAT TCT-3' 
EST03' 
EcoRI SL T 1 B complementary sequence 
5'-GCT AGA ATT CTC AAC GAA AAA TAA CTT-3' 
RASTA2 
ricin A chain complementary sequence SL T A2 complementary 
5'-CTC CAC CAT CGT CAC AGT TTC CGG CAG ATG 
sequence 
GAA GAG TC-3' 
RTAF2 
ricin A chain complementary sequence 
5'-AAA CTG TGA CGA TGG TGG AG-3' 
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Figure 3.4.2 Recombinant mutagenic peR used for the production 
of DNA coding for a ricin A chain SL T A2 fusion protein 
(RASTA2). 
Reaction 1: In the first reaction the pre ricin A chain sequence is amplified using the 
primers PS DO and RTAF2. This reaction produces DNA coding for pre ricin A 
chain with additional Pst 1 and Shine-Dalgamo sequences at the 5' end coded in the 
primer PSDO (product A). 
Reaction 2: In the second reaction the SLTA2 and SLT B chain sequences are 
amplified. In addition to this sequence a small portion of R T A sequence is included 
in the primer RAST A2. An EcoR 1 site is included in the primer EST03' which adds 
an EcoR 1 site to the 3' end of this amplified fragment (product B). 
Reaction 3: In the final reaction the first two peR products A and B are combined in 
the absence of any primers (removed by gel isolation). The small region of homology 
between product A and product B facilitates annealing of the two fragments and 
extension is catalysed by Vent DNA polymerase. 
Dotted lines represent DNA generated from the SLT 1 template sequence. The closed 
lines represent DNA generated from the pre RTA sequence. 
193 
Figure 3.4.2 Recombinant mutagenic peR used for the production 
of DNA coding for a ricin A chain SLT A2 fusion protein. 
Template DNA pKH206 
psoo~ 
~----------------
~ 
RTAF2 
Reaction 1 
~'----- Products A 
Reaction 3 
Final 
product 
\ Product A 
Template DNA 
dsM13SLTwt 
Reaction 2 
products B 
--'''. RASTA2 
--_ .. ... ..... " .. .......................... " ........ . 
--_ ............................. ....... ...... ........ . 
ProductS 
..--"",,,,,,,,,,,, .. ,,,,, .. ,,,,,,, ,,, , ,, ,,,,,, ,,,, ,,: 
• 
\ 
\ '---------------------""'" .... " "" .. """".,,. ,,.. ................ .... '--------------------_ ............ , ... , . "" .. " .. ,. ,. ,., .. " .. , ., ..... ' 
Pstl1 SO ! OmpF RTA SLT A2! SLTB IEcoR 1 
! I 
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Figure 3.4.3 Plasmid pRAST A2. 
Construction of pRAST A2 allowed expression of chimeric protein in Escherichia 
coli JMI 05. The plasmid was constructed by ligation of an EcoR I / PsI I fragment 
from M13RASTA2 into the EcoR I / PsI 1 sites of the expression plasmid pUCI9. 
Transcription is under control of the inducable lac Z promoter. 
pRASTA2 
89111 
4000bp 
lac Z promoter 
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3.4.2 Expression and purification of RASTA2. 
The expression system and the method of purification used for the production of 
RAST A2 in pUC 19 expression vector was identical to that used for the expression 
and purification of SL T 1 wild-type section 3.1.2. The only change to the protocol 
was the temperature at which the induction of expression was performed. In earlier 
experiments induction, was performed at 37°C. However the yield of total 
recombinant protein in this instance was extremely low « 1 O~g/l starting culture) 
and the toxin obtained by this method contained a disproportionate amount of 
unassembled B chains. A second expression experiment was carried out where the 
induction temperature was reduced to 30°C. Expression at this temperature resulted 
in an increased yield of approximately 30~g 11 starting culture. A thirty fold excess 
of unassociated B chain remained however. 
Recombinant protein was quantified in terms of the holotoxin concentration rather 
than the total protein concentration. This was achieved by comparing aliquots of 
RASTA2 with known amounts of ricin A chain on silver stained polyacrylamide 
gels, using scanning densitometery. Recombinant protein was stored at 4°C in pns 
for short periods oftime. Protein kept for longer periods was stored at -70°C in PBS. 
The excess of SL T 1 B chain was quantified by comparing the ratio of A and B chain 
in the wild-type SL T preparation with that of RASTA2 using scanning densitometry 
of silver stained polyacrylamide gels. 
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The result of expression of pRAST A2 using the method described is shown in figure 
3.4.4. Expression of pRASTA2 resulted in the production of a chimeric protein with 
the predicted molecular mass. The yield of total holotoxin was lower than the yield 
of wild-type SL T produced in the same system. The yield was increased by a factor 
of 3 when the temperature was reduced to 30°C (the temperature at which ricin A 
chain is routinely expressed). At both 37°C and at 30°C the holotoxin preparation 
obtained after purification on a Gb3-Sepharose column was contaminated with a 
thirty fold excess of SL T 1 B chain when compared with a SL T wild-type holotoxin 
preparation. 
Several attempts to label RASTA2 with 1251 yielded very low levels of radiolabelled 
A chain. Metabolic labelling was used as an alternative to iodination, the method for 
which is described in section 2.6.6. RASTA2 was expressed in the presence of 1 OOO~l 
Ci e5S]-methionine in defined M9 media minus methionine. Radiolabelled 
recombinant protein was purified in an identical manner to that of the non-labelled 
protein using a 1 ml GbrSepharose affinity matrix column. The results of expression 
of radio labelled RASTA2 are shown in figure 3.4.5. The procedure described 
resulted in a small amount of radio labelled holotoxin as shown in figure 3.4.5. Due 
to the scarcity of material produced by this procedure the amount of e5S]-RASTA2 
was not quantified in terms of protein concentration. 2.5 ml of purified e5S]-
methionine labelled RAST A2 was obtained with specific activity of 650cpml~1. The 
calculated specific activity includes the excess labelled B chain. 
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Figure 3.4.4 Analysis of expression and purification of RAST A2 by 
15% SDS polyacrylamide gel electrophoresis and Western blot 
analysis. 
Figure 3.4.4 shows the expression and subsequent purification of the chimeric 
protein RASTA2 separated on a 15% SDS polyacrylamide gel followed by Western 
blot analysis (10 antibody sheep anti RT A). Protein coded in pRASTA2 under 
transcriptional control of the lacZ promoter, was expressed in Escherichia coli 
JMI05. Lane 1 shows precolumn periplasm extracted from transformed Escherichia 
coli. Lanes 3-7 show purified chimeric protein eluted from a 1 ml GbrSepharose 
analogue affinity column with 6M GuHCI pH 6.7. each track contains IOOlllof 
dialysed protein precipitated with TCA. Lane 8 shows the position of ricin A chain. 
Lane 9 shows molecular mass markers. 
Lane 1 Precolumn periplasm 
Lane 2 eluted fraction15 (lOO J..lI) 
Lane 3 eluted fraction 16 (lOO J..ll) 
Lane 4 eluted fraction 17 (lOO J..lI) 
Lane 5 eluted fraction 18 (lOO J..lI) 
Lane 6 eluted fraction 19 (100 Ill) 
Lane 7 eluted fraction 20 (100 Ill) 
Lane 8 1 J..lg ricin A chain (lCI) 
Lane 9 Molecular mass markers 
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Figure 3.4.4 Analysis of expression and purification of RASTA2 by 
15% SDS polyacrylamide gel electrophoresis and Western blot 
analysis. 
RASTA2-+ 
RTA-+ 
1 2 3 4 5 
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Figure 3.4.5 Analysis of expression and purification of metabolically 
labelled RASTA2 by 150/0 SDS polyacrylamide gel electrophoresis. 
pRASTA2 coding for chimeric RASTA2 protein under transcriptional control of the 
lac Z promoter in Escherichia coli JMI05, was grown in methionine free M9 
minimal media. Protein expression was induced in the presence of eSS]-methionine. 
Lane 1 shows molecular mass markers. Lane 2 shows precolumn periplasm extracted 
from induced, transformed Escherichia coli. Lane 3 shows 30111 of purified esS]-
RAST A2 protein. The positions of the chimeric A chain and the SL T 1 B chain are 
indicated. 
Lane 1 Molecular mass markers 
Lane 2 Precolumn periplasm (51l1) 
Lane 3 eluted purified RASTA2 (301l1) 
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Figure 3.4.5 Analysis of expression and purification of metaboIicalIy 
labelled RASTA2 by 15% SDS polyacrylamide gel electrophoresis. 
M 1 2 
46 
30 ~RASTA2 
14 
~ SLT 1 B 
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3.4.3 Discussion. 
The use of four primer recombinant PCR allowed the production of a gene fusion 
between the coding region of ricin A chain with an omp F signal sequence with the 
A2 B chain coding region of the SL T 1 operon. The conventional method whereby 
the resulting full length PCR product produced in the third round of PCR is 
amplified using outside 3' and 5' primers did not produce product of the correct size. 
This was probably due of the large difference in annealing temperatures between the 
two primers used. Combination of large quantities of the first two reaction products 
in the presence of nuc1eotides and Vent DNA polymerase however, did result in a 
sufficient quantity of DNA fragment for subsequent cloning into M13mp18. DNA 
sequencing confirmed the sequence of this fragment in M 13mp 18 which was then 
cloned into pUC 19 for expression. 
Expression in pRASTA2 at 37°C resulted in a very poor yield of chimeric holotoxin. 
Since ricin A chain is routinely expressed at 30°C this temperature was applied to the 
expression of RASTA2 protein. Induction of expression by IPTO at the lower 
temperature resulted in a slightly increased yield ofholotoxin approximately 30~lg 
from 1 liter of starting culture. At both temperatures the quantity of SL T 1 13 chain 
present in the periplasm extract was disproportionate (in thirty fold excess) with that 
ofthe chimeric A chain. Since the A and B chains of RAST A2 are transcribed as a 
single polycistronic mRNA the reason for the excess 13 chain is presumably due 
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either to the efficiency at which the A chain is transported to the periplasm or that the 
chimeric A chain is unstable and undergoes degradation in in vivo. 
Repeated efforts to iodinate RASTA2 with [1251] were unsuccessful. Efficient 
labelling of the B chain was seen, however no labelling of the A chain could be 
detected on polyacrylamide gels. Analysis of the crystal structure of SL T I B chain 
reveals an abundance of exposed tyrosine residues on the surface of the B chain 
pentamer making SL T 1 B an extremely good substrate for the iodination reaction. 
Presumably, during iodination ofRASTA2, the large excess ofSLT I B acts as a 
sink for the iodine and prevents efficient labelling of the A chain. Since labelled 
RASTA2 is essential for subsequent analysis of this protein, metabolic labelling was 
used as an alternative approach. Metabolic labelling with e5S]-methionine resulted 
in a small quantity of radio labelled purified protein. The concentration of this 
preparation was not determined because such a small quantity was obtained. Its 
activity by volume was calculated by liquid scintillation counting to be 650cpm/Jll. 
Two previous reports have highlighted the importance of the A2 subdomain for 
interaction with the B chain pentamer in addition to the crystal structure (Iladdad and 
Jackson (1993); Austin et af (1994)). Both of these studies however report the 
production of C-terminal deletion mutants of SLT 10r ST. The portion responsible 
for holotoxin assembly being defined as those residues,which when deleted, preclude 
holotoxin assembly. These are rather indirect methods and the potential negative 
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effects of gross structural changes can not be ruled out in these studies. Evidence 
presented in chapter 4 clearly demonstrates that the A2 portion (defined as residues 
262 to 293) alone is capable of association with the B chain pentamer. Since 
RAST A2 A chain can be purified by its interaction with the receptor analogue 
affinity matrix via the B subunit pentamer the A chain must be associated with the n 
chains. This data provides the first evidence that the C terminal 31 amino acids of 
SLT 1 A are sufficient for holotoxin assembly. Despite reports that a proportion of 
the A-B contacts are made with the Al portion ofSLT I clearly these contacts are 
not essential for holotoxin assembly or maintenence of toxin integrity under the 
conditions tested. 
The characterisation ofRASTA2 is described in chapter 5. Despite the very low level 
expression of RAST A2 in Escherichia coli sufficient material was obtained to use in 
cytotoxicity and in vitro proteases sensitivity studies. The radio labelling of RAST A2 
was very dissapointing. Only a minute quantity of radiolabelled A chain was 
obtained. It was considered that this material might be adequate for a single 
experiment which is described in chapter 5. The results of this experiment however 
were unsatisfactory. 
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Chapter 5 
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3.5 Characterization of a ricin A chain SLT A2 fusion protein 
RASTA2. 
Introduction 
The fusion protein RASTA2 (cloning and expression are described in chapter 4) was 
produced to predict whether processing of SL T 1 was actually necessary or not. The 
chimeric A chain of RAST A2 was designed to remain intact during endocytosis and 
subsequent trafficking in sensitive eukaryotic cells. The reasons for our assumption 
of a protease-resistant RASTA2 are discussed in section 1.6. The fusion protein 
RASTA2 contains a full length ricin A chain, with an N-terminal periplasmic signal 
sequence, fused with the C-terminal 31 residues of SL T A2. The resulting A chain 
has catalytic activity comparable with ricin A chain and is able to associate with the 
SL T 1 B chain pentamer to form a chimeric holotoxin. The toxic A chain docs not 
however contain the loop region (residues 242-261) known to be the site of 
proteolytic activation of wild-type SLT liST (Burgess and Roberts (1993); Garred et 
at (1995a)). In this study, the biological characteristics of this fusion protein will be 
investigated both in vitro and in vivo. Any relevance to the proteolytic processing 
requirements of SL T 1 will then be discussed. 
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3.5.1 N-glycosidase activity of RASTA2. 
The N-glycosidase activity of RASTA2 towards isolated rabbit reticulocyte 
ribosomes was compared with that of ricin A chain in vitro using the aniline assay 
(section 2.7.3). Rabbit reticulocyte ribosomes were incubated with four decreasing 
amounts of re comb in ant RASTA2 protein (IOOOng, 500ng, IOOng, lOng) prior to 
treatment with acetic-aniline. The resulting acetic-aniline treated RNA was run on a 
denaturing formamide 1.2% agarose gel (section 2.3.4). Separated RNA was 
visualized by ethidium bromide staining. Figure 3.5.1 shows a gel prepared in this 
manner. Depurination ofrRNA followed by treatment with acetic-aniline results in 
cleavage of the RNA backbone at position 4324 releasing an RNA fragment from the 
5' end of28S rRNA of394 bases which is diagnostic for the action of ribosome 
inactivating proteins. The gel shown in figure 3.5.1 clearly demonstrates that the 
recombinant chimeric protein RASTA2 has N-glycosidase activity. Although this 
assay was not performed in order to quantify precisely the level of activity of this 
protein, comparison of the extent of depurination using scanning densitometry shows 
that at 100ng RASTA2 is comparable with that of lOOng RTA. Therefore it can be 
assumed that RAST A2 has roughly the same activity to that of recombinant ricin A 
chain. 
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Figure 3.5.1 N-glycosidase activity of RAST A2 
Figure 3.5.1 shows ethidium bromide stained rRNA separated on a denaturing 1.2% 
agarose gel. Rabbit reticulocyte ribosomes were treated with decreasing amounts of 
toxin at 300 e for 30 min. The resulting RNA was isolated and treated with acetic-
aniline at 600 e for 2 min. Aniline treated RNA was separated by denaturing agarose 
gel electrophoresis. Specific depurination due to the action of SL T 1 followed by 
acetic-aniline treatment leads to release of a 394 base RNA fragment indicated by an 
arrow. 
Lane 1 1000ng RAST A2 - aniline 
Lane 2 1000ng RASTA2 + aniline 
Lane 3 500ng RAST A2 + aniline 
Lane 4 100ng RAST A2 + aniline 
Lane 5 lOng RAST A2 + aniline 
Lane 6 1 OOng R T A + aniline 
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Figure 3.5.1 N-glycosidase activity ofRASTA2 
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3.5.2 In vitro sensitivity of RASTA2 to proteinase K and trypsin. 
The sensitivity of RASTA2 to trypsin and proteinase K was compared to that of ricin 
A chain. RT A is, like several other ribosome inactivating proteins, characteristically 
insensitive to proteases. SLT however is very sensitive to trypsin (section 3.3.2). The 
chimeric RASTA2 A chain was designed to be refractory to proteolysis. Addition of 
endogenously added protease provides a quick and simple assessment of protease 
sensitivity. Figure 3.5.2 shows a western blot, probed with sheep anti RTA 
antibodies, ofRTA and RASTA2 treated with the proteases trypsin and proteinase K. 
As expected, ricin A chain is almost totally resistant to digestion with either 
proteinase K or trypsin. Only where RT A is treated with I O~g/ml proteinase K at 
37°C for 7 min is there any sign of reduction in the 30 kDa band. Some low level 
degradation is seen on treatment of RTA with 1 0 ~g/ml trypsin for 7 mins and with 
proteinase K at ooe for 40 min also. RAST A2 is also highly resistant to protease. 
Only when treated with 10 ~g/ml proteinase K at 37°e can A chain degradation be 
detected. 
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Figure 3.5.2 Reducing 15% SDS polyacrylamide gel electrophoresis 
followed by Western blot analysis of proteinase K-and trypsin-
treated ricin A chain and RAST A2. 
RT A and RAST A2 were treated with trypsin or proteinase K at 0.1 and 10 J..lg/ml 
at 37°C for 7 min. In addition both RTA and RASTA2 were treated with proteinase 
K at 10J..lg/ml at O°C for 40 min. Tryptic digests were stopped by addition of 1 J..lI of 
TLCK Img/ml in 0.05M sodium acetate acetic acid pH5.0. Proteinase K digests were 
boiled for 5 min prior to addition of sample loading buffer. The resulting proteins 
were separated on a 15% SDS P AG under reducing conditions. Protein was 
visualized by western blot analysis using sheep anti RTA as primary antibody. 
1 ) R TA - protease 7) RAST A2 - protease 
2) RTA + Proteinase K O.IJ..lg/ml 8) RAST A2 + Trypsin 0.1 J..lglml 
3) RTA + Proteinase K 10J..lg/rnl 9) RASTA2 + Trypsin 10J..lglml 
4) RTA + Trypsin 0.1 J..lg/rnl 10) RASTA2 + proteinase K 0.1 J..lglml 
5) RTA + Trypsin 10 J..lglrnl 11) RAST A2 + proteinase K 10J..lg/ml 
6) RTA + Proteinase K 10J..lg/rnl ooe 12) RASTA2 +proteinase K 10J..lg/ml ooe 
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Figure 3.5.2 Reducing 15%) SDS polyacrylamide gel electrophoresis 
followed by Western blot analysis of proteinase K-and trypsin-
treated ricin A chain and RASTA2. 
1 2 3 4 5 6 7 8 9 10 11 12 M 
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3.5.3 Cytotoxicity of RASTA2 compared with that of ricin and wild-
type SLT 1. 
The cytotoxicity ofRASTA2 was characterized with respect to ICso and to the 
kinetics of cell killing by plotting percentage protein synthesis inhibition as a 
function of toxin concentration or time respectively. The method used to determine 
cytotoxicity is given in section 2.7.4. The results of cytotoxicity experiments are 
shown in figures 3.5.3, 3.5.4 and 3.5.5. Cytotoxicity curves for SL T 1 wild-type and 
ricin are also included for comparison. The effect of a thirty fold excess of 
unassociated SL T 1 B chain was also investigated. This experiment was used to rulc 
out any effects of having such an excess ofB chain present in RASTA2 on its 
cytotoxicity. 
In the presence of a thirty fold excess of SL T 1 B chain the cytotoxicity of wild-type 
SL T 1 remains unchanged. This indicates that the large excess of B chain co-purified 
with RAST A2 should not significantly effect its cytotoxicity. Over a three hour 
incubation of toxin on Vero cells, wild-type SLT 1 gave an ICso of 0.019 ng/ml 
compared to 0.022 ng/ml in the presence of excess B chain (figure 3.5.3). Over a 
three hour toxin incubation, ICso values for RASTA2, ricin and SLT 1 were 7ng/ml, 
19n9/ml and 0.02ng/ml respectively (figure 3.5.4). After a 6 hour incubation of toxin 
ICso values for RASTA2, ricin and SL T 1 were O.3ng/ml, 0.35ng/ml and 0.007ng/ml 
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respectively (figure 3.5.5). From kinetic experiments the TI/2 values for RASTA2, 
ricin and SLT 1 were 133 min, 113 min and 57 min respectively (figure 3.5.6). 
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Figure 3.5.3 The effect of excess SL T 1 B chain on the cytotoxicity of 
SLT 1 wild-type: 3 hour toxin incubation. 
1 X 10-4 to 10 ng/ml of SLT 1 wild-type and 1 x 10-4 to 10 ng/ml of SL T 1 wild-type 
mixed with a thirty fold molar excess of purified SL T 1 wild-type B chain diluted in 
DMEM, was incubated with 1.2 to 1.5 X 104 Vero cells plated in 96 well tissue 
culture plates for 2.5 hours at 37°C in a 5% CO2 incubator. Following incubation 
with toxin the cell monolayers were washed once with PBS and 100111 of PBS 
containing lllCi of e5S]-methionine was added to each well. Cells were incubated 
for a further 30 min. Monolayers were then washed three times with 5% ice cold 
trichloroacetic acid and neutralized by a single wash with PBS. Acid-precipitated 
protein was then released with lOOll1 ofO.5M NaOH and incorporated radioactivity 
was quantified by liquid scintillation counting. 
All values are the mean of four replicate samples. Protein synthesis inhibition was 
calculated as the percentage incorporation of radioactivity compared with the mean 
of six no toxin controls. 
Toxin IC50 ng/ml 
SLT 1 wt 0.019 
SLT 1 +B 0.022 
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Figure 3.5.3 The effect of excess SL T 1 B chain on the cytotoxicity of 
SLT 1 wild-type: 3 hour toxin incubation. 
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Figure 3.5.4 Cytotoxicity of RAST A2, ricin and SL T 1 wild-type: 3 
hour incubation of toxin. 
1 x 10-4 to 10 ng/ml of each recombinant holotoxin, diluted in DMEM, was incubated 
with 1.2 to 1.5 x 104 Vero cells plated in 96 well tissue culture plates for 2.5 hours at 
37°C in a 5% CO2 incubator. Following incubation with toxin the cell mono layers 
were washed once with PBS and lOOlll of PBS containing 1 IlCi of eSS]-mcthionine 
was added to each well. Cells were incubated for a further 30 min. Monolayers were 
then washed three times with 5% ice cold trichloroacetic acid and neutralized by a 
single wash with PBS. Acid-precipitated protein was then released with 1 OOIlI of 
0.5M NaOH and incorporated radioactivity was quantified by liquid scintillation 
counting. 
All values are the mean of four replicate samples. Protein synthesis inhibition was 
calculated as the percentage incorporation of radioactivity compared with the mean 
of six no toxin controls. 
Toxin ICsong/ml 
RASTA2 7 
ricin 19 
rSLT I wt 0.02 
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Figure 3.5.4 Cytotoxicity of RASTA2, ricin and SLT 1 wild-type: 3 
hour incubation of toxin. 
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Figure 3.5.5 Cytotoxicity of RASTA2, ricin and SLT 1 wild-type: 6 
hour incubation of toxin. 
1 x 1 0-4 to 10 ng/ml of each recombinant holotoxin, diluted in DMEM, was incubated 
with 1.2 to 1.5 xI04 Vero cells plated in 96 well tissue culture plates for 5.5 hours at 
37°C in a 5% CO2 incubator. Following incubation with toxin the cell monolayers 
were washed once with PBS and 100).11 of PBS containing 1 ).1Ci of eSS]-methionine 
was added to each well. Cells were incubated for a further 30 min. Monolayers were 
then washed three times with 5% ice cold trichloroacetic acid and neutralized by a 
single wash with PBS. Acid-precipitated protein was then released with 1 OO~tl of 
0.5M NaOH and incorporated radioactivity was quantified by liquid scintillation 
counting. 
All values are the mean of four replicate samples. Protein synthesis inhibition was 
calculated as the percentage incorporation of radioactivity compared with the mean 
of six no toxin controls. 
Toxin IC50 ng/ml 
RASTA2 0.3 
ricin 0.35 
SLT I wt 0.007 
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Figure 3.5.5 Cytotoxicity ofRASTA2, ricin and SLT 1 wild-type: 6 
hour incubation of toxin. 
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Figure 3.5.6 The kinetics of cytotoxicity of RASTA2, ricin and SL T 
1 wild-type in Vero cells. 
100 ng/ml of each recombinant holotoxin, diluted in DMEM, was incubated with 1.2 
to 1.5 xl 04 Vero cells plated in 96 well tissue culture plates for time periods between 
20 and 120 min at 37°C in a 5% CO2 incubator. Following incubation with toxin the 
cell mono layers were washed once with PBS and 1 00~1 of PBS containing 1 ~ICi of 
eSS]-methionine was added to each well. Cells were incubated for a further 30 min. 
Monolayers were then washed three times with 5% ice cold trichloroacetic acid and 
neutralized by a single wash with PBS. Acid-precipitated protein was then released 
with 1 OO~I of 0.5M NaOH and incorporated radioactivity was quantified by liquid 
scintillation counting. 
All values are the mean of four replicate samples. Protein synthesis inhibition was 
calculated as the percentage incorporation of radioactivity compared with the mean 
of six no toxin controls. The time axis shows the total period of toxin incubation i.e. 
that including the 30 min label. 
Toxin tl/2 min 
RASTA2 133 
ricin 113 
SLT 1 wt 57 
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Figure 3.5.6 The kinetics of cytotoxicity of RASTA2, ricin and SL T 
1 wild-type in Vero cells. 
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3.5.4 In vivo processing ofRASTA2 in Vero cells. 
In order to determine whether RAST A2 remains intact during trafficking and 
translocation in Vero cells attempts were made to radioactively label RAST A2. 
Using an identical protocol used for the iodination of SLT I and potential processing 
mutants no iodinated RASTA2 could be obtained. An alternative method using 
metabolic labelling was used and is described in section 3.4.2 and 2.6.6. 
Metabolic labelling yielded a very small quantity of RASTA2-e5 S]-methionine. Due 
to the scarcity of this material this protein was not quantified, instead the entire 
preparation was used. In vivo proteolytic processing experiments with RAST A2 were 
carried out in an identical manner to those using iodinated toxin, however time points 
of four and six hours were used. This experiment yielded a very weak signal from the 
recovered protein. As a result of the low intensity of the signal, the flurographcd gel 
was exposed to Kodak biomax film for three weeks at -70°C. The results of this 
experiment are shown in figure 3.5.7. Within the limits of the experiment RASTA2 
does not appear to be processed after four hours exposure to Vero cells however after 
six hours a cleavage fragment of 30kDa can be seen. Since this experiment was 
carried out on only one occasion and the autoradiograph is so faint the results should 
be interpreted with caution. 
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Figure 3.5.7 In vivo proteolytic processing of RAST A2 in Vero cells. 
Vero cells, grown to a confluent monolayer in 3 cm tissue culture dishes, were 
incubated at 37°C in a 5% CO 2 incubator with e5S]-methionine labelled RASTA2 
for the specified period of time. Following incubation the toxin was washed off and 
cells lysed in cell lysis buffer. Celllysates were centrifuged to remove cell debris and 
nuclei. Protein was precipitated with acetone. The resulting protein pellets were 
re suspended in reducing sample loading buffer and separated on 15% SDS 
polyacrylamide gels. The positions of full length RAST A2 A chain is indicated. The 
position of the 30kDa molecular mass marker is indicated. 
Lane M 
Lane 0 
Lane 4 
Lane 6 
Molecular mass markers 
Untreated RAST A2 
F our hours toxin exposure 
Six hours toxin exposure 
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Figure 3.5.7 III vivo proteolytic processing ofRASTA2 in Vero cells. 
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3.5.5 Discussion 
The chimeric toxin described in chapter 4 was made in an attempt to determine 
whether the presence of A2 could prevent toxicity of RT A (perhaps by blocking its 
translocation). Should no such block in toxicity arise then it might be assumed that 
A2 need not in fact be cleaved from Al in cells lacking the furin enzyme or with 
mutant SL T A chains which are refractory to proteolysis. Evidence is presented in 
chapter 4 which clearly demonstrates assembly of RASTA2 into a holotoxin and that 
the integrity of the receptor binding site is maintained. In the current chapter the 
biological characteristics of this protein are investigated. 
The N-glycosidase activity ofRASTA2 was investigated by the aniline assay. 
Although this assay was not performed in a quantitative manner the results which are 
obtained can be considered semi-quantitative. From a simple titration of RAST A2 it 
appears that this protein has comparable activity to that of ricin A chain. This result 
is to be expected if the A2-B chain portion of the protein does not prevent access to 
the active site. The activity of RTA is greater than that of intact SL T I, presumably 
because wild-type SL T 1 has its active site specifically obscured by the side chain of 
Met 260. RAST A2 therefore has elevated N-glycosidase activity to that of SL T I 
since Met 260 is unlikely to be correctly positioned to interfere with the active site of 
the RTA moiety. 
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Since the RASTA2 preparation used for these experiments was contaminated with a 
large excess of SL T 1 B chain, the effect of additional B chain on the cytotoxicity of 
SL T 1 wt was investigated. It was considered that such a large amount of 
unassociated B chain might compete for receptors on the surface ofVero cells and 
thus provide at least a partial protection against the toxin. However no difference in 
IC50 values was detected between toxin applied in the absence or presence of excess 
B chain (figure 3.5.3). Presumably Vero cells have such a large quantity ofSLT 1 
binding sites that the portion occupied by toxin in these experiments is negligible. 
Alternatively SL T 1 holotoxin may have an increased affinity for Gb) compared to 
that of SL T 1 B chain alone and thus effectively competes for binding to the 
receptor. Since it appears that the excess B chain does not interfere with cytotoxicity 
measurements, direct comparisons between RASTA2, SL T 1 and ricin can be made. 
Since SLTP4 (described in chapter 3) was toxic to Vero cells despite its apparent 
resistance to proteolytic processing, it was predicted that in the absence of any 
proteolytic processing, RAST A2 too would also be cytotoxic. The increased 
cytotoxicity of SL T 1 compared to that of ricin is probably a result of reccptor-
mediated targeting via the B chains. For this reason it was expected that RASTA2 
would show similar IC50 and t)/2 values to that of SL T 1. RASTA2 is potently toxic 
to Vero cells giving an ICso of7ng/ml after three hours and OJ ng/ml after six hours. 
However these figures more closely resemble ricin than SL T 1 (ricin IC50 19n9/ml, 
0.35 ng/ml SLT 1 0.02 ng/ml, 0.007 ng/ml after three and six hours respectively). 
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Likewise the kinetics of entry are also more like ricin than SL T 1 (RASTA2 133min. 
ricin 113min, SLT 1 57min). 
The sensitivity of RAST A2 to protease in vitro was compared with that of ricin A 
chain. From figure 3.5.2 it can be seen that the chimeric A chain has similar protease 
sensitivity characteristics to that ofRTA. Only when RASTA2 is treated with 
proteinase Kat 37°e for 7 min at 10Jlg/ml is degradation seen. This degradation 
seems to take the form mostly of total fragmentation rather than more specific 
proteolysis which may represent cleavage around the RTA-A2 junction. The low 
concentration at which RAST A2 was obtained did not allow more protein to be used 
in this analysis. These results provide some evidence that RAST A2 is in fact 
refractory to proteolysis although the conditions tested in vitro are very different to 
those that the toxin may meet in vivo. 
The in vivo protease sensitivity was investigated using metabolically labelled 
RASTA2. Unfortunately the results from this experiment are rather poor since 
radiolabelled RAST A2 could not be obtained at a high enough specific activity. 
However sufficient radiolabelled RASTA2 holotoxin was obtained to carry out a 
single experiment. The results from this experiment are shown in figure 3.5.7. As 
previously stated the radio-labelled RASTA2 used for studying the in vivo 
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proteolytic processing had very low specific activity, as a consequence, this 
experiment yielded very unsatisfactory results which were on the very limits of 
detection. The results from this experiment however do indicate that RAST A2 does 
undergo slow proteolytic processing. A cleavage fragment of approximately 30kDa 
is seen after incubation of RASTA2 with Vero cells after six hours. No fragment is 
seen after 4 hours. RASTA2 has a tll2 of 133 minutes so that after six hours more 
than 80% of these cells are dead. Therefore the toxin recovered from cells after six 
hours has presumably been subjected to a host of cellular proteases not only those 
within components of the secretory pathway. If this is the case the proteolytic 
cleavage observed in this experiment might represent proteolytic degradation rather 
than a specific proteolytic event essential for cytotoxicity. 
This data, if correct may be interpreted to mean that RAST A2 is translocationally 
defective. IfRASTA2 were capable of membrane translocation as an intact A chain, 
the ICso values might be expected to concur with those for wild-type SL T 1 (or 
indeed be higher due to the enhanced N-glycosidase activity of the hybrid versus 
SL TAl). The fact that the fusion is not apparently processed in a physiologically 
relevant time scale and that it displays cytotoxicity closer to that of ricin and SLTP4 
is consistent with a model where A2 obstructs membrane translocation or its 
presence in some other way introduces a rate limiting step. Since the kinetics and 
cytotoxicity of RAST A2 are so similar to ricin this explanation would infer that ricin 
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A chain does not need to fully translocate the membrane either, but that it can act on 
ribosomes on the cytosolic side of the translocating ER membrane. 
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Chapter 6 
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3.6.1 Final discussion. 
The aims of the present study are listed at the end of section 1. To extend our 
knowledge of the proteolytic processing requirements for the bacterial toxin 
Escherichia coli Shiga-like toxin 1. The approach adopted was the production of 
several mutant forms of SL T 1 altered in a region of the A chain primary sequence 
where the proposed cleavage is thought to occur. In addition to these, a chimeric 
toxin was created between ricin A chain and the A2 portion of SL T 1, previously 
thought to be removed by a processing step. Attempts were made to design this 
fusion (RAST A2) such that it is refractory to proteolytic cleavage in vivo. 
In chapter 1 a wild-type SL T 1 Escherichia coli expression clone and a revised 
method of toxin purification are described. Once a method for the rapid production 
of unnicked SLT 1 in quantities sufficient for biochemical analysis was established, 
the production of a range of mutant toxins was easily afforded by expression and 
purification using the same protocol. A total of four SL T 1 toxins mutant in the A 
chain were produced by this method. Since the fusion protein described in chapter 4 
incorporates the cell binding B chain pentamer of SL T 1, this toxin was also purified 
in an identical manner. 
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SL TP 1 is a toxin which has the two disulphide bonded loop arginine residues 
mutated to glycine residues. It is these two arginines which are thought to form the 
furin recognition motif responsible for proteolytic cleavage of toxin during target cell 
intoxication. These mutations were previously reported by Burgess and Robcrts 
(1993) and similar mutations were made by Garred et al (1995a). This toxin remains 
fully toxic to Vero cells although there is a transient reduction in cytotoxicity relative 
to wild-type when incubated with cells for less than 3 hours. Both Burgess and 
Roberts (1993) and Garred et al (1995a) report a 10 fold reduction in cytotoxicity of 
an identical or similar mutant compared with wild-type toxin. In the present study a 
25 fold reduction is observed. 
In the report by Garred et al (1995a), the proteolytic processing of this toxin was 
followed by precipitating iodinated toxin from Vero cells, 2 and 4 hours after 
exposure to toxin. This approach was also adopted in the present study to trace the 
proteolytic processing events of the mutants described. In this study however, shorter 
incubation times were used in case the processing seen by Garred et al (1995) was 
associated with even!s in the cytosol. However even with incubations of toxin as 
short as 30 min, when SL T 1 may still be located within the endomembrane system, 
SLTPI was seen to be processed in Vero cells. This indicated that the toxin remained 
sensitive to target cell proteases, most likely contained within the endocytic pathway. 
The slight reduction in cytotoxicity during short incubations with toxin can probably 
be accounted for by a rate limiting step, possibly the novel processing stcp itsclf, or 
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perhaps an impediment in translocation. In an identical way to the study of Garred et 
aI, the effects ofbrefeldin A and a membrane permeable protease inhibitor calpain 
inhibitor I were investigated here. As in the previous study, SLTPI was not 
efficiently processed to the Al size in cells pretreated with either brefeldin A or 
calpain inhibitor I under the experimental conditions used. These results suggest that 
SLTPI undergoes an alternative processing event during toxin uptake into target 
cells. This processing must occur in a compartment of the early secretory pathway 
which the toxin cannot reach in cells treated with brefeldin A (a reagent causing 
reversible collapse ofthe Golgi in Vero cells (Fujiwara et al (1988)) and which 
therefore prevents trafficking from the TGN to the Golgi and ER). In contrast, the 
wild-type toxin is processed in cells treated with BF A and thus must be cleaved in a 
vesicle prior to the BF A-blocked transport step, probably the TGN. ealpain inhibitor 
I is an inhibitor ofthe calcium dependent protease calpain. The exact cellular 
location of calpain is unclear although its thought that it may be cytosolically located 
(Murachi (1983)). Preincubation ofVero cells with calpain inhibitor I does not affect 
the potency of wild-type SL Tl. However, Vero cells are afforded a protection of 
almost five fold in the presence of this reagent to SL TP 1. These data together suggest 
that SLTPI is processed in a earlier compartment of the secretory pathway to that of 
wild-type toxin and that the alternative cleavage can be inhibited by calpain inhibitor 
I. This data is in agreement with Garred et al (1995a). 
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Since SLTPI is clearly still sensitive to target cell proteases further mutant toxins 
were produced in an attempt to produce a toxin which would not be processed at all. 
SLTP3 contains the mutations already described in SLTP!. In addition SLTP3 
contains four additional mutant residues. The extra mutations introduced to SL TP3 
involve two pairs of Ala/Ser residues which lie either side of the loop arginines. 
These residues were selected as a result of a report by Takao et at (1988) in which 
tryptic digests of SL T 1 were investigated using mass spectrometry. They found that 
the preparation of SL T } used for analysis was already pre-nicked between residucs 
Ala 253 and Ser 254. This cleavage could not have been performed by trypsin. It was 
rationalized that the propensity of these target sites to cleavage during the 
preparation of toxin might mean they are accessible to intracellular proteases. 
Furthermore, since they lie very close to the loop furin-site residues, alternative 
cleavage at either of the Ala/Ser pairs would generate nicked, disulphide bondcd 
toxin consisting of an AI-like fragment indistinguishable in size (by SDS PAGE) 
from the the wild-type version. This would fit with the data of Garred el al(1995a). 
To investigate the possible involvement of these residues in in vivo protcolytic 
processing, they were therefore mutated to glycine and alanine. A second pair of 
Ala/Ser residues on the C-terminal side of the proposed nicking site were also 
mutated to glycine and alanine residues. Where the two paired Ala/Ser residucs were 
mutated alone (SL TP2), the resulting holotoxin was essentially wild-type in its 
biological properties. These same Ala/Ser to Gly and Ala mutations were also made 
within the SLTP} framework to generate SLTP3. SLTP3 was 6 fold less toxic to 
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Vero cells after a short toxin incubation and was as toxic as the wild-type after 
prolonged incubation (more than 3 hours). Furthermore SL TP3 is proteolytically 
processed at the same rate as SL TP 1 and behaves like SL TP 1 in the presence of 
calpain inhibitor 1 and BF A. From these data it appears that the Ala/Ser paired 
residues do not play any role in toxin processing. 
As a final point, the A 1 fragment generated from both SL TP I and SL TP3 appears 
identical in size to that of the wild-type-generated Al fragment (within the 
constraints of the gel system used). In the study by Garred et al (I995a), toxins 
processed in vivo and run under reducing and non reducing conditions revealed that 
the fragment generated from both the wild-type and the mutant toxin (equivalent to 
SLTPl in the present study) was produced by cleavage within the disulphide bonded 
loop. As the A I fragments from SL TP I and SL TP3 are also the same size as those 
from the wild-type (as judged by SDS-PAGE) it would appear that cleavage of these 
mutants also occurs in the loop, close to the natural cleavage site. 
A fourth set of mutations was introduced to SL T I at a site which lies upstream of 
the proposed primary cleavage site. This site (220Arg--Arg223) resembles a minimal 
recognition sequence for furin. In the protein SL TP4, Arg220 and Arg223 were 
mutated to glycine residues within the SL TP3 framework. In contrast to the mutants 
SL TP 1 and SL TP3, SL TP4 does not appear to be processed at all under any of the 
conditions tested here. However this protein remains cytotoxic to Vero cells albeit 
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with reduced potency. Following a three hour incubation of toxin SL TP4 is 134 fold 
less toxic than wild-type and remains 62 fold less toxic after prolonged incubation. 
These data provide the first evidence that SL T 1 does not require any proteolytic 
cleavage for toxicity. 
Since the fragments generated in vivo from SL TPI and SLTP3 (and Garred et al 
1995a) seem to be generated from within the disulphide loop, it seems unlikely that 
the Arg220--Arg223 (mutated in SLTP4) constitutes the site of any alternative 
cleavage and certainly no visualisation of a truncated A 1 fragment was ever seen in 
vivo. It is proposed that the additional mutations in SL TP4 result in a downstream 
steric effect which renders the alternative cleavage site refractory to proteolysis. 
To further test the hypothesis that SLT 1 does not have an absolute requirement for 
proteolytic processing, a ricin A chain SL T 1 fusion protein was engineered. The 
creation of the fusion protein RAST A2 by PCR is described in Chapter 4. Ricin A 
chain is thought to remain intact during target cell intoxication and is 
characteristically insensitive to proteolysis in vitro (Chaddock et at (1995); Walker et 
at (1996». The chimeric holotoxin produced in this study incorporates a full length 
ricin A chain followed by the A2 portion of SL T 1 excluding the protease sensitive 
loop region. The fused A chain is transcribed as a bicistronic message with SL T 1 B 
chain, the two translation products being targeted to the Escherichia coli periplasm 
where they associate to form holotoxin. In addition to information about proteolytic 
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processing this experiment provides the first direct evidence that the C-terminal 31 
residues of SL T 1 A chain are sufficient for B chain association. The fact that the 
chimeric A chain can be purified using affinity chromatography specific for the B 
chain interaction shows that the A chain is associated with the B chain pentamer. In a 
similar manner to the experiments conducted using cholera toxin A2 fused with 
enzymatic markers such as maltose binding protein and bacterial alkaline 
phosphatase (Jobling and Holmes (1992», the portion of SL T 1 A2 required for 
holotoxin assembly was identified. 
Since the mutant toxin SL TP4 was cytotoxic in spite of protease resistance during 
intoxication it was predicted that the RASTA2 protein, designed to be refractory to 
proteolysis, would also be cytotoxic. This was the case, RASTA2 was an effective 
toxin giving an ICso value of 7ng/ml after 3 hours and O.3ng/ml after 6 hours. 
The in vivo proteolytic processing ofRASTA2 was examined using protein 
metabolically labelled with eSS]-methionine. However the results from this 
experiment were rather poor since RAST A2 could not be obtained at a high specific 
activity. Figure 3.5.7 shows radio-labelled RASTA2 protein recovered from Vero 
cells after four and six hours. No cleavage of protein is seen over four hours. 
However there is evidence of cleavage after six hours. Unfortunately these results 
were obtained at the detection limits of the experiment (the autoradiograph pictured 
in figure 3.5.7 represents a three week exposure on hypersensitive film) and time 
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allowed the assay to be performed only once. However from these data it appears 
that RASTA2 is processed albeit slowly to a fragment of approximately 30kDa. This 
cleavage is only detected between four and six hours, a time point at which its likely 
that there is more than 80% cell death. If this is the case, the cleaved toxin recovered 
may be a result of exposure to a host of cellular proteases as the cell dies rather than 
proteolytic enzymes contained within the endocytic pathway. The observed cleavage 
of RAST A2 might therefore be a result of degradation rather than a specific 
proteolytic processing event leading to the production of a translocationally 
competent fragment. Finally, the chimeric A chain may be structurally unstable since 
its expression in Escherichia coli yields very small quantities of A chain but very 
large quantities ofB chain with which it is co-expressed. This potential instability 
may account for its proteolysis. 
To conclude it appears that SLT 1 does not require proteolytic processing in order to 
be cytotoxic. However the possibility remains that a very small fraction of both 
SL TP4 and RASTA2, which cannot be detected using the assays performed here 
becomes nicked during intoxication. Since the enzymatic activity of RAST A2 is 
greater than that of SL TP4 it was expected that this protein would have greater 
cytotoxicity. However this was not the case. One possible explanation of these data is 
that in the absence of proteolytic processing membrane translocation is impaired. If 
time had allowed further experiments, subcellular fractionation might have been 
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possible to see if these proteins are associated with membrane after time points 
where toxicity is seen. Again if time had allowed, isolation of proteolytic fragments 
from SL TP 1 and SL TP3 followed by protein sequencing might have enabled the 
exact site of alternative processing to be assertained. The absence of a model in vitro 
translocation assay makes the study of the exact translocation requirements of SLT 1 
difficult. One possible method of studying these cleavage-defective proteins in vivo 
might be to examine whether there is a preference for modification of bound 
ribosomes over free ribosomes. A differential preference for bound ribosomcs might 
indicate that the toxin remains membrane associated. This is an assay under 
development at Warwick and may yield interesting information in the future. Precise 
evaluation of the enzymatic differences between SLT 1 and RASTA2 and ricin 
would also be useful in this study. For example, if the greater enzymatic activity of 
RAST A2 could be confirmed the lower cytotoxicity (even when RAST A2 is 
imported by the ST Gb3 receptors) would suggest that membrane translocation of 
RASTA2 is severly impaired. Perhaps therefore A2 inhibits this process, or perhaps 
therefore RA translocation is less efficient than that of SL T in vivo. 
The expression problems encoutered with RASTA2 might be overcome by a variety 
of methods. Substitution of the OmpF signal sequence with that of wild-type SL T 1 
would be likely to increase the efficiency of targeting expressed protein to the 
periplasm in Escherichia coli. IfRASTA2 is indeed structurally unstable then the use 
of a non-structured spacer arm between the folding domains of the RT A and SL T 
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components might help improve stability and as a result improve the yield of protein 
after expression. Since the large excess of SL T 1 B chain appears to drastically 
reduce the efficiency of iodination of the chimeric A chain, its removal by gel 
filtration would probably allow RAST A2 to be labelled to a specific activity which 
would allow in vivo proteolytic processing experiments to be carried out since RTA 
is routinely labelled with C25 I]. 
In the present study, attempts to demonstrate furin and calpain cleavage of SL T 1 and 
the mutants were also made. However the prepartions of furin and calpain used were 
old and seemingly inactive since cleavage of the wild-type SL T I could not be 
demonstrated. However with more time, investigation of the roles of these 
proteolytic enzymes in vitro could yield interesting information. 
The study of proteolytic processing in several bipartite bacterial toxins such as PE 
and DT has led to the general conclusion that these toxins require proteolytic 
processing prior to translocation to the cytosol where they act on their cytosolic 
targets. It was previously considered that like PE and DT, SLT I / ST also required 
proteolytic activation as an essential step to render it cytotoxic. Studies where the 
protease-sensitive site of PE is disrupted, showed that toxicity is dramatically 
reduced. linno et al (1989) mutated arginine-276 and 279 of PE which resulted in 
reduction of cytotoxicity of 3-4 and 2.5 logs respectively. The cell binding, 
endocytosis and catalytic activities of these mutant toxins apparently remained the 
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same. Thus the lack of a toxic effect was thought to be a result of a block in 
proteolytic processing . .In a later study, PE proteolytic processing was seen to be 
mediated between residues 279 and 280 (Ogata et at (1990)). Therefore it appears 
that mutation of re si dues 276-279 causes an effective block in an essential 
proteolytic activation step. 
DT likewise has an absolute requirement for proteolytic processing (Sandvig and 
Olsnes (1981 )). Cleavage after residue Arg-190 is probably the site at which 
proteolytic activation occurs (Moskaug et at (1988)). As previously discussed in 
section one, there are several other examples of bacterial toxins which must be 
activated by proteolysis. This activation can occur either during secretion from the 
producing organism or during transport within a target cell in order to be cytotoxic. 
In the present study, results are presented which suggest that unlike many other 
bacterial toxins SL T 1 does not require proteolytic activation in order to be cytotoxic. 
A protease-insensitive mutant toxin (SL TP4) described here, remains a potent toxin 
giving ICso values just 65 fold less than the wild-type toxin. Since no cleavage 
fragment can be visually detected even after six hours of toxin exposure to Vero 
cells, it appears that SL T 1 can remain cytotoxic in the absence of proteolytic 
activation. This study provides the first evidence of a toxin with a bipartite A chain 
which is not seen to require proteolytic processing for cytotoxicity. The implication 
from this work is that a full length A chain (or possibly holotoxin) has the ability to 
translocate a membrane to gain entry to the cytosol (thought to be the ER, Sandvig et 
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al (1992)). The reduction in cytotoxicity seen may reflect a reduced competence for 
translocation. 
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Appendix 1 
Alignment of the active site residues of SLT 1 A subunit (residues 138-210) with that 
of ricin A subunit (residues 149-218). Generated from the ALIGN program from 
Intelligenics. (Window length 20, word length 1, density at less, gap penalty 3) 
Identical residues are indicated by a closed circle chemically similar residues are 
indicated by a closed rectangle, dashes indicate gaps introduced into the sequence of 
ricin A chain. Calderwood et al (1990). 
138 174 
SLT A SYLDLMSHSGTSLTQSVARAMLRFVTVTAEALRFRQI 
•• • ••••••••••••••••••• ricin A SALYVYSTG GTQLP -TLARSF 11 C IQMISEAARFQYI 
149 184 
175 210 
SLT A QRGFRTILDDLSGRSYVMTAEDVDLTLNWGRLSSVL 
• ••• •• •••• • •••••• 
ricin A EGEMRTRIRYN - RRSAPDPS -VI TLENSWGRLSTAI 
185 218 
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Appendix 2 
The structure of GbrSepharose receptor analogue affinity matrix. Gb3-Sepharose 
contains the trissacharide globotriose linked via a 6 carbon spacer arm to activated 
Sepharose-4B. The hatched line represents solid Sepharose support. GbrSepharose 
was a kind gift from Dr D. Muller (Warwick, UK). 
HO 
H 
o 
H NH 
o 11 
VVV\ f:\o--! 
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Appendix 3 
Plasmid pKH206. Plasmid pKH206 contains the coding sequence of ricin A chain 
fused to the Omp F periplasmic signal sequence in the high level expression vector 
pKK223.3. Plasmid pKH206 was a kind gift from R. Argent (Warwick, UK). Argent 
et al (1994) 
R1 
PKH206 
(5400 bp) 
246 
Appendix 4 
Plasmid pSBC32. Plasmid pSBC32 contains the coding sequence of SL T 1 B chain 
in the high level expression vector pKK223.3. This plasmid was a kind gift from Dr 
SB Calderwood. Calderwood et at (1990) 
pS8C32 
he I1 Nco I 
Tq .. · 
Nco 1/5spl 
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Appendix 5 
DNA and amino acid sequences of the Shiga-like toxin 1 operon from Escherichia 
coli phage H19B. The Shine-Dalgamo sequences are indicated with diamonds. The 
proposed signal peptide cleavage sites are indicated by arrows. Numbers on the right 
of each row indicate amino acids those on the left indicate DNA bases. Active site 
residues are blocked. Calderwood et al (1990). 
355 
G1'O CTA ACT ".,. TTC ".,. OTT ATC ".,. TCA OTT M T GTG GTG 
Va l Leu Thr Phe Phe Phe Va l Ile Phe Se r Vil l Mn Val Val 
GCG MG GM ".,. Ace TTA GAC TTC TCG ACT GCA M G ACC TAT 
Ala Lys Clu Phe Thr Leu Asp Phe Ser Thr Ala Lye Thr Tyr 13 
~~;~tGAT TCG CTG MT GTC ATT CGC TCT GCA ATA OOT ACT CCA 
Val ASp Ser Leu Asn VaI lIe Arg Se r Ala lIe Gly Thr Pro 27 
418 
TTA CAG ACT ATT TCA TCA GGA GGT ACG TCT TTA CTG A1'O ATT 
Leu GIn Thr Ile Ser Ser Gly Gly Thr Ser Leu Leu Het Ile 41 
523 GAT AGT GGC TCA GGG GAT MT TTG ".,. GCA OTT GAT GTC AGA 
Asp Ser Gly Ser Gly Asp As n Leu Phe Ala Va l Aap Vd Arg 55 
565 
GGG ATA GAT CCA GAC GM GGG eGG ".,. MT MT CTA CGG CTT 
Gly Ile Asp Pro Glu Glu Gly Arg Ph. Aan ABn Leu Arg Leu 69 
607 
ATT OTT CM CGA MT MT TTA TAT GTG ACA GGA ".,. OTT MC 
lle Val Glu Arg Asn Asn Leu «¥I Val Thr Cly Phe Val Aan 83 
649 
AOO ACA MT MT OTT ".,. TAT CGC ".,. GCT GAT ".,. TCA CAT 
Arg Thr Aan Aan Val Phe Tyr Arg Phe Ala Aap Phe Ser His 97 
691 
GTT ACC TTT CCA GGT ACA ACA GCQ GTT ACA TTO TCT GGT CAC 
Va l Thr Phe Pro Gly Thr Thr Ala Val Thr Leu Ser Cl y Asp 111 
733 
AGT AGC TAT Ace ACG TTA CAG caT OTT GCA GGG ATC ACT CGT 
Ser Ser ,et'Thr Thr Leu Cln Arg Vd Ala Cly Ile Se r Ar9 125 
775 
ACG GGG A1'O CAC ATA MT CGC CAT TCG TTO ACT ACT TCT TAT 
Thr Cl y Me t Cln Ile .... n Arg His Se r Leu Thr Thr Ser Tyr 139 
817 
CTG GAT TTA A1'O TCG CAT AGT GGA Ace TCA CTG ACC CAC TCT 
Leu Asp Leu Me t Ser His Se r Cly Thr Ser Leu Thr Cln Ser 153 
859 
GTG CCA ACA CCG A1'O TTA CGC ".,. GTT ACT GTG ACA CCT, CM 
val Ala Arg Ala Met Leu Arg Phe Val Th r Val Thr Ala _ 167 
901 
GCT TTA CGT ".,. eGG CAA ATA CAG AOO GGA ".,. CGT ACA ACA 
aIlt Leu Gm! Phe Arg Gin 11 e Cln Arg Gly Phe Arg Thr Thr 181 
9<13 
CTG CAT GAT CTC AGT GGG CGT TCT TAT GTA 1.1'0 ACT GCT CM 
Leu Asp Asp Leu Ser Cly Arg Se r Tyr Val Met Thr Ala Glu 195 
98S 
GAT OTT CAT CTT ACA TTG MC TOO GGA AOO TTG AGT ACC GTC 
Asp Val As p Leu Thr Leu Asn r.n;Cly Arg Leu Ser Ser Val 209 
19f.6 CCT GAC TAT CAT GGA CM GAC TCT OTT caT GTA GGA AGA 
Le u Pro Asp Tyr His Cly GIn Asp Ser Val Arg Val Gly Arg 223 
1069 ATT TCT ".,. OOA ACC ATT MT GCA ATT CTG OOA ACC GTG CCA 
Il e Ser Phe Gly Ser 11e Asn Ala Il e Leu Cly Ser Val Al a 237 ' 
1111 
TTA ATA CTG MT TOT CAT CAT CAT GCA TCG CGA CTT c ce ACA 
Leu Ile Leu Asn Cys His His HiD Ala Ser Arg Val Al a Arg 251 
1153 
A1'O GCA TCT GAT GAG ".,. CCT TCT A1'O 1'OT CCG GCA GAT GGA 
Met Ala Ser Asp Glu Phe Pro Se r Met ey. Pro Ala As p Glr 265 
1195 
AGA GTC caT GGG ATT ACC CAC MT AM ATA TTG TOO GAT TCA 
Arg Val Arg Gly lie Thr His As n Lys Il e Leu Trp As p Ser 279 
1237 
TCC ACT CTG GGG CCA ATT CTG A1'O CGC AGA ACT ATT AGC ACT 
Ser Thr Leu Gly Al a tl e Le u Met Arg Arg Thr Il e Ser Ser 293 
1279 
q GGG OOT AM A1'O AM AM ACA TTII TTA ATA GCT GCA TCG 
1321 
_M:t_ ~y~!,~ _T~~ ~e~ _~': :l! _A:a_~!. ~e!:. -10 
CTT TCA ".,. ".,. TCA GCA AGT GCG CTG GCG ACG CCT GAT TGT 
Leu Se r Phe Phe Se r Al a Ser Ala Le u Al a Thr Pro As p ey s 4 --- --------------------~ 
GTA ACT GGA M G G1'O GAG TAT ACA AM TAT MT GAT GIIC GAT 
Va l Thr Gly Lys Val Glu Tyr Thr Ly . Tyr As n As p A. s p As p 18 
118~ TTT ACA GTT AM GTG GGT GAT AM GM TT A ".,. ACC M C 
Th r Phe Thr Val Lys Val Cly lis p Lys Glu l.eu Phe Thr II s n 32 
I~U TOO MT CTT CAG TCT CTT CTT CTC AGT GCG CM A''T ACG 
Ar g Trp Asn Leu GI n Se r Leu Leu Le u Se r Al a GIn I l e Th r 46 
1~ A1'O ACT GTA Ace ATT AAA ACT MT GCC 1'OT CAT MT GGA 
Gly Met Thr Val Thr li e Lys Thr As n Al a Cys Hi s As n Gly 60 1531 
GGG 0011 TTC AGC GM CTT ATT TTT CGT TGA CTC IIGA IITA GCT Gl y Gly Ph. Se r Glu Val ll e Phe Ar g 
1573 
CAG TGA AM TAG CAG GCG CAG 
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